# EDGAR Filing Document

**Accession Number:** 0001625297
**File Stem:** 0001625297-25-000050
**Filing Date:** 2025-7
**Character Count:** 354812
**Document Hash:** 762cdcc54ac31e96ff8439adb38ea534
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001625297-25-000050.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001625297-25-000050

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 80

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INDIVIOR PLC
- **CENTRAL INDEX KEY:** 0001625297
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37835
- **FILM NUMBER:** 251170659

**BUSINESS ADDRESS:**
- **STREET 1:** 234 BATH ROAD
- **CITY:** SLOUGH, BERKSHIRE
- **STATE:** X0
- **ZIP:** SL1 4EE
- **BUSINESS PHONE:** 804-379-1090

**MAIL ADDRESS:**
- **STREET 1:** 234 BATH ROAD
- **CITY:** SLOUGH, BERKSHIRE
- **STATE:** X0
- **ZIP:** SL1 4EE

?xml version='1.0' encoding='ASCII'? indv-20250630

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-37835

**Indivior PLC**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **England and Wales** | | **98-1204773** |
| State or other jurisdiction of incorporation or organization |  | (I.R.S. Employer Identification No.) |
|  | 10710 Midlothian Turnpike Suite 125<br>North Chesterfield, VA 23235 |  |
|  | (address of principal executive offices)(zip code) |  |
|  | Registrant's telephone number, including area code:<br>(804) 379-1040 |  |

---

---

| | | |
|:---|:---|:---|
| Securities Registered pursuant to Section 12(b) of the Act: | Securities Registered pursuant to Section 12(b) of the Act: | Securities Registered pursuant to Section 12(b) of the Act: |
| <u>Title of each class</u> | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
| Ordinary shares, $0.50 nominal value per share | INDV | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| ☑ | Large accelerated filer | ☐ | Accelerated filer |
| ☐ | Non-accelerated filer | ☐ | Smaller reporting company |
| | | ☐ | Emerging growth company |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of July 1, 2025, the number of outstanding ordinary shares was 124,769,820.

------

**Table of Contents**

---

| | |
|:---|:---|
| [**Table of Contents**](#i45972d1a22464d3793ed15fb1f183c44) | [1](#i45972d1a22464d3793ed15fb1f183c44) |
| [PART I - FINANCIAL INFORMATION](#i235c3e97072a44dc9da2b9a699341c40) | [2](#i235c3e97072a44dc9da2b9a699341c40) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1. Unaudited Financial Statements.](#i51a4e7c96d3f42e095f40de4deb051c2) | [2](#i51a4e7c96d3f42e095f40de4deb051c2) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.](#i5258aaec48514265b096b70307e39e8a) | [24](#i5258aaec48514265b096b70307e39e8a) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 3. Quantitative and Qualitative Disclosures About Market Risk.](#ib9ccf462939645828b54fa2f2317a82f) | [30](#ib9ccf462939645828b54fa2f2317a82f) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 4. Controls and Procedures](#id0d9300805634bbe94084e8dfb87d568) | [30](#id0d9300805634bbe94084e8dfb87d568) |
| [PART II - OTHER INFORMATION](#i9de62eb76d7a4b799a84055232bfd09a) | [31](#i9de62eb76d7a4b799a84055232bfd09a) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1. Legal Proceedings.](#iafb42d24fa084755aef470d692fff627) | [31](#iafb42d24fa084755aef470d692fff627) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1A. Risk Factors.](#i70863fec05aa4009989abbb5680e010a) | [31](#i70863fec05aa4009989abbb5680e010a) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.](#i9a7f0d4cf93048059a216fa73b1bd015) | [31](#i9a7f0d4cf93048059a216fa73b1bd015) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 3. Defaults Upon Senior Securities.](#i0f40f63ef3d4491b8e73f3b78fdf7e3d) | [31](#i0f40f63ef3d4491b8e73f3b78fdf7e3d) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 4. Mine Safety Disclosures.](#ie8c6f442e7574843aa90dd8fa99abcff) | [31](#ie8c6f442e7574843aa90dd8fa99abcff) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 5. Other Information.](#ic8ecb9c3afc34da7a80a08a069f7f309) | [31](#ic8ecb9c3afc34da7a80a08a069f7f309) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 6. Exhibits.](#i37e74da2cbe6495ebb32033733bc98ce) | [33](#i37e74da2cbe6495ebb32033733bc98ce) |
| [SIGNATURES](#i3dc1439096644c26af9549a3dea3d2f1) | [34](#i3dc1439096644c26af9549a3dea3d2f1) |

---

**Important cautionary note regarding forward-looking statements**

Certain statements contained herein, as well as in other filings we make with the SEC and other written and oral information we release, regarding our performance or other events or developments in the future constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, express and implied statements pertaining to the Company's financial guidance including revenue, gross margin and operating margin for 2025 and its medium- and long-term growth outlook; expected growth from new products in the Rest of the World; expected levels of future rebate payments, research and development expenses, and capital expenditures; potential future investment opportunities; and statements containing the words "believe," "anticipate," "plan," "expect," "intend," "estimate," "forecast," "strategy," "target," "goal," "guidance," "outlook," "potential," "project," "priority," "may," "will," "should," "would," "could," "can," the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.

Actual results may differ materially from those expressed or implied in such statements because they relate to future events. For information about some of the risks and important factors that could affect our future results and financial condition, see the discussion of "Risk Factors" in our Annual Report on Form 10-K filed March 3, 2025, our Quarterly Report on Form 10-Q filed May 1, 2025, Part II Item 1A herein, and our other filings with the U.S. Securities and Exchange Commission.

We have based the forward-looking statements in this report on our current expectations and beliefs concerning future events. Forward-looking statements contained in this report speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether due to new information, future developments or otherwise.

------

**PART I - FINANCIAL INFORMATION**

**Item 1. Unaudited Financial Statements.**

**Index to Unaudited Condensed Consolidated Financial Statements**

---

| | |
|:---|:---|
| Condensed Consolidated Statements of Operations | <u>[3](#i0ef80ef2ef954756b72b386f7be2aa21_25)</u> |
| Condensed Consolidated Statements of Comprehensive Income (Loss) | <u>[4](#i0ef80ef2ef954756b72b386f7be2aa21_28)</u> |
| Condensed Consolidated Balance Sheets | <u>[5](#i0ef80ef2ef954756b72b386f7be2aa21_31)</u> |
| Condensed Consolidated Statements of Stockholders' Deficit | <u>[6](#i0ef80ef2ef954756b72b386f7be2aa21_34)</u> |
| Condensed Consolidated Statements of Cash Flow | <u>[8](#i0ef80ef2ef954756b72b386f7be2aa21_37)</u> |
| Notes to Condensed Consolidated Financial Statements | <u>[9](#i0ef80ef2ef954756b72b386f7be2aa21_43)</u> |

---

------

**Indivior PLC**

**Condensed Consolidated Statements of Operations**

**(Amounts in millions, except per share data)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Net revenue** | $**302** | $**299** | $**568** | $**583** |
| Cost of sales | 52 | 79 | 96 | 117 |
| **Gross profit** | **250** | **220** | **472** | **466** |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 158 | 152 | 290 | 295 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 21 | 26 | 43 | 54 |
| &nbsp;&nbsp;&nbsp;&nbsp;Litigation settlement |  | 160 | 1 | 160 |
| **Operating income (loss)** | **72** | **(118)** | **138** | **(43)** |
| **Other (income) and expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest (income)<sup>1</sup> | (6) | (6) | (10) | (13) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense<sup>1</sup> | 15 | 9 | 27 | 18 |
| **Income (loss) before income taxes** | **62** | **(121)** | **121** | **(48)** |
| Income tax expense (benefit)<sup>1</sup> | 44 | (23) | 56 | (12) |
| **Net income (loss)** | $**18** | $**(97)** | $**65** | $**(36)** |
| <sup>1</sup> Sign convention modified beginning in Q2 2025 (for all periods presented) | <sup>1</sup> Sign convention modified beginning in Q2 2025 (for all periods presented) | <sup>1</sup> Sign convention modified beginning in Q2 2025 (for all periods presented) | <sup>1</sup> Sign convention modified beginning in Q2 2025 (for all periods presented) |  |
| **Earnings (loss) per share** |  |  |  |  |
| Basic | $0.15 | $(0.72) | $0.53 | $(0.27) |
| Diluted | $0.14 | $(0.72) | $0.52 | $(0.27) |
| **Shares used in computing earnings (loss) per share** |  |  |  |  |
| Basic | 125 | 135 | 125 | 135 |
| Diluted | 126 | 135 | 125 | 135 |

---

See Notes to Condensed Consolidated Financial Statements.

------

**Indivior PLC**

**Condensed Consolidated Statements of Comprehensive Income (Loss)**

**(Amounts in millions)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Net income (loss)** | $**18** | $**(97)** | $**65** | $**(36)** |
| **Other comprehensive income (loss), net of tax** |  |  |  |  |
| &nbsp;&nbsp;Foreign currency translation | 2 |  | 3 | (2) |
| &nbsp;&nbsp;Other comprehensive income (loss) | 2 |  | 3 | (2) |
| **Total comprehensive income (loss)** | $**20** | $**(97)** | $**69** | $**(38)** |

---

See Notes to Condensed Consolidated Financial Statements.

------

**Indivior PLC**

**Condensed Consolidated Balance Sheets**

**(Amounts in millions, except per share data)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| **Assets** | | |
| **Current assets** | | |
| &nbsp;&nbsp;Cash and cash equivalents | $510 | $319 |
| &nbsp;&nbsp;Short-term investments |  | 1 |
| &nbsp;&nbsp;Accounts receivable, net of allowances of $2 (2025) and $3 (2024) | 240 | 254 |
| &nbsp;&nbsp;Inventories | 149 | 167 |
| &nbsp;&nbsp;Prepaid expenses | 28 | 31 |
| &nbsp;&nbsp;Current tax receivable | 3 | 33 |
| &nbsp;&nbsp;Other current assets | 20 | 21 |
| **Total current assets** | **951** | **827** |
| Long-term investments | 27 | 27 |
| Property, plant and equipment, net | 117 | 100 |
| Operating lease right of use assets, net | 35 | 39 |
| Goodwill and other intangible assets, net | 7 | 6 |
| Deferred tax assets | 270 | 277 |
| Other non-current assets | 44 | 39 |
| **Total assets** | $**1452** | $**1316** |
| **Liabilities and shareholders' deficit** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;Accrued rebates and product returns | $709 | $562 |
| &nbsp;&nbsp;Accounts payable and accrued expenses | 196 | 216 |
| &nbsp;&nbsp;Accrued litigation settlement expenses, current | 105 | 99 |
| &nbsp;&nbsp;Current portion of long-term debt | 18 | 18 |
| &nbsp;&nbsp;Operating lease liabilities, current | 11 | 10 |
| &nbsp;&nbsp;Income taxes payable | 17 | 7 |
| &nbsp;&nbsp;Other current liabilities |  | 11 |
| **Total current liabilities** | **1056** | **924** |
| Long-term debt, less current portion | 308 | 315 |
| Accrued litigation settlement expenses, non-current | 299 | 365 |
| Operating lease liabilities, non-current | 29 | 32 |
| Other non-current liabilities | 18 | 18 |
| **Total liabilities** | $**1709** | $**1652** |
| Commitments and contingencies (Note 12) |  |  |
| **Shareholders' deficit** |  |  |
| &nbsp;&nbsp;Common stock, par value $0.50 per share<br>Issued shares: 125 (2025) and 125 (2024) | 62 | 62 |
| &nbsp;&nbsp;Additional paid-in capital | 101 | 90 |
| &nbsp;&nbsp;Share repurchase commitment |  | (10) |
| &nbsp;&nbsp;Accumulated other comprehensive loss | (33) | (36) |
| &nbsp;&nbsp;Accumulated deficit | (388) | (443) |
| **Total shareholders' deficit** | **(257)** | **(337)** |
| **Total liabilities and shareholders' deficit** | $**1452** | $**1316** |

---

See Notes to Condensed Consolidated Financial Statements.

------

**Indivior PLC**

**Condensed Consolidated Statements of Stockholders' Deficit**

**(Amounts in millions, except per share data)**

**(Unaudited)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | | | | | |
| | **Shares** | **Amount** |<br>**Additional paid-in capital** |<br>**Share repurchase commitment** |<br>**Accumulated other comprehensive loss** |<br>**Accumulated deficit** |<br>**Total shareholders' equity (deficit)** |
| **Balance, January 1, 2025** | **125** | $**62** | $**90** | $**(10)** | $**(36)** | $**(443)** | $**(337)** |
| Net income |  |  |  |  |  | 47 | 47 |
| Other comprehensive income |  |  |  |  | 1 |  | 1 |
| Common stock issued | 1 |  |  |  |  |  | 1 |
| Common stock repurchased and canceled | (1) |  |  |  |  | (10) | (11) |
| Share-based compensation |  |  | 6 |  |  |  | 6 |
| Share repurchase liability movement, net |  |  |  | 10 |  |  | 10 |
| Settlement of tax on equity awards |  |  | (3) |  |  |  | (3) |
| **Balance, March 31, 2025** | **125** | **62** | **93** | **—** | **(35)** | **(406)** | **(285)** |
| Net income |  |  |  |  |  | 18 | 18 |
| Other comprehensive loss |  |  |  |  | 2 |  | 2 |
| Share-based compensation |  |  | 8 |  |  |  | 8 |
| **Balance, June 30, 2025** | **125** | $**62** | $**101** | $**—** | $**(33)** | $**(388)** | $**(257)** |

---

See Notes to Condensed Consolidated Financial Statements.

------

**Indivior PLC**

**Condensed Consolidated Statements of Stockholders' Deficit**

**(Amounts in millions, except per share data)**

**(Unaudited)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | | | | | |
| | **Shares** | **Amount** |<br>**Additional paid-in capital** |<br>**Share repurchase commitment** |<br>**Accumulated other comprehensive loss** |<br>**Accumulated deficit** |<br>**Total shareholders' equity (deficit)** |
| **Balance, January 1, 2024** | **137** | $**68** | $**88** | $**(23)** | $**(30)** | $**(288)** | $**(184)** |
| Net income |  |  |  |  |  | 61 | 61 |
| Other comprehensive loss |  |  |  |  | (3) |  | (3) |
| Common stock issued | 1 | 1 | 1 |  |  |  | 2 |
| Common stock repurchased and canceled | (2) | (1) |  |  |  | (35) | (36) |
| Share-based compensation |  |  | 6 |  |  |  | 6 |
| Share repurchase liability movement, net |  |  |  | 14 |  |  | 14 |
| Settlement of tax on equity awards |  |  | (20) |  |  |  | (20) |
| Other |  |  | (1) |  |  |  | (1) |
| **Balance, March 31, 2024** | **136** | **68** | **74** | **(9)** | **(32)** | **(262)** | **(161)** |
| Net loss |  |  |  |  |  | (97) | (97) |
| Common stock repurchased and canceled | (2) | (1) |  |  |  | (33) | (34) |
| Share-based compensation |  |  | 6 |  |  |  | 6 |
| Share repurchase liability movement, net |  |  |  | 5 |  |  | 5 |
| **Balance, June 30, 2024** | **134** | $**67** | $**80** | $**(4)** | $**(32)** | $**(393)** | $**(281)** |

---

See Notes to Condensed Consolidated Financial Statements.

------

**Indivior PLC**

**Condensed Consolidated Statements of Cash Flows**

**(Amounts in millions)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| **Net income (loss)** | $**65** | $**(36)** |
| **Adjustments to reconcile net income (loss) to net cash from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of right-of-use assets | 5 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 14 | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of tangible and intangible assets |  | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on equity investments | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 7 | (24) |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact from foreign exchange movements | (5) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other adjustments, net | 1 |  |
| **Change in operating assets and liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 15 | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Current inventories | 22 | (35) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current and non-current assets | 31 | 393 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued legal and settlement expenses | (60) | (335) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current and non-current liabilities | 131 | 61 |
| **Net cash provided by operating activities** | **233** | **51** |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment | (22) | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of in-process research and development and intangible assets | (1) | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of investments in debt securities | (11) | (9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and maturities of debt securities | 11 | 42 |
| **Net cash (used in) provided by investing activities** | **(22)** | **26** |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the issuance of common stock | 1 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for repurchases of common stock | (11) | (71) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of debt | (8) | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other |  | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Settlement of tax on equity awards | (3) | (20) |
| **Net cash used in financing activities** | **(22)** | **(91)** |
| **Net increase (decrease) in cash and cash equivalents** | **189** | **(14)** |
| Exchange differences | 1 |  |
| Cash and cash equivalents at beginning of period | 319 | 316 |
| **Cash and cash equivalents at end of period** | $**510** | $**302** |

---

See Notes to Condensed Consolidated Financial Statements.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

**1. Business Overview, Basis of Presentation, and Recently Issued Accounting Standards**

**Business Overview** 

Indivior PLC and its subsidiaries (together, "Indivior" or the "Company") is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). The Company's vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide.

**Basis of Consolidation**

The accompanying unaudited interim condensed consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Indivior PLC and its subsidiaries and related notes as contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.

The accounting policies of the Company are consistent with those disclosed in *"Item 1. Financial Statements - Note 2 Summary of Significant Accounting Policies"* of our Annual Report on Form 10-K for the year ended December 31, 2024.

Columns and rows within tables may not add due to rounding. Percentages and per share data have been calculated using actual, non-rounded figures.

**Use of Estimates and Judgments**

The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Significant estimates are used in determining items such as accruals for returns, incentives and rebates, certain accrued expenses, acquisitions, and ongoing litigation. Actual results may differ from those estimates.

**Recently Adopted Accounting Standards**

No new accounting standards were adopted during the six months ended June 30, 2025.

**Recently Issued Accounting Standards Not Yet Adopted** 

*ASU 2024-03: Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)—Disaggregation of Income Statement Expenses (as clarified by ASU 2025-01)*

This standard requires disclosure in the notes to the financial statements of specified information about certain costs and expenses and is required to be applied by the Company for fiscal periods beginning after December 15, 2027. As this accounting standard only impacts disclosures, it is not expected to have a material impact on the Company's financial statements.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

**New Legislation**

In July 2025, legislation commonly referred to as the One Big Beautiful Bill Act was enacted, introducing amendments to U.S. tax laws with various effective dates from 2025 to 2027, primarily impacting companies domiciled in the U.S. The Company is evaluating the implications of these tax law changes and does not currently anticipate significant impacts.

**2. Segment, Geographic and Other Revenue Information**

The Company operates in a single operating and reportable segment for all periods presented and the CEO has been identified as the chief operating decision maker ("CODM"). The CODM uses income from operations to measure the profitability of the segment. These amounts are reported on the Condensed Consolidated Statements of Operations. The measure of segment assets is reported on the Condensed Consolidated Balance Sheets as total consolidated assets.

The financial data provided to the CODM is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| US: |  |  |  |  |
| &nbsp;&nbsp;SUBLOCADE\* | $195 | $179 | $359 | $346 |
| &nbsp;&nbsp;Sublingual & other | 52 | 63 | 107 | 126 |
| &nbsp;&nbsp;PERSERIS<sup>1</sup> | 8 | 13 | 12 | 23 |
| **Total U.S.** | **256** | **255** | **478** | **496** |
| Rest of World | 46 | 44 | 90 | 87 |
| **Net revenue** | **302** | **299** | **568** | **583** |
| Cost of sales | 52 | 79 | 96 | 117 |
| **Gross profit** | **250** | **220** | **472** | **466** |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Selling and marketing* | 80 | 66 | 147 | 132 |
| &nbsp;&nbsp;&nbsp;&nbsp;*General and administrative* | 78 | 86 | 142 | 163 |
| &nbsp;&nbsp;**Total selling, general and administrative** | **158** | **152** | **290** | **295** |
| &nbsp;&nbsp;Research and development | 21 | 26 | 43 | 54 |
| &nbsp;&nbsp;Litigation settlement |  | 160 | 1 | 160 |
| **Total operating expenses** | **178** | **338** | **334** | **509** |
| **Operating income (loss)** | **72** | **(118)** | **138** | **(43)** |
| Other (income) and expenses: |  |  |  |  |
| &nbsp;&nbsp;Interest (income) | (6) | (6) | (10) | (13) |
| &nbsp;&nbsp;Interest expense | 15 | 9 | 27 | 18 |
| **Income (loss) before income taxes** | **62** | **(121)** | **121** | **(48)** |
| Income tax expense (benefit) | 44 | (23) | 56 | (12) |
| **Net income (loss)** | $**18** | $**(97)** | $**65** | $**(36)** |
| \*Total SUBLOCADE net revenue | $209 | $192 | $385 | $371 |
| Depreciation and amortization | $3 | $4 | $5 | $7 |
| Share-based compensation expense | $8 | $6 | $14 | $12 |

---

<sup>1</sup>Marketing and promotion activities for PERSERIS were discontinued in July 2024.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

Significant segment expenses within net income (loss) include cost of sales, selling and marketing, general and administrative, research and development, and litigation settlement at the consolidated level. Other segment items within net income (loss) include interest (income), interest expense, and income tax expense (benefit). Our CODM is also regularly provided depreciation and amortization and share-based compensation expense, both of which are presented above and are recorded within cost of sales and selling, general and administrative expenses.

Revenue recognized from performance obligations satisfied in previous periods was $26 million and $45 million in the three and six months ended June 30, 2025 and $16 million and $23 million during the three and six months ended June 30, 2024, respectively.

**3. Income Tax**

Indivior is subject to taxation in several different jurisdictions. The Company's tax provision for each period presented was calculated using a forecasted annual tax rate, adjusted for discrete items occurring during the applicable period to arrive at an effective tax rate. The effective income tax rates for the relevant periods were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Total income (loss) before income taxes | $62 | $(121) | $121 | $(48) |
| Total income tax expense (benefit) | $44 | $(23) | $56 | $(12) |
| **Total effective tax rate** | **71%** | **19%** | **46%** | **25%** |

---

Our income tax rate for the three months ended June 30, 2025 differs from the U.K. Federal statutory rate of 25%, primarily due to a tax reserve on a U.K. HMRC settlement which became probable during the quarter, partially offset by U.K. innovation deductions. The HMRC settlement relates to aspects of prior years' intercompany financing arrangements and is not expected to impact our future tax rates.

Our income tax rate for the six months ended June 30, 2025 differs from the U.K. Federal statutory rate of 25%, primarily due to a tax reserve on a U.K. HMRC settlement which became probable during the quarter, U.K. global minimum top-up tax, share based compensation shortfall tax expense and a valuation allowance against corporate interest limitation carryforwards, partially offset by U.K. innovation deductions and intragroup financing transactions.

Our income tax rate for the three months ended June 30, 2024 differs from the U.K. Federal statutory rate of 25%, primarily due to disallowed transaction expenses, a valuation allowance against corporate interest limitation carryforwards, disallowed compensation, and a reduction to U.K. innovation deductions, partially offset by intragroup financing transactions.

Our income tax rate for the six months ended June 30, 2024 differs from the U.K. Federal statutory rate of 25%, due primarily to intragroup financing transactions and share based compensation excess tax benefits, partially offset by a valuation allowance against corporate interest limitation carryforwards, disallowed transaction expenses and disallowed compensation.

We are subject to income taxation in many jurisdictions. Unrecognized tax benefits reflect the differences between tax positions we have taken or expect to take on income tax returns and the amounts recognized in our financial statements. Resolution of the related tax positions with the relevant tax authorities may take many years to complete, and such timing is not entirely within our control.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

Changes in unrecognized tax benefits are summarized as follows for the six months ended June 30, 2025.

---

| | |
|:---|:---|
| (In millions) |  |
| **Balance at December 31, 2024** | $4 |
| Additions for tax positions of prior years | 33 |
| **Balance at June 30, 2025** | $37 |

---

During the three and six months ended June 30, 2025, we recorded $33 million in tax reserves related to a settlement with U.K. HMRC which became probable during the quarter, in relation to a finance structure in place from 2019 through May 2024. No other material changes to the Company's unrecognized tax benefit have occurred since December 31, 2024.

During the three and six months ended June 30, 2025, the Company accrued and expensed interest of $5 million.

The total amount of unrecognized tax benefits relating to the Company's tax positions is subject to change based on future events including, but not limited to, the settlement of ongoing tax audits and assessments and the expiration of applicable statutes of limitations.

The Company is not subject to U.K. examinations by tax authorities for fiscal years before 2019 and U.S. federal income tax examinations by tax authorities for fiscal years before 2021. There are ongoing U.K. and U.S. state and local audits covering 2018 - 2022. An estimate of reasonably possible additional tax liabilities and interest that could arise on resolution of these examinations, including the impact from later periods, is in the range of nil to $12 million.

**4. Inventories**

Inventories are comprised of:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Raw materials and consumables | $35 | $33 |
| Work in progress | 37 | 51 |
| Finished goods | 94 | 94 |
| **Total Inventories, net** | $**165** | $**178** |

---

Inventory expected to be sold more than one year from the balance sheet date is classified as noncurrent inventory and recorded in other noncurrent assets on the condensed consolidated balance sheets. At June 30, 2025 and December 31, 2024, the noncurrent portion of inventory was $17 million and $10 million, respectively and consisted primarily of raw materials and consumables (see *Note 13. Revision of Previously Issued Financial Statements*).

Inventory write-downs reflected in the carrying amounts above at June 30, 2025 and December 31, 2024 were $25 million and $26 million, respectively.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

**5. Property, Plant and Equipment, Net**

A summary of property, plant and equipment is as follows:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Land and buildings | $83 | $76 |
| Plant and equipment | 76 | 76 |
| Construction in progress | 51 | 38 |
| **Gross property, plant and equipment** | **210** | **190** |
| Less: Accumulated depreciation | (93) | (90) |
| **Total property, plant and equipment, net** | $**117** | $**100** |

---

The Company capitalizes interest expense, if material, as part of the cost of construction of property, plant and equipment. Interest expense capitalized was $2 million and $3 million in the three and six months ended June 30, 2025 and $1 million and $1 million in the three and six months ended June 30, 2024, respectively.

Capital expenditures of $1 million and nil were included in accounts payable and accrued expenses at June 30, 2025 and June 30, 2024, respectively.

**6. Accounts Payable and Accrued Expenses**

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Accounts payable | $50 | $63 |
| Accrued employee-related obligations | 57 | 60 |
| Accrued indirect tax and government fees | 26 | 23 |
| Accruals for third-party services | 54 | 64 |
| Accrued other expenses | 8 | 6 |
| **Total accounts payable and accrued expenses** | $**196** | $**216** |

---

**7. Accrued Litigation Settlement Expenses**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Current** | **Non current** | **Total** | **Current** | **Non current** | **Total** |
| **Accrued litigation settlement expenses** | | | | | | |
| DOJ-related | $51 | $247 | $298 | $52 | $296 | $348 |
| Antitrust claims | 20 |  | 20 | 24 |  | 24 |
| Opioid litigation | 27 | 52 | 79 | 15 | 61 | 76 |
| Other | 8 |  | 8 | 8 | 8 | 16 |
| **Total accrued litigation settlement expenses** | $**105** | $**299** | $**404** | $**99** | $**365** | $**464** |

---

**DOJ-related**

In July 2020, the Company settled criminal and civil liability with the U.S. Department of Justice (DOJ), the U.S. Federal Trade Commission (FTC), and U.S. state attorneys general. A scheduled payment of $52 million was made during the six months ended June 30, 2025 with respect to this matter.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

**Opioid litigation**

The accrual of $79 million at June 30, 2025 reflects the present value of the agreed amount in a settlement covering certain opioid litigation (including cases in the Opioid MDL). The provision is measured using a risk-free rate.

**Antitrust claims**

An installment of $5 million was paid in the six months ended June 30, 2025 in relation to the last remaining antitrust litigation. The remaining accrual of $20 million at June 30, 2025 reflects the NPV at the risk-free rate of the amounts to be paid in 2025. This final settlement resolves all of the Company's remaining legacy antitrust litigation.

See *Note 12. Commitments and Contingencies* for additional information on legal matters.

**8. Debt**

The Company has a note purchase agreement with an original principal amount of $350 million and a committed revolving credit facility of $50 million, both of which mature in November 2030. None of the $50 million revolving credit facility has been drawn upon.

The outstanding balance of the note purchase agreement of $341 million and $350 million as of June 30, 2025 and December 31, 2024, respectively, is secured by substantially all of the assets of subsidiaries of the Company, primarily in the form of guarantees issued by respective subsidiaries. Interest expense was $9 million and $17 million for the three and six months ended June 30, 2025 and $7 million and $13 million for the three and six months ended June 30, 2024, respectively.

The Company was in compliance with all debt covenants at June 30, 2025.

**9. Financial Instruments and Fair Value Measurements**

Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, debt, investments in corporate debt securities and investments in equity securities. The carrying value of these financial instruments, excluding debt instruments and the Company's investments in corporate debt and equity securities, approximates fair value because of the short-term nature of these instruments.

The following three levels of inputs are used to measure fair value:

Level 1 — Quoted prices in active markets for identical assets and liabilities.

Level 2 — Significant other observable inputs.

Level 3 — Significant unobservable inputs.

The Company's only financial instruments which are measured at fair value on a recurring basis are equity securities. The fair value of equity securities is based on quoted market prices (Level 1 inputs) on the measurement date. The fair value of equity securities at June 30, 2025 and December 31, 2024 was nil and $1 million, respectively.

The fair value of corporate debt securities at June 30, 2025 and December 31, 2024 was $28 million and $27 million, respectively. The fair value of corporate debt securities held at amortized cost was calculated based on quoted market prices which would be classified as Level 1 in the fair value hierarchy above. At June 30, 2025, the Company's debt securities were held by a separate cell of an insurance company as part of an agreement to fund insurance coverage. These debt securities are classified as long-term investments on the condensed consolidated balance sheets as access to the investments is subject to contractual restrictions, regardless of the underlying investment maturity.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

The fair value of debt at June 30, 2025 and December 31, 2024 was $341 million and $350 million, respectively. The fair value of debt is based on unobservable inputs and is classified as Level 3 in the hierarchy above. The most comparable proxy benchmark, Single B corporate bond indexes, indicated a minimal offsetting change in spread. Along with the short period since the initial issuance date, an adjustment to the initial credit spread of the term loan is not warranted at June 30, 2025 and the carrying value reasonably reflects of fair value.

**10. Earnings Per Share**

The following table summarizes the calculation of basic and diluted loss per share for each period:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Net income (loss)** | $**18** | $**(97)** | $**65** | $**(36)** |
| Basic weighted-average shares outstanding | 125 | 135 | 125 | 135 |
| Effect of potentially dilutive securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock awards<sup>1</sup> | 1 |  | 1 |  |
| **Diluted weighted-average shares outstanding** | **126** | **135** | **125** | **135** |
| **Basic earnings (loss) per share** | **0.15** | **(0.72)** | **0.53** | **(0.27)** |
| **Diluted earnings (loss) per share** | **0.14** | **(0.72)** | **0.52** | **(0.27)** |

---

<sup>1</sup>The potential shares excluded from the diluted earnings per share computation because of the antidilutive impact were nil in the three and six months ended June 30, 2025 and 2 million for the three and six months ended June 30, 2024.

The weighted average number of shares is adjusted for the number of shares granted to the extent market conditions have been met at the balance sheet date and determined using the treasury stock method.

Conditional awards of 2 million and 5 million shares were granted in the three and six months ended June 30, 2025 and 2 million in the three and six months ended June 30, 2024 under the Company's Long-Term Incentive Plan, respectively.

**11. Share-Based Payments**

The Company operates three equity-settled executive and employee share plans. For share-based payment awards, the fair value at the grant date is calculated using appropriate pricing models. The programs and related accounting are described in "*Item 8. Financial Statements—Note 15. Share-Based Payments*" of our Annual Report on Form 10-K for the year ended December 31, 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Compensation expense related to share-based payments | $**8** | $**6** | $**14** | $**12** |

---

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

***Indivior Long-Term Incentive Plan (LTIP)***

A summary of the service-based restricted share awards and performance-based share awards activity under the LTIP for the six months ended June 30, 2025 is presented below (values in thousands):

---

| | | |
|:---|:---|:---|
| | **Outstanding Service-Based Restricted Share Awards** | **Outstanding Performance-Based Share Awards** |
| **Shares at December 31, 2024** | 1036 | 4717 |
| Granted | 2309 | 2979 |
| Issued | (208) | (286) |
| Canceled/forfeited/adjusted | (301) | (1940) |
| **Shares at June 30, 2025** | 2836 | 5471 |

---

The weighted average fair value per share of the service-based restricted share awards granted was $10.11 for the six months ended June 30, 2025, based on the fair market value at the date of grant. The total fair value of restricted share awards issued was $3 million for the six months ended June 30, 2025.

The weighted average fair value per share of the performance-based share awards granted per share was $8.68 for the six months ended June 30, 2025, calculated using the weighted average fair market value for each of the component goals at the date of grant. The total fair value of performance-based share awards issued was nil for the six months ended June 30, 2025.

Total compensation cost for unvested awards not yet recognized at June 30, 2025 was approximately $25 million and $33 million for service-based restricted share awards and performance-based restricted awards, respectively. We recognize compensation cost over the expected remaining weighted-average period of 2.4 years and 2.6 years for service-based restricted share awards and performance-based share awards, respectively.

*Share Options*

The Company did not grant any share options in the six months ended June 30, 2025. No share options were exercised in six months ended June 30, 2025.

**12. Commitments and Contingencies** 

*Legal Proceedings and Contingencies*

The Company records accruals for loss contingencies associated with legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. Certain ongoing legal proceedings or threats of legal proceedings to which the Company is a party, but in which the Company believes the possibility of an adverse impact is remote, are not discussed in this Note.

**Civil Opioid Litigation**

The Company has been named as a defendant in more than 400 civil lawsuits alleging that manufacturers, distributors, and retailers of opioids engaged in a longstanding practice to market opioids as safe and effective for the treatment of long-term chronic pain to increase the market for opioids and their own market shares for opioids, or alleging individual personal injury claims. Most of these cases have been consolidated and are pending in a federal multi-district litigation in the U.S. District Court for the Northern District of Ohio. *See In re National Prescription Opiate Litigation*, MDL No. 2804 (N.D. Ohio) (the "Opioid MDL"). Nearly two-thirds of the cases in the Opioid MDL were filed by cities and counties, while nearly one-third of the cases were filed by private plaintiffs, most of whom assert claims relating to neonatal abstinence syndrome ("NAS"). Cases brought by cities and counties outside of the MDL include,

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

for example, 35 actions pending in New York state court, 9 writs filed in Pennsylvania state court, and actions brought in federal district courts in Florida and Georgia. Litigation against the Company in the Opioid MDL and the other federal courts is stayed. The New York state court has not yet entered a case management order. The Company has not yet been served with a complaint in any of the Pennsylvania state court matters.

Additionally, on May 23, 2024, the Consumer Protection Division of the Office of the Attorney General of Maryland served on Indivior Inc. an administrative subpoena related generally to opioid products marketed and sold in Maryland. Indivior Inc.'s response to the subpoena remains ongoing.

Pursuant to mediation, the Company, the Plaintiffs' Executive Committee (PEC), and an executive committee of state attorneys general, reached agreement on settlement terms, which would allow subdivisions, including those cities and counties that filed suit against Indivior as discussed above, to potentially sign on to the terms of the settlement. No states have indicated that they do not intend to opt in except the State of Maryland. Maryland could elect to join later in the process. The process for the subdivisions of the various states to elect whether to participate in the settlement will take time. The Company separately executed a master settlement agreement with the Tribal Leadership Committee (TLC). Whether the settlements will be finalized and the actions dismissed depends on sufficient participation in each agreement. The Company presently anticipates that the opt-in process will be complete in or before November 2025; however, there is no assurance that this will occur at that time. The Company has recorded a related provision of $79 million, reflecting the NPV of the agreed amount (See *Note 7. Accrued Litigation Settlement Expenses*). These settlements do not resolve private plaintiff cases against the Company (whether in the MDL or proceeding separately).

With respect to cases outside the MDL that were not filed by cities or counties and therefore could not be part of the above settlement:

On October 28, 2024, Indivior Inc. was named as one of numerous defendants in five individual complaints involving claims related to NAS and filed in West Virginia state court, that were transferred to West Virginia's Mass Litigation Panel. *See In re Opioid Litigation*, No. 22-C-9000 NAS (W.V. Kanawha Cnty. Cir. Ct.) ("WV MLP Action"). The plaintiffs filed a notice of appeal in the West Virginia Supreme Court as to all defendants, including Indivior, on February 27, 2025. The West Virginia Supreme Court has set a briefing schedule under which briefing on the appeal will close on August 4, 2025.

The Company has begun its evaluation of all of the claims, believes it has meritorious defenses, and intends to vigorously defend itself in all actions that would not be resolved by the proposed settlement. Given the status and preliminary stage of litigation, no estimate of total possible loss for those matters can be made at this time.

**Dental Allegations**

The Company has been named as a defendant in numerous lawsuits alleging that SUBOXONE Film was defectively designed and caused dental injury, and that the Company failed to properly warn of the risks of such injuries. The plaintiffs generally seek compensatory damages, as well as punitive damages and attorneys' fees and costs. Plaintiffs and potential plaintiffs related to these lawsuits generally can be grouped as follows:

Dental MDL Plaintiffs: 1,877 cases naming 21,402 plaintiffs have been consolidated in multi-district litigation in the Northern District of Ohio. *See In Re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation*, MDL No. 3092 (N.D. Oh.) (the "Dental MDL").

Dental MDL Schedule A Plaintiffs: One complaint filed in the Dental MDL on June 14, 2024 attached a schedule of nearly 10,000 plaintiffs (the "Schedule A Plaintiffs"). The parties negotiated a tolling agreement for the Schedule A Plaintiffs that would permit plaintiffs' counsel additional time to investigate issues such as whether and when the Schedule A Plaintiffs used any Indivior product before determining whether to file individual complaints that ultimately would be coordinated with the Dental MDL. Plaintiffs

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

indicated to the court they will dismiss more than 1,400 plaintiffs in the future, pursuant to a mechanism to be provided by the court. On July 11, 2025, the plaintiffs filed an amended Schedule A that reduced the number of Schedule A claimants to 8,333.

State Court Plaintiffs: One complaint has been filed in New Jersey state court, and the parties have agreed to toll the claims of more than 975 other individuals in Delaware, New Jersey, and Virginia. Complaints have not yet been filed on behalf of the tolled individuals.

Applications to file class actions based on similar allegations as in the Dental MDL, but also relating to SUBOXONE Tablets, were filed in Quebec and British Columbia against various subsidiaries of the Company, among other defendants, in April 2024.

The Company has begun its evaluation of the claims, believes it has meritorious defenses, and intends to vigorously defend itself. Given the status and preliminary stage of litigation, no estimate of possible loss can be made at this time.

**U.K. Shareholder Claims**

On September 21, 2022, certain shareholders issued representative and multiparty claims against Indivior PLC in the High Court of Justice for the Business and Property Courts of England and Wales, King's Bench Division. The claims made in both the representative and multiparty actions generally allege that Indivior PLC violated the U.K. Financial Services and Markets Act 2000 ("FSMA 2000") by making false or misleading statements or material omissions in public disclosures, including the 2014 Demerger Prospectus, regarding an alleged product-hopping scheme regarding the switch from SUBOXONE Tablets to SUBOXONE Film. Indivior PLC filed an application to strike out the representative action. On December 5, 2023, the High Court handed down a judgment allowing Indivior PLC's application to strike out the representative action. On January 23, 2025, the Court of Appeals affirmed the application to strike out. On June 11, 2025, the UK Supreme Court refused the application for permission to appeal the Court of Appeal's decision. The multiparty actions against Indivior remain pending and on June 25, 2025 those certain shareholders served their "Claim Form" on Indivior PLC related to the multiparty action. The Company has begun its evaluation of the remaining claims, believes it has meritorious defenses, and intends to vigorously defend itself. Given the status and preliminary stage of the litigation, no estimate of possible loss can be made at this time.

**U.S. Shareholder Claims**

A class action lawsuit was filed against Indivior PLC, Mark Crossley (the former CEO of the Company), and Ryan Preblick (the CFO of the Company) on August 2, 2024, alleging violations of certain U.S. federal securities laws, and the lead plaintiff filed an amended complaint on December 5, 2024 which also named Richard Simkin (the former CCO of the Company) as a defendant. The defendants moved to dismiss. On April 22, 2025, the court heard oral argument and granted the motion to dismiss. The court indicated that a formal opinion will follow, and the plaintiffs will have 30 days from the date of the opinion to amend their complaint.

The Company has begun its evaluation of the claims, believes it has meritorious defenses, and intends to vigorously defend itself. Given the status and preliminary stage of the litigation, no estimate of possible loss can be made at this time.

**Opiant Shareholder Claims**

On November 8, 2023, plaintiff James Litten filed a class action complaint in the Delaware Court of Chancery alleging that former officers and directors of Opiant Pharmaceuticals, Inc. ("Opiant") breached fiduciary duties of care, loyalty, and good faith in connection with Indivior PLC's 2022 acquisition of Opiant. The court granted Opiant's motion to dismiss on June 6, 2025. The plaintiff's time to appeal has expired.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

**13. Revision of Previously Issued Financial Statements**

As previously disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, during the first quarter of 2025, the Company identified an error in the methodology used to accrue for Indivior's share of the annual U.S. fee imposed on drug manufacturers (the "Branded Fee"). This resulted in an overstatement of the Branded Fee accrual for the periods presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

The overstatement of the Branded Fee accrual did not materially impact the Company's previously issued financial statements for any of the prior quarters or the annual periods in which they occurred. However, in accordance with Staff Accounting Bulletin No. 108 of the Securities and Exchange Commission, the Company concluded that correcting the cumulative misstatement in the current period would be material to its results of operations for the quarter ended March 31, 2025. Accordingly, the Company has revised, or will revise in future filings as applicable, its previously issued Consolidated Financial Statements as of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 to correct this accrual overstatement. Additionally, the Company has revised, or will revise in future filings as applicable, its quarterly financial data for the three months ended March 31, June 30, September 30, and December 31, 2024. A summary of the corrections to the impacted financial statement line items is presented below. An adjustment to reclassify a portion of inventories as other noncurrent assets as of December 31, 2024 and 2023 has also been reflected below.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

**Consolidated Balance Sheets**

---

| | | | |
|:---|:---|:---|:---|
| | **As reported** | **Adjustment** | **Revised** |
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| Inventories | $178 | $(10) | $167 |
| Current tax receivable | 34 | (1) | 33 |
| **Total current assets** | **839** | **(12)** | **827** |
| Deferred tax assets | 280 | (3) | 277 |
| Other noncurrent assets | 29 | 10 | 39 |
| **Total assets** | $**1319** | $**(4)** | $**1316** |
| Accounts payable and accrued expenses | $232 | $(16) | $216 |
| **Total current liabilities** | **939** | **(16)** | **924** |
| **Total liabilities** | **1668** | **(16)** | **1652** |
| Accumulated deficit | (454) | 12 | (443) |
| Total shareholders' deficit | (348) | 12 | (337) |
| Total liabilities and shareholders' deficit | $**1319** | $**(4)** | $**1316** |
|  | **December 31, 2023** | **December 31, 2023** | **December 31, 2023** |
| Inventories | $135 | $(9) | $126 |
| **Total current assets** | **1266** | **(9)** | **1257** |
| Deferred tax assets | 288 | (2) | 286 |
| Other noncurrent assets | 28 | 9 | 36 |
| **Total assets** | $**1760** | $**(2)** | $**1758** |
| Accounts payable and accrued expenses | $204 | $(10) | $195 |
| **Total current liabilities** | **1290** | **(10)** | **1281** |
| **Total liabilities** | 1951 | (9) | 1942 |
| Accumulated deficit | (295) | 7 | (288) |
| Total shareholders' deficit | (191) | 7 | (184) |
| **Total liabilities and shareholders' deficit** | $**1760** | $**(2)** | $**1758** |

---

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

**Consolidated Statements of Operations**

---

| | | | |
|:---|:---|:---|:---|
| | **As reported** | **Adjustment** | **Revised** |
| | **Year ended December 31, 2024** | **Year ended December 31, 2024** | **Year ended December 31, 2024** |
| Selling, general and administrative expenses | $618 | $(6) | $612 |
| Total operating expenses, net | 925 | (6) | 919 |
| **Operating income** | **32** | **6** | **38** |
| **Income before income taxes** | **14** | **6** | **20** |
| Income tax expense | (11) | (2) | (13) |
| **Net income** | $**2** | $**5** | $**7** |
| **Earnings per Share** |  |  |  |
| Basic | $0.02 | $0.03 | $0.05 |
| Diluted | $0.02 | $0.03 | $0.05 |
|  | **Year ended December 31, 2023** | **Year ended December 31, 2023** | **Year ended December 31, 2023** |
| Selling, general and administrative expenses | $569 | $(4) | $565 |
| Total operating expenses, net | 1076 | (4) | 1072 |
| **Operating loss** | **(156)** | **4** | **(152)** |
| **Loss before income taxes** | **(149)** | **4** | **(145)** |
| Income tax benefit | 20 | (1) | 19 |
| **Net loss** | $**(129)** | $**3** | $**(126)** |
| **Loss per Share** |  |  |  |
| Basic | $(0.94) | $0.02 | $(0.92) |
| Diluted | $(0.94) | $0.02 | $(0.92) |
|  | **Year ended December 31, 2022** | **Year ended December 31, 2022** | **Year ended December 31, 2022** |
| Selling, general and administrative expenses | $469 | $(4) | $466 |
| Total operating expenses, net | 831 | (4) | 827 |
| **Operating loss** | **(81)** | **4** | **(77)** |
| **Loss before income taxes** | **(89)** | **4** | **(86)** |
| Income tax benefit | 44 | (1) | 43 |
| **Net loss** | $**(44)** | $**3** | $**(42)** |
| **Loss per Share** |  |  |  |
| Basic | $(0.32) | $0.02 | $(0.30) |
| Diluted | $(0.32) | $0.02 | $(0.30) |

---

The consolidated statements of comprehensive income (loss) and the consolidated statements of shareholders' deficit were also revised to reflect the net income (loss) noted above for the years ended December 31, 2024, 2023 and 2022.

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

**Consolidated Statements of Cash Flows**

---

| | | | |
|:---|:---|:---|:---|
| | **As reported** | **Adjustment** | **Revised** |
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| Net income | $2 | $5 | $7 |
| Deferred income taxes | 6 | 1 | 7 |
| Change in operating assets and liabilities: |  |  |  |
| &nbsp;&nbsp;Inventories | (45) | 2 | (43) |
| &nbsp;&nbsp;Other current and noncurrent assets | 378 | (1) | 377 |
| &nbsp;&nbsp;Other current and noncurrent liabilities | 14 | (6) | 8 |
| **Net cash provided by operating activities** | $**36** | $**—** | $**36** |
|  | **December 31, 2023** | **December 31, 2023** | **December 31, 2023** |
| Net loss | $(129) | $3 | $(126) |
| Deferred income taxes | (65) | 1 | (64) |
| Change in operating assets and liabilities: |  |  |  |
| &nbsp;&nbsp;Inventories | (15) | 9 | (6) |
| &nbsp;&nbsp;Other current and noncurrent assets | (410) | (9) | (418) |
| &nbsp;&nbsp;Other current and noncurrent liabilities | 114 | (4) | 110 |
| **Net cash used in operating activities** | $**(300)** | $**—** | $**(300)** |
|  | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** |
| Net loss | $(44) | $3 | $(42) |
| Deferred income taxes | (105) | 1 | (104) |
| Change in operating assets and liabilities: |  |  |  |
| &nbsp;&nbsp;Other current and noncurrent liabilities | (97) | (4) | (100) |
| **Net cash used in operating activities** | $**(4)** | $**—** | $**(4)** |

---

------

**Indivior PLC**

**Notes to the Condensed Consolidated Financial Statements**

**(Dollars and shares in millions)**

**(Unaudited)**

Revisions to unaudited selected quarterly financial data presented in our Annual Report on Form 10-K for the year ended December 31, 2024 are summarized as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **As reported** | **Adjustment** | **Revised** |
| | **Three months ended March 31, 2024** | **Three months ended March 31, 2024** | **Three months ended March 31, 2024** |
| Selling, general and administrative expenses | $145 | $(2) | $143 |
| Total operating expenses, net | 172 | (2) | 171 |
| **Operating income** | **73** | **2** | **75** |
| **Income before income taxes** | **71** | **2** | **73** |
| Income tax expense | (11) |  | (11) |
| **Net income** | $**60** | $**1** | $**61** |
|  | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** |
| Selling, general and administrative expenses | $153 | $(2) | $152 |
| Total operating expenses, net | 340 | (2) | 338 |
| **Operating loss** | **(119)** | **2** | **(118)** |
| **Loss before income taxes** | **(122)** | **2** | **(121)** |
| Income tax benefit | 24 |  | 23 |
| **Net loss** | $**(98)** | $**1** | $**(97)** |
|  | **Three months ended September 30, 2024** | **Three months ended September 30, 2024** | **Three months ended September 30, 2024** |
| Selling, general and administrative expenses | $144 | $(2) | $142 |
| Total operating expenses, net | 207 | (2) | 206 |
| **Operating income** | **34** | **2** | **35** |
| **Income before income taxes** | **28** | **2** | **30** |
| Income tax expense | (8) |  | (8) |
| **Net income** | $**21** | $**1** | $**22** |
|  | **Three months ended December 31, 2024** | **Three months ended December 31, 2024** | **Three months ended December 31, 2024** |
| Selling, general and administrative expenses | $177 | $(2) | $175 |
| Total operating expenses, net | 206 | (2) | 205 |
| **Operating income** | **44** | **2** | **46** |
| **Income before income taxes** | **36** | **2** | **38** |
| Income tax expense | (16) |  | (17) |
| **Net income** | $**20** | $**1** | $**21** |

---

**14. Subsequent Events**

Based upon Indivior's desire to consolidate manufacturing locations, on July 31, 2025, Indivior UK Ltd. provided notice of termination for convenience of the Master Development and Supply Agreement, made as of January 1, 2022, as amended by the first amendment dated January 1, 2024, and the second amendment dated January 1, 2025 (collectively, the "Agreement"), between it and Curia Massachusetts, Inc. ("Curia") to Curia. Such termination will take effect on January 31, 2026. Indivior does not expect to incur material termination penalties based upon its continued sourcing of product during the notice period which is expected to reach the contract minimums.

The notice of termination does not affect the Master Development and Supply Agreement effective the August 1, 2023 by and between Curia New Mexico, LLC and Indivior UK Limited.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements included in Part I, Item 1 of this quarterly report on Form 10-Q and with our audited consolidated financial statements, including the accompanying notes, and Management's Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2024. As discussed in *Note 13. Revision of Previously Issued Financial Statements,* the Company revised its previously issued financial statements to correct an accrual overstatement that did not have a material impact for any of the prior quarters or the annual periods in which they occurred. Amounts included in the discussion below for the three and six months ended June 30, 2024 reflect the revisions.

Indivior is a global pharmaceutical company working to help change patients' lives by pioneering life-transforming treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery.

**Operating Results**

**Overview**

For the periods presented, the Company operated as one business segment, which is predominantly the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders, and nalmefene nasal spray for emergency opioid overdose reversal. Substantially all our net revenue was derived from sales of SUBLOCADE and other buprenorphine-based sublingual products (including SUBOXONE Film, SUBOXONE Tablet and SUBUTEX Tablet). SUBLOCADE accounted for 69% and 68% of our net revenue for the three and six months ended June 30, 2025, respectively, and 64% and 64% for the three and six months ended June 30, 2024, respectively. Other buprenorphine-based sublingual products accounted for 27% and 29% of our net revenue for the three and six months ended June 30, 2025, respectively, and 31% and 32% for the three and six months ended June 30, 2024, respectively. In the U.S., SUBOXONE Film had an oral buprenorphine medically assisted treatment (BMAT) average share of 14.4% and 16.3% in the three months ended June 30, 2025 and 2024, respectively, according to data from IQVIA.

**Recent Developments**

For a discussion of recent developments with respect to litigation and tax settlements, see *Note 12. Commitments and Contingencies* and *Note 3. Income Tax*, respectively.

In February 2025, the Company announced the appointment of Joe Ciaffoni as Chief Executive Officer, effective May 2025, and Mark Crossley stepped down as Chief Executive Officer. During the three months ended June 30, 2025, the Company continued to strengthen its executive team through the appointment of Patrick Barry, Chief Commercial Officer and Vanessa Procter, Executive Vice President of Corporate Affairs.

In July 2025, the Company completed cancellation of its London Stock Exchange listing and now trades exclusively on Nasdaq, which aligns to the Company's capital markets footprint and a stronger focus on SUBLOCADE growth in the U.S. Effective June 30, 2025, the Company became a member of the U.S. small-cap Russell 2000® Index and the broad-market Russell 3000® Index.

------

**Results of operations**

**Net revenue**

Net revenue for the three and six months ended June 30, 2025 and 2024 was driven by sales of SUBLOCADE and other buprenorphine-based sublingual products (including SUBOXONE Film and SUBOXONE Tablet).

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| *(in millions)* | **2025** | **2024** | **% Change** | **2025** | **2024** | **% Change** |
| U.S.: |  |  |  |  |  |  |
| &nbsp;&nbsp;SUBLOCADE\* | 195 | 179 | 9% | 359 | 346 | 4% |
| &nbsp;&nbsp;Film/other | 52 | 63 | (18)% | 107 | 126 | (15)% |
| &nbsp;&nbsp;PERSERIS | 8 | 13 | (37)% | 12 | 23 | (49)% |
| Total U.S. | 256 | 255 | —% | 478 | 496 | (4)% |
| Rest of the World | 46 | 44 | 5% | 90 | 87 | 4% |
| Net revenue | $**302** | $**299** | 1% | $**568** | $**583** | (3)% |
| \*Total SUBLOCADE net revenue (U.S. and Rest of the World) | $**209** | $**192** | 9% | $**385** | $**371** | 4% |

---

Total net revenue increased by $3 million, or 1%, and decreased by $15 million, or 3%, in the three and six months ended June 30, 2025, respectively, and U.S. net revenue increased by $1 million and decreased by $18 million, or 4%, in the three and six months ended June 30, 2025, respectively, as compared to the same periods in 2024.

***U.S. net revenue.*** The U.S. is our largest market. Rebates, discounts and returns and other offsets to gross revenues are reflected in net revenue. U.S. net revenue from SUBLOCADE increased by $17 million, or 9%, and $13 million, or 4%, in the three and six months ended June 30, 2025, respectively, as compared to the same periods in 2024, reflecting volume increases and the benefit of changes in estimate related to rebate accruals. U.S. net revenue from other products declined $16 million and $31 million in the three and six months ended June 30, 2025, reflecting the impact of increased competitive activity resulting in lower pricing and market share in the U.S. for SUBOXONE Film and the decline in PERSERIS net revenue following the decision to discontinue commercial sales support in July 2024.

***Rest of the World net revenue.*** In the three and six months ended June 30, 2025, net revenue attributable to Rest of the World increased by $2 million, or 5%, and $3 million, or 4%, respectively, as compared to the same periods in 2024, reflecting positive contributions from newer products (SUBLOCADE / SUBUTEX<sup>®</sup> Prolonged Release and SUBOXONE Film) that were partially offset by ongoing generic erosion of the legacy tablet business. In the three and six months ended June 30, 2025, SUBLOCADE / SUBUTEX Prolonged Release net revenue in Rest of World was $14 million and $27 million, respectively, as compared to $13 million and $25 million for the same periods in 2024, respectively. We expect incremental growth from new products to continue to at least offset the decline in the legacy tablet business in 2025.

Estimates, assumptions and judgements applied to determine the provision for rebates, discounts and returns are set out in *"Item 8. Financial Statements—Note 2. Summary of Significant Accounting Policies"* in our Annual Report on Form 10-K for the year ended December 31, 2024.

------

The following table provides a summary of activities with respect to accrued rebates and product returns and prompt pay discounts for the six months ended June 30, 2025:

---

| | | |
|:---|:---|:---|
| **Accrued rebates and product returns and prompt pay discounts** *(in millions)* | **June 30, 2025** | **June 30, 2024** |
| **Opening balance at January 1**  | $**565** | $**535** |
| Accruals related to sales made in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period | 758 | 761 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior period | (45) | (23) |
| Payments and credits | (566) | (681) |
| **Closing balance at end of period**  | $**712** | $**592** |

---

Accrued rebates and product returns include chargebacks as these are paid by Indivior. Prompt pay discounts are recorded as offsets to accounts receivable as of June 30, 2025. Accrued rebates and product returns and prompt pay discounts increased to $712 million as of June 30, 2025 from $592 million as of June 30, 2024, primarily as a result of the timing of payment of government rebates due to late receipt and processing of invoices. The processing time also favorably impacted our cash balance at June 30, 2025. We expect rebate payments to increase in the third quarter and the accrual balance to revert to levels more in line with those at the 2024 year-end.

**Expenses**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| *(in millions)* | **2025** | **2024** | **% Change** | **2025** | **2024** | **% Change** |
| Cost of sales | $52 | $79 | (34)% | $96 | $117 | (18)% |
| Gross margin | 83% | 74% | **9%** | 83% | 80% | **3%** |
| Operating expenses: |  |  |  |  |  |  |
| Selling, general and administrative | 158 | 152 | 4% | 290 | 295 | (2)% |
| Research and development | 21 | 26 | (20)% | 43 | 54 | (20)% |
| Litigation settlement expenses<sup>(1)</sup> |  | 160 | NM | 1 | 160 | NM |
| &nbsp;&nbsp;Total operating expenses | 178 | 338 | (47)% | 334 | 509 | (34)% |
| Net interest expense | 10 | 3 | 237% | 17 | 5 | 254% |
| Income tax expense (benefit) | $44 | $(23) | (289)% | $56 | $(12) | (569)% |

---

________________

(1)See *Item 1. Financial Statements—Note 7. Accrued Litigation Settlement Expenses.*

***Cost of sales***. Cost of sales decreased by $27 million, or 34%, and $21 million, or 18%, in the three and six months ended June 30, 2025, respectively, as compared to the same periods in 2024. The decrease primarily reflects costs incurred in the 2024 periods of $41 million related to the discontinuation of marketing and promotion of PERSERIS, partially offset by a SUBLOCADE inventory write-down of $10 million in the three months ended June 30, 2025, for finished goods expected to approach expiration prior to sale.

***Gross margin***, which we define as gross profit divided by net revenue, was 83% and 83% in the three and six months ended June 30, 2025, respectively, as compared to 74% and 80% in the same periods in 2024, respectively. The increase primarily reflects costs of $41 million in the 2024 periods related to the discontinuation of marketing and promotion of PERSERIS. We expect gross margin to continue in the low-to-mid 80 percent range for the remainder of 2025.

***Selling, general and administrative expenses***. Selling, general and administrative expenses increased by $6 million, or 4%, and decreased by $5 million, or 2%, in the three and six months ended

------

June 30, 2025, respectively, as compared to the same periods in 2024. Higher expenses in the three months ended June 30, 2025 reflect a $14 million increase in marketing, primarily for U.S. SUBLOCADE, partly offset by lower general and administrative expenses driven by streamlining actions taken in 2024, including narrowing the Company's commercial focus on OUD treatments and discontinuing marketing and promotion of PERSERIS. For the six months ended June 30, 2025, excluding the benefit of a one-time change in estimate related to Indivior's share of the Branded Fee, lower selling, general and administrative expenses benefited from the streamlining actions described above.

***Research and development expenses***. Research and development expenses decreased by $5 million, or 20%, and $11 million, or 20%, in the three and six months ended June 30, 2025, respectively, as compared to the same periods in 2024, primarily reflecting the Company's actions to refocus its development pipeline on the Phase 2 OUD assets (INDV-2000 and INDV-6001). We expect research and development expenses to continue to track below 2024 levels throughout 2025.

***Net interest expense***. Net interest expense was $10 million and $17 million in the three and six months ended June 30, 2025, respectively, as compared to net interest expense of $3 million and $5 million in the three and six months ended June 30, 2024. Higher net interest expense in the 2025 periods includes $4 million related to an expected U.K. tax settlement and reflected interest expense on the larger amount borrowed under the Company's new borrowing arrangement secured in late 2024 as well as a decrease in interest income on lower investment balances.

***Income tax expense (benefit)***. Income tax expense of $44 million and $56 million in the three and six months ended June 30, 2025, respectively, as compared to income tax benefit of $23 million and $12 million in the three and six months ended June 30, 2024, resulted in an effective tax rate of 71% and 46% in the three and six months ended June 30, 2025, respectively. Both periods benefited from intragroup financing transactions; however, in the three and six months ended June 30, 2025 this benefit was fully offset by a tax reserve for an HMRC settlement which became probable during the quarter and a U.K. global minimum top-up tax. The HMRC settlement relates to aspects of prior years' intercompany financing arrangements and is not expected to impact our future tax rates. In the three and six months ended June 30, 2024, the Company recognized a share-compensation excess tax benefit.

In July 2025, legislation commonly referred to as the One Big Beautiful Bill Act was enacted, introducing amendments to U.S. tax laws with various effective dates from 2025 to 2027, primarily impacting companies domiciled in the U.S. The Company is evaluating the implications of these tax law changes and does not currently anticipate significant impacts.

*Known Risks and Uncertainties*

Many risks and uncertainties are discussed in the Risk Factors section in <u>[Item 1A](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001625297/000162529725000016/indv-20241231.htm#i0dee1f47aaf64e24a87b163e8539f55e)</u> of our Annual Report on Form 10-K filed March 3, 2025 and Quarterly Report on Form 10-Q filed May 1, 2025, which we incorporate by reference herein. In addition to that discussion, we note continuing uncertainty regarding U.S. federal government tariffs, and changes thereto, may impact our revenues. Also, we note that approximately 85% of our revenues are derived from sales within in the U.S. and all of our key products, chiefly SUBLOCADE, OPVEE and SUBOXONE Film are manufactured primarily in the U.S. However, it remains unclear whether the tariffs will apply to raw materials and work in process which are part of our pharmaceutical manufacturing process, and whether tariffs apply to intellectual property owned by our U.K. subsidiary and licensed to other members of our group, including our U.S. subsidiary. Additionally, we do not know whether other countries will impose retaliatory tariffs that may impact the sale of our products and our margins outside of the United States.

*Regulatory Uncertainties*

The budget reconciliation legislation of 2025, One Big Beautiful Bill Act (the "OBBBA"), was signed into law in July 2025. The OBBBA contains a variety of provisions that could impact our business and results of operations, and States, Medicaid plans and providers may respond to policy and sector change by limiting patient eligibility and care delivery in ways that affect access to treatment for OUD, including:

------

innovative or higher cost treatments could be deprioritized or removed from states formularies, changes to Medicaid funding and eligibility rules, including more frequent redeterminations for beneficiaries receiving coverage through Medicaid, and a requirement for adults made eligible under the ACA to meet work or community engagement standards (from which persons with substance use disorder are exempt); changes to federal requirements regarding Medicaid state directed payments and provider taxes; and establishes a new rural health transformation program, among other provisions. Additional federal and state guidance is expected to be issued in order to implement these OBBBA provisions, most of which have effective dates in 2027 and 2028. Additionally, in June 2025, CMS finalized the Marketplace Integrity and Affordability Regulation which modifies the ACA exchange open enrollment periods and eligibility for premium tax credits among other requirements.

**Liquidity and Capital Resources**

**Overview**

The Company's financial condition is summarized as follows:

---

| | | |
|:---|:---|:---|
| *(In millions)* | **June 30, 2025** | **December 31, 2024** |
| **Financial assets:** |  |  |
| Cash and cash equivalents | $510 | $319 |
| Investments - short-term |  | 1 |
| Investments - long-term | 27 | 27 |
| **Total cash and investments** | $**538** | $**347** |
| **Borrowings:** |  |  |
| Short-term borrowings | $18 | $18 |
| Long-term borrowings | $308 | $315 |

---

**Cash flows**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|<br>*(in millions)* | **2025** | **2024** |
| **Net cash provided by (used in):** |  |  |
| Operating activities | $233 | $51 |
| Investing activities | (22) | 26 |
| Financing activities | $(22) | $(91) |

---

*Operating activities*

Net cash provided by operating activities was $233 million and $51 million during the six months ended June 30, 2025 and 2024, respectively, an increase of net cash provided of $182 million. Net cash provided by operating activities in the six months ended June 30, 2025 reflected higher cash generated from operations and benefited from timing of receipt and processing of approximately $120 million in government rebate invoices, most of which were paid in July 2025.

Both periods reflected scheduled payment of litigation settlements. Refer to *Item 1. Financial Statements—Note 7. Accrued Litigation Settlement Expenses* for additional details.

*Investing activities*

Net cash used in investing activities was $22 million and net cash provided by investing activities was $26 million in the six months ended June 30, 2025 and 2024, respectively, a decrease of net cash

------

provided of $49 million. The change reflects lower proceeds from maturities of investments, partly offset by an increase in capital expenditures.

We expect approximately $50 million to $70 million of capital expenditures for the full year 2025, primarily to finalize the SUBLOCADE suite at the Raleigh Manufacturing Facility*,* after which time we expect capital expenditures to revert to levels more in line with Indivior's history.

The Company expects to continue evaluating investment opportunities in commercial and development stage assets, with no current commitments.

*Financing activities*

Net cash used in financing activities decreased by $70 million in the six months ended June 30, 2025. Net cash used in financing activities in the current period primarily reflects lower cash outflows for shares repurchased and canceled and the settlement of tax on equity awards, partially offset by higher scheduled amortization payments under the Company's new debt facility. In 2025, the annual scheduled amortization is 5% of the original gross loan balance.

*Current Liabilities*

Our current liabilities exceed our current assets by $106 million and total liabilities exceed our total assets by $257 million. The Company sustains negative working capital because of the timing of rebate payments relative to the collection of accounts receivable.

**Capital Resources**

The Company believes its existing cash and cash equivalents and investments together with cash generated from operations and debt will enable its anticipated cash needs to be met, including working capital, capital expenditures, litigation settlement payments, milestone payments, income taxes, debt repayments and other funding requirements, for at least the twelve-month period following the issuance of this Form 10-Q. The Company will need to sustain sales volume performance with no material change in the timing of its collections and rebate payments to maintain necessary liquidity in the near term and to meet our obligations in the long term. The Company is also subject to contingent liabilities as described in *Item 1. Financial Statements—Note 12. Commitments and Contingencies*.

**Capital Expenditures**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|<br>*(in millions)* | **2025** | **2024** |
| Purchases of property, plant and equipment | $22 | $6 |

---

The Company's capital expenditures primarily reflect investments in the expansion of the Raleigh Manufacturing Facility.

**Contractual Obligations**

Our contractual obligations as of June 30, 2025, which require material cash requirements in the future, consist of debt repayments, litigation settlements, commercial commitments related to contract manufacturing and supply of materials, capital expenditures, lease and employee-related obligations, contractual milestones and contingent value rights. Refer to *"Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations"* of our Annual Report on Form 10-K for the year ended December 31, 2024. As of June 30, 2025 no material changes to our contractual obligations have occurred beyond the ordinary course of business.

------

**Research and Development Expenses, Patents and Licenses, etc.**

No material changes have occurred from the information provided in *Item 1. Business—Research and Development*," "*Item 1. Business—Intellectual Property*," and "*Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations—Operating Results"* of the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

INDV-2000 (Selective OREXIN-1 Receptor Antagonist): For the Phase 2 proof of concept study, the first subject first visit was achieved on June 10, 2024. The estimated last subject last visit is currently expected in late 2025.

**Trend Information**

For a discussion of trend information, see "*Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations—Operating Results.*"

**Critical Accounting Estimates**

Our significant accounting policies, which include management's estimates and judgments, are included in *"Item 1. Financial Statements - Note 2 Summary of Significant Accounting Policies"* of our Annual Report on Form 10-K for the year ended December 31, 2024. No significant changes to our accounting policies occurred during the quarter ended June 30, 2025. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates is included in the Critical Accounting Estimates section of *"Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations"* of our Annual Report on Form 10-K for the year ended December 31, 2024.

**Recently Issued Accounting Standards**

For a discussion of recently issued accounting standards, refer to *Item 1. Financial Statements - Note 1. Business Overview, Basis of Presentation, and Recently Issued Accounting Standards*.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

No material changes in market risk have occurred from the information provided in *Item 7A. Quantitative and Qualitative Disclosures About Market Risk* in the Company's Annual Report on Form 10-K.

**Item 4. Controls and Procedures.**

**Disclosure Controls and Procedures** 

Under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures as defined in Rules 13a-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that Indivior PLC's disclosure controls and procedures were effective as of June 30, 2025.

**Changes in Internal Control over Financial Reporting**

There was no change in the Company's internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f), "ICFR") that occurred during the quarter ended June 30, 2025 that has materially affected, or is likely to materially affect, the Company's ICFR.

------

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings.**

The descriptions of our litigation and regulatory matters, and other matters, contained in *Item 1. Financial Statements—Unaudited Condensed Consolidated Financial Statements - Note 12. Commitments and Contingencies* to our financial statements are incorporated herein by reference.

**Item 1A. Risk Factors.**

The Company omits its existing risk factor "*Our ordinary shares are listed to trade on more than one stock exchange, and this may result in price variations.*"

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Shares of common stock repurchased by the Company during the quarter ended June 30, 2025, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number of shares purchased** | **Average price paid per share**<sup>(1)</sup> | **Total number of shares purchased as part of publicly announced plans or programs** | **Maximum number of shares that may yet be purchased under the plans or programs**<sup>(2)</sup> |
| Apr. 1 to Apr. 30 | 2484<sup>(3)</sup> | $9.53 |  | 12465585 |
| May 1 to May 31 | 2669<sup>(3)</sup> | $12.41 |  | 12465585 |
| June 1 to June 30 | 9894<sup>(3)</sup> | $13.86 |  | 12465585 |

---

(1)The average price paid per share on the London Stock Exchange was translated to U.S. dollars using the average exchange rate for the noted periods as follows: Apr. 1 to Apr. 30 (GB£1:U.S.$1.313643), May 1 to May 31 (GB£1:U.S.$1.3364), and Jun. 1 to Jun. 30 (GB£1:U.S.$1.355268).

(2)Reflects balance of shares that might be repurchased under the authority granted by shareholders at the AGM held May 8, 2025. No Board authority to repurchase shares existed after January 31, 2025.

(3)Reflects shares netted to pay applicable withholding taxes on the release of awards under the 2020 LTIP, 2022 LTIP, and 2023 DBP.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

(a)(i) Given changes in holdings of voting securities held by U.S. residents, Indivior has determined that as of June 30, 2025, it no longer qualifies as a "foreign private issuer" under applicable U.S. securities laws and, beginning January 1, 2026, will become subject to the rules and regulations of the SEC applicable to U.S. domestic issuers including, among other things, the rules governing solicitation of proxies and the furnishing and content of proxy statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Separately, following discussions, and based upon Indivior's desire to consolidate manufacturing locations, on July 31, 2025, Indivior UK Limited provided notice of termination for convenience of the Master Development and Supply Agreement, made as of January 1, 2022, as amended by the first amendment dated January 1, 2024, and the second amendment dated January 1, 2025 (collectively, the "Agreement"), between it and Curia Massachusetts, Inc. ("Curia") to Curia. Such termination will take

------

effect on January 31, 2026. Indivior does not expect to incur material termination penalties based upon its continued sourcing of product during the notice period which is expected to reach the contract minimums.

The notice of termination does not affect the Master Development and Supply Agreement effective the August 1, 2023 by and between Curia New Mexico, LLC and Indivior UK Limited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) On May 8, 2025, Indivior's shareholders approved amendments to the Indivior Articles effective upon the conclusion of the 2025 Annual General Meeting. Among other things, the amended Indivior Articles include additional and revised provisions regarding proposals by Indivior Shareholders to bring a resolution before a general meeting related to the nomination of candidates for election as directors.

Indivior Shareholders who wish to present a proposal <u>in accordance with Exchange Act Rule 14a-8</u> for inclusion in Indivior's proxy materials to be distributed in connection with Indivior's 2026 Indivior AGM must submit their proposal in accordance with such rule's requirements, including ensuring it is received by Indivior's Company Secretary at the address set forth below no later than the close of business on November 27, 2025. Under such rule, if the date of the 2026 Indivior AGM is more than 30 days before or after May 8, 2026, then the deadline to timely receive such material will be a reasonable time before Indivior begins to print and send proxy materials relating to the 2026 Indivior AGM. Failure to deliver a proposal in accordance with this procedure may result in it not being deemed timely received.

The Indivior Articles require that Indivior Shareholders who intend to propose, <u>outside of Exchange Act Rule 14a-8</u>, any resolution, including nominating candidates for election as directors, at the 2026 Indivior AGM must provide notice of such proposals in writing to Indivior's Company Secretary at the address set forth below no earlier than the close of business on January 8, 2026, and no later than the close of business on February 7, 2026. However, if the date of the 2026 Indivior AGM is more than 30 days before or more than 60 days after May 8, 2026, such shareholder's notice must be delivered in writing not earlier than the close of business on the 120<sup>th</sup> day prior to the date of the 2026 Indivior AGM and not later than the close of business on the later of: (A) the 90th day prior to the date of the 2026 Indivior AGM or (B) the 10<sup>th</sup> day following the day on which public announcement of the date of the 2026 Indivior AGM is first made by Indivior. The notice must set forth the information required by the Indivior Articles, including, if the proposal involves a director nomination, prescribed information about the candidate and about the shareholder proposing the candidate. In addition to satisfying the requirements of the Indivior Articles, to comply with the SEC's universal proxy rules, Indivior Shareholders who intend to solicit proxies in support of director nominees, other than Indivior's nominees, must provide a notice that complies with the requirements of Exchange Act Rule 14a-19 no later than March 9, 2026, or if the date of the 2026 Indivior AGM is more than 30 days before or after May 8, 2026, then such notice must be provided by the later of 60 days prior to the date of the 2026 Indivior AGM or the 10<sup>th</sup> day following the day on which public announcement of the date of the 2026 Indivior AGM is first made by Indivior.

Proposals should be sent to Indivior's Company Secretary in writing to Indivior PLC, Attn: Company Secretary, 234 Bath Road, Slough, Berkshire, U.K., SL1 4EE. To be included in Indivior's proxy materials, the proposal must comply with the requirements as to form and substance established by the SEC and the Indivior Articles and must be a proper subject for shareholder action under English law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) As previously disclosed in a Current Report on Form 8-K filed June 24, 2025, effective June 20, 2025, each of Keith Humphreys, Daniel Ninivaggi, Barbara Ryan, Mark Stejbach, and David Wheadon, being the U.S. based non-executive directors of the Board of Directors (collectively, the "NEDs"), entered into a Purchase Plan with JP Morgan Securities LLC ("JPMS") pursuant to which JPMS will make quarterly purchases of the Company's securities on behalf of each NED (the "Purchase Plan"). The NEDs intend for the Purchase Plan to qualify under SEC Rule 10b5-1. The Purchase Plan instructs JPMS to make purchases commencing on October 1, 2025 through and including July 6, 2026. The NEDs have instructed JPMS to make quarterly purchases of the Company's Ordinary Shares equal to approximately 70% (80% in the case of Dr. Wheadon) of their after-tax, base retainer fee for service as a director. The number of shares to be purchased cannot be determined at this time and will depend upon future market prices but is expected to consist of a minimum of $680,000 and a maximum of $715,000 worth of

------

Company shares (aggregate purchase price, before deduction of standard and customary commissions and fees).

**Item 6. Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) See Exhibit Index below

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1# | <u>[Articles of Association](ex31articlesofassociationa.htm)</u> of Indivior PLC (adopted at the 2025 Annual General Meeting of Indivior PLC). |
| 4.1 | <u>[Contingent Value Rights Agreement dated as of March 2, 2023 between Indivior, Inc., Computershare Inc. and Computershare Trust Company, N.A.](https://www.sec.gov/Archives/edgar/data/1625297/000162828023019402/exhibit421-20f.htm)</u> (incorporated by reference to Exhibit 4.21 to registration statement on Form 20-F filed May 23, 2023). |
| 10.1.1\*†† | <u>[Non-Executive Director Purchase Plan](https://www.sec.gov/Archives/edgar/data/1625297/000162529725000042/a99210b5-1purchaseplanneds.htm)</u> among Keith Humphreys, Daniel Ninivaggi, Barbara Ryan, Mark Stejbach, David Wheadon, and J.P. Morgan Securities LLC effective June 20, 2025 (incorporated by reference to Exhibit 99.2 to Current Report on Form 8-K filed June 24, 2025). |
| 10.1.2\* | <u>[Letter Agreement](https://www.sec.gov/Archives/edgar/data/1625297/000162529725000042/a993sideletter.htm)</u> among Indivior PLC and Keith Humphreys, Daniel Ninivaggi, Barbara Ryan, Mark Stejbach, and David Wheadon, made as of June 20, 2025 (incorporated by reference to Exhibit 99.3 to Current Report on Form 8-K filed June 24, 2025). |
| 10.2\*# | <u>[Form of Non-Executive Director Letter of Appointment](ex102formofnon-executivedi.htm)</u>. |
| 10.3\*# | <u>[Form of Non-Executive Director Deed of Indemnity](ex103formofnon-executivedi.htm)</u>. |
| 31.1# | <u>[Certification of Chief Executive Officer](ex311ceosoxcert2q2025.htm)</u> under Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2# | <u>[Certification of Chief Financial Officer](ex312cfosoxcert2q2025.htm)</u> under Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1† | <u>[Certification of Chief Executive Officer](ex321ceosoxcert2q2025.htm)</u> under Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2† | <u>[Certification of Chief Financial Officer](ex322cfosoxcert2q2025.htm)</u> under Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.1# | Inline Interactive Data File |
| 101.INS# | Inline XBRL Instance Document—this instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document |
| 101.SCH# | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL# | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF# | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB# | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE# | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104# | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

__________________

\*Management Contract

#Filed herewith

†&nbsp;&nbsp;&nbsp;&nbsp;Furnished herewith

†† Certain information has been redacted from this exhibit in reliance on Item 601(b)(10)(iv) of Regulation S-K. If requested by the Commission or its staff, the registrant agrees to promptly provide on a supplemental basis an unredacted copy of the exhibit and its materiality and privacy or confidentiality analyses.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INDIVIOR PLC (Registrant)

<u>By: /s/ Ryan Preblick</u> 

Ryan Preblick, Chief Financial Officer

(Principal Financial Officer)

July 31, 2025

## Exhibit 3.1

**09237894**

**<u>Exhibit 3.1</u>**

ARTICLES OF ASSOCIATION

of

INDIVIOR PLC

Public Limited Company (09237894)

(Articles adopted by special resolution on 30 October 2014 and amended by special resolution on 23 December 2014, 30 September 2022, 4 May 2023 and 8 May 2025)

&nbsp;&nbsp;&nbsp;&nbsp;

------

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [GLOSSARY](#ia3cd7fee1a79434f900cac5527053e79) | [55](#ia3cd7fee1a79434f900cac5527053e79) |

---

&nbsp;&nbsp;&nbsp;&nbsp;

------

**1. Exclusion of Model Articles**

The articles prescribed in any legislation relating to companies do not apply as the articles of the company.

**2. Definitions**

(A)The following table gives the meaning of certain words and expressions as they are used in these articles. However, the meaning given in the table does not apply if it is not consistent with the context in which a word or expression appears. At the end of these articles there is a Glossary which explains various words and expressions which appear in the text. The Glossary also explains some of the words and expressions used in the memorandum. The Glossary is not part of the memorandum or articles and does not affect their meaning.

---

| | |
|:---|:---|
| "address" | includes a number or address used for sending or receiving documents or information by electronic means; |
| "Affiliate Shareholder" | means any shareholder which is considered to be an affiliate of the company for the purposes of United States federal securities laws; |
| "amount" (of a share) | means the nominal amount of a share; |
| "these articles" | means these articles of association, including any changes made to them, and the expression "this article" refers to a particular article in these articles of association; |
| "auditors" | means the auditor of the company and, where two or more people are appointed to act jointly, any one of them; |
| "Bank of England base rate" | means the base lending rate most recently set by the Monetary Policy Committee of the Bank of England in connection with its responsibilities under Part 2 of the Bank of England Act 1998; |
| "certificated share" | means a share which is not a CREST share and is normally held in certificated form; |
| "chair" | means the chair of the board of directors; |
| "clear days"<br>"Companies Act" | in relation to the period of a notice means that period excluding the day when the notice is served or deemed to be served and the day for which it is given or on which it is to take effect;<br>means the Companies Act 2006, as amended from time to time; |
| "CREST" | means the electronic settlement system for securities traded on a recognised investment exchange and owned by Euroclear UK & International Limited, or any similar system; |

---

&nbsp;&nbsp;&nbsp;&nbsp;

------

---

| | |
|:---|:---|
| "CREST share" | means a share which is noted on the shareholders' register as being held through CREST in uncertificated form; |
| "Determination Date" | means the date on which the company determines that it does not qualify as a "foreign private issuer" as defined in Exchange Act Rule 3b-4(c); |
| "directors" | means the executive and non-executive directors of the company who make up its board of directors (and "director" means any one of them) or, where applicable, the directors present at a meeting of the directors at which a quorum is present; |
| "DTC" | means the Depository Trust Company; |
| "DTC Depositary"  | means any depositary, custodian, nominee or similar entity that holds legal title to the shares in the capital of the company for DTC, including Cede & Co.;  |
| "electronic facility" | means a device, system, procedure, method or facility providing an electronic means of attendance at or participation in (or both attendance at and participation in) a general meeting determined by the board pursuant to <u>Article 49</u>; |
| "Exchange Act" | means the U.S. Securities Exchange Act of 1934, as amended from time to time; |
| "holder" | in relation to any shares means the person whose name is entered in the register as the holder of those shares; |
| "legislation" | means every statute (and any orders, regulations or other subordinate legislation made under it) applying to the company; |
| "general meeting" | means a general meeting of the company convened and held in any manner permitted by these articles, including without limitation a general meeting of the company at which all or some persons entitled to be present attend and participate by means of electronic facility or facilities, and such persons shall be deemed to be present at that general meeting for all purposes of the Companies Act and the articles and attend and participate, attending and participating and attendance and participation shall be construed accordingly; |
| "the office" | means the company's registered office; |
| "ordinary shareholder" | means a holder of ordinary shares; |

---

&nbsp;&nbsp;&nbsp;&nbsp;

------

---

| | |
|:---|:---|
| "ordinary shares" | means the company's ordinary shares; |
| "paid up" | means paid up or treated (credited) as paid up; |
| "pay" | includes any kind of reward or payment for services; |
| "register" | means the company's register of shareholders and, at any time when the company has shares in issue which are CREST shares, means the Operator register of members (maintained by CREST) and the issuer register of members (maintained by the company); |
| "seal" | means any common or official seal that the company may be permitted to have under the legislation; |
| "secretary" | means the secretary, or (if there are joint secretaries) any one of the joint secretaries, of the company and includes an assistant or deputy secretary and any person appointed by the directors to perform any of the duties of the secretary; |
| "shareholder" | means a holder of the company's shares; |
| "uncertificated securities rules" | means any provision in the legislation which relates to CREST shares or to the transfer of CREST shares or how the ownership of CREST shares is evidenced; and |
| "United Kingdom" | means Great Britain and Northern Ireland. |

---

(B)References in these articles to a document being "signed" or to "signature" include references to its being executed under hand or under seal or by any other method and, in the case of a communication in electronic form, such references are to its being authenticated as specified by the legislation.

(C)References in these articles to "writing" and to any form of "written" communication include references to any method of representing or reproducing words in a legible and non-transitory form whether sent or supplied in electronic form or otherwise.

(D)Any words or expressions defined in the legislation in force when these articles or any part of these articles are adopted will (if not inconsistent with the subject or context in which they appear) have the same meaning in these articles or that part save the word "company" includes any body corporate.

(E)References to a meeting will not be taken as requiring more than one person to be present if any quorum requirement can be satisfied by one person.

(F)Headings in these articles are only included for convenience. They do not affect the meaning of these articles.

(G)Where these articles refer to a person who is entitled to a share by law, this means a person who has been noted in the register as being entitled to a share as a result of the death or

&nbsp;&nbsp;&nbsp;&nbsp;

------

bankruptcy of a shareholder or some other event which gives rise to the transmission of the share by operation of law.

(H)Nothing in these articles shall preclude the holding and conducting of a meeting in such a way that persons who are not present together at the same physical location may by electronic means attend and speak and vote at it.

**3. Limited Liability**

The liability of the company's members is limited to any unpaid amount on the shares in the company held by them.

**4. Change of Name**

The company may change its name by resolution of the directors.

**5. Rights Attached to Shares**

The company can issue shares with any rights or restrictions attached to them as long as this is not restricted by any rights attached to existing shares. These rights or restrictions can be decided either by an ordinary resolution passed by the shareholders or by the directors as long as there is no conflict with any resolution passed by the shareholders. These rights and restrictions will apply to the relevant shares as if they were set out in these articles.

**6. Redeemable Shares**

Subject to any rights attached to existing shares, the company can issue shares which can be redeemed. This can include shares which can be redeemed if the holders want to do so, as well as shares which the company can insist on redeeming. The directors can decide on the terms and conditions and the manner of redemption of any redeemable share. These terms and conditions will apply to the relevant shares as if they were set out in these articles.

**7. Variation of Rights**

(A)If the legislation allows this, the rights attached to any class of shares can be changed if this is approved either in writing by shareholders holding at least three quarters of the issued shares of that class by amount (excluding any shares of that class held as treasury shares) or by a special resolution passed at a separate general meeting of the holders of the relevant class of shares. This is called a "class meeting".

(B)All the articles relating to general meetings will apply to any such class meeting, with any necessary changes. The following changes will also apply:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)a quorum will be present if at least two shareholders who are entitled to vote are present in person (including by means of electronic facility or facilities) or by proxy (including by means of electronic facility or facilities) who own at least one third in amount of the issued shares of the class (excluding any shares of that class held as treasury shares);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)any shareholder who is present in person (including by means of electronic facility or facilities) or by proxy (including by means of electronic facility or facilities) and entitled to vote can demand a poll; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)at an adjourned class meeting, one person entitled to vote and who holds shares of the class, or his proxy, will be a quorum.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(C)The provisions of this article will apply to any change of rights of shares forming part of a class. Each part of the class which is being treated differently is treated as a separate class in applying this article.

**8. Matters not constituting Variation of Rights**

If new shares are created or issued which rank equally with any other existing shares, or if the company purchases or redeems any of its own shares, the rights of the existing shares will not be regarded as changed or abrogated unless the terms of the existing shares expressly say otherwise.

**9. Shares**

The directors can decide how to deal with any shares in the company. They can, for instance, offer the shares for sale, reclassify them, grant options to acquire them, allot them or dispose of the shares in any other way. The directors are free to decide who they deal with, when they deal with the shares and the terms on which they deal with the shares. However, in making their decision they must take account of:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the provisions of the legislation relating to authority, pre-emption rights and other matters;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the provisions of these articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)any resolution passed by the shareholders; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)any rights attached to existing shares.

**10. Payment of Commission**

In connection with any share issue or any sale of treasury shares for cash, the company can use all the powers given by the legislation to pay commission or brokerage. The company can pay the commission in cash or by allotting fully or partly-paid shares or other securities or by a combination of both.

**11. Trusts Not Recognised**

(A)The company will only be affected by, or recognise, a current and absolute right to whole shares. The fact that any share, or any part of a share, may not be owned outright by the registered owner (for example, where a share is held by one person as a nominee or otherwise as a trustee for another person) is not of any concern to the company. This applies even if the company knows about the ownership of the share.

(B)The only exceptions to this are where the rights of the kind described are expressly given by these articles or are of a kind which the company has a legal duty to recognise.

**12. Suspension of Rights Where Non-Disclosure of Interest** 

(A)The company can under the legislation send out notices to those it knows or has reasonable cause to believe have an interest in its shares. In the notice, the company will ask for details of those who have an interest and the extent of their interest in a particular holding of shares. In these articles this notice is referred to as a "statutory notice" and the holding of shares in respect of which a person fails to give the information requested by a statutory notice or makes a false or inadequate statement as referred to in <u>Article 12(B)</u> are referred to as the "identified shares".

&nbsp;&nbsp;&nbsp;&nbsp;

------

(B)When a person receives a statutory notice, he has 14 days to comply with it. If he does not do so or if he makes a statement in response to the notice which is false or inadequate in some important way, the company can decide to restrict the rights relating to the identified shares and send out a further notice to the holder, known as a restriction notice. The restriction notice will take effect when it is delivered. The restriction notice will state that the identified shares no longer give the shareholder any right to attend or vote either personally or by proxy at a general meeting or to exercise any other right in relation to general meetings.

(C)Where the identified shares make up 0.25 per cent. or more (in amount or in number) of the existing shares of a class (calculated exclusive of any shares of that class held as treasury shares) at the date of delivery of the restriction notice, the restriction notice can also contain the following further restrictions:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the directors can withhold any dividend or part of a dividend (including scrip dividend) or other money which would otherwise be payable in respect of the identified shares without any liability to pay interest when such money is finally paid to the shareholder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the directors can refuse to register a transfer of any of the identified shares which are certificated shares unless the directors are satisfied that they have been sold outright to an independent third party. The independent third party must not be connected with the shareholder or with any person appearing to be interested in the shares. Any sale through a recognised investment exchange or any other stock exchange outside the United Kingdom or by way of acceptance of a takeover offer will be treated as an outright sale to an independent third party. For this purpose, any associate (as that term is defined in section 435 of the Insolvency Act 1986) is included in the class of persons who are connected with the shareholder or any person appearing to be interested in the shares. In order to enforce the restriction in this sub-paragraph, the directors can give notice to the relevant shareholder requiring him to change identified shares which are CREST shares to certificated shares by the time given in the notice and to keep them in certificated form for as long as the directors require. The notice can also say that the relevant shareholder may not change any identified shares which are certificated shares to CREST shares. If the shareholder does not comply with the notice, the directors can authorise any person to instruct the Operator to change any identified shares which are CREST shares to certificated shares in the name and on behalf of the relevant shareholder.

(D)Once a restriction notice has been given, the directors are free to cancel it or exclude any shares from it at any time they think fit. In addition, they must cancel the restriction notice within seven days of being satisfied that all information requested in the statutory notice has been given. Also, where any of the identified shares are sold and the directors are satisfied that they were sold outright to an independent third party, they must cancel the restriction notice within seven days of receipt of notification of the sale. If a restriction notice is cancelled or ceases to have effect in relation to any shares, any moneys relating to those shares which were withheld will be paid to the person who would have been entitled to them or as he directs.

(E)The restriction notice will apply to any further shares issued in right of the identified shares. The directors can also make the restrictions in the restriction notice apply to any right to an allotment of further shares associated with the identified shares.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(F)If a shareholder receives a restriction notice, he can ask the company for a written explanation of why the notice was given, or why it has not been cancelled. The company must respond within 14 days of receiving the request.

(G)If the company gives a statutory notice to a person it has reasonable cause to believe has an interest in any of its shares, it will also give a copy at the same time to the person who holds the shares. If the company does not do so or the holder does not receive the copy, this will not invalidate the statutory notice.

(H)This article does not restrict in any way the provisions of the legislation which apply to failures to comply with notices under the legislation.

(I)For the purposes of this <u>Article 12</u>:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)where any person appearing to be interested in identified shares has been served with a statutory notice and such identified shares are held by a DTC Depositary, the provisions of this <u>Article 12</u> shall be deemed to apply only to those identified shares held by the DTC Depositary in which such person appears to be interested and not (so far as that person's apparent interest is concerned) to any other shares held by the DTC Depositary in which such person does not have an interest; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)where the shareholder on whom a statutory notice has been served is a DTC Depositary, the obligations of the DTC Depositary shall be limited to disclosing to the company such information relating to any person appearing to be interested in the shares held by it as has been recorded by the DTC Depositary and the provision of such information shall be at the company's cost.

**13. Uncertificated Shares**

(A)Under the uncertificated securities rules, the directors can allow the ownership of shares to be evidenced without share certificates and for these shares to be transferred through CREST. The directors can select and make arrangements for any class of shares to participate in CREST in this way, provided that the shares of the class are identical in all respects.

As long as the directors comply with the uncertificated securities rules, they can also withdraw a class of shares from being transferred through CREST and from allowing ownership of them to be evidenced without share certificates.

CREST shares do not form a class of shares separate from certificated shares with the same rights.

(B)If the company has any shares in issue which are CREST shares, these articles apply to those shares, but only as far as they are consistent with:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)holding shares in an uncertificated form;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)transferring shares through CREST;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)any provision of the uncertificated securities rules; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)the company exercising any of its powers or functions or doing anything through CREST,

and, without affecting the general nature of this article, no provision of these articles applies so far as it is inconsistent with the maintenance, keeping or entering up by the Operator, so

&nbsp;&nbsp;&nbsp;&nbsp;

------

long as that is permitted or required by the uncertificated securities rules, of an Operator register of securities in respect of CREST shares.

(C)CREST shares can be changed to become certificated shares and certificated shares can be changed to become CREST shares, provided the requirements of the uncertificated securities rules are met.

(D)If under these articles or the legislation the company can sell, transfer or otherwise dispose of, forfeit, re-allot, accept the surrender of or otherwise enforce a lien over a CREST share, then, subject to these articles and the legislation, the directors may:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)require the holder of that CREST share by written notice to change that CREST share to a certificated share within a period specified in the notice and to keep it as a certificated share for as long as the directors require;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)appoint any person to take any other steps, by instruction given through CREST or otherwise, in the name of the holder of that share as may be necessary to effect the transfer of that share and these steps will be as effective as if they had been taken by the registered holder of that share; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)take any other action that the directors consider appropriate to achieve the sale, transfer, disposal, forfeiture, re-allotment or surrender of that share or otherwise to enforce a lien in respect of that share.

(E)Unless the directors decide otherwise, CREST shares held by a shareholder will be treated as separate holdings from any certificated shares which that shareholder holds.

(F)Unless the uncertificated securities rules otherwise require or the directors otherwise determine, shares which are issued or created from or in respect of CREST shares will be CREST shares and shares which are issued or created from or in respect of certificated shares will be certificated shares.

(G)The company can assume that entries on any record of securities kept by it as required by the uncertificated securities rules and regularly reconciled with the relevant Operator register of securities are a complete and accurate reproduction of the particulars entered in the Operator register of securities and therefore will not be liable in respect of anything done or not done by or on its behalf in reliance on such assumption; in particular, any provision of these articles which requires or envisages action to be taken in reliance on information contained in the register allows that action to be taken in reliance on information contained in any relevant record of securities (as so maintained and reconciled).

**14. Right to Share Certificates**

(A)When a shareholder is first registered as the holder of any class of certificated shares, he is entitled, free of charge, to one certificate for all of the certificated shares of that class which he holds. If a shareholder holds certificated shares of more than one class, he is entitled to a separate share certificate for each class. This does not apply if the legislation allows the company not to issue share certificates.

(B)If a shareholder receives more certificated shares of any class, he is entitled, without charge, to a certificate for the extra shares.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(C)If a shareholder transfers some of the shares represented by a share certificate, he is entitled, free of charge, to a new certificate for the balance to the extent the balance is to be held in certificated form.

(D)Where a certificated share is held jointly, the company does not have to issue more than one certificate for that share. When the company delivers a share certificate to one joint shareholder, this is treated as delivery to all of the joint shareholders.

(E)The time limit for the company to provide a share certificate under this article is as prescribed by the legislation or, if this is earlier, within any prescribed time limit or within a time specified when the shares were issued.

**15. Replacement of Share Certificates**

(A)If a shareholder has two or more share certificates for shares of the same class, he can ask the company for these to be cancelled and replaced by a single new certificate. The company must comply with this request.

(B)A shareholder can ask the company to cancel and replace a single share certificate with two or more certificates for the same total number of shares. The company may comply with this request.

(C)A shareholder can ask the company for a new certificate if the original is:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)damaged or defaced; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)said to be lost, stolen or destroyed.

(D)If a certificate has been damaged or defaced, the company can require the certificate to be returned to it before issuing a replacement. If a certificate is said to be lost, stolen or destroyed, the company can require satisfactory evidence of this and insist on receiving an indemnity before issuing a replacement.

(E)The directors can require the shareholder to pay the company's exceptional out-of- pocket expenses incurred in connection with the issue of any certificates under this article.

(F)Any one joint shareholder can request replacement certificates under this article.

**16. Share Certificates Sent at Holder's Risk**

Every share certificate will be sent at the risk of the member or other person entitled to the certificate. The company will not be responsible for any share certificate which is lost or delayed in the course of delivery.

**17. Execution of Share Certificates**

Share certificates must be sealed or made effective in such other way as the directors decide, having regard to the terms of issue and any listing requirements. The directors can resolve that signatures on any share certificates can be applied to the certificates by mechanical or other means or can be printed on them or that signatures are not required. A share certificate must state the number and class of shares to which it relates and the amount paid up on those shares.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**18. Company's Lien on Shares Not Fully Paid**

The company has a lien on all partly paid shares. This lien has priority over claims of others to the shares. The lien is for any money owed to the company for the shares. The directors can decide to give up any lien which has arisen and can also decide to suspend any lien which would otherwise apply to particular shares.

**19. Enforcing Lien by Sale**

(A)If a shareholder fails to pay the company any amount due on his partly paid shares, the directors can enforce the company's lien by selling all or any of them in any way they decide. The directors cannot, however, sell the shares until all the following conditions are met:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the money owed by the shareholder must be payable immediately;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the directors must have given notice to the shareholder. The notice must state the amount of money due, it must demand payment of this sum and state that the shareholders' shares may be sold if the money is not paid;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)the notice must have been served on the shareholder or on any person who is entitled to the shares by law and can be served in any way that the directors decide; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)the money has not been paid by at least 14 clear days after the notice has been served.

(B)The directors can authorise any person to sign a document transferring the shares. Any such transferee will not be bound to ensure that his purchase moneys are transferred to the person whose shares have been sold, nor will his ownership of the shares be affected by any irregularity or invalidity in relation to the sale to him.

**20. Application of Proceeds of Sale**

If the directors sell any shares on which the company has a lien, the proceeds will first be used to pay the company's expenses associated with the sale. The remaining money will be used to pay off the amount which is then payable on the shares and any balance will be passed to the former shareholder or to any person who would otherwise be entitled to the shares by law. But the company's lien will also apply to any such balance to cover any money still due to the company in respect of the shares which is not immediately payable. The company has the same rights over the money as it had over the shares immediately before they were sold. The company need not pay over anything until the certificate representing the shares sold has been delivered to the company for cancellation.

**21. Calls**

(A)The directors can call on shareholders to pay any money which has not yet been paid to the company for their shares. This includes the nominal value of the shares and any premium which may be payable on those shares. The directors can also make calls on people who are entitled to shares by law. If the terms of issue of the shares allow this, the directors can do any one or more of the following:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)make calls at any time and as often as they think fit;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)decide when and where the money is to be paid;

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)decide that the money may be paid by instalments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)revoke or postpone any call.

(B)A shareholder who has received at least 14 clear days' notice giving details of the amount called and of the time and place for payment, must pay the call as required by the notice. A person remains liable jointly and severally with the successors in title to his shares to pay calls even after he has transferred the shares to which they relate.

**22. Timing of Calls**

A call is treated as having been made as soon as the directors have passed a resolution authorising it.

**23. Liability of Joint Holders**

Joint shareholders are jointly and severally liable to pay any calls in respect of their shares. This means that any of them can be sued for all the money due on the shares or they can be sued together.

**24. Interest Due on Non-Payment**

Where a call is made and the money due remains unpaid, the shareholder will be liable to pay interest on the amount unpaid from the day it is due until it has actually been paid. The directors will decide on the annual rate of interest, which must not exceed the Bank of England base rate by more than five per cent. The shareholder will also be liable to pay all expenses incurred by the company as a result of the non-payment of the call. The directors can decide to forego payment of any or all of such interest or expenses.

**25. Sums Due on Allotment Treated as Calls**

If the terms of a share require any money to be paid at the time of allotment, or at any other fixed date, the money due will be treated in the same way as a valid call for money on shares which is due on the same date. If this money is not paid, everything in these articles relating to non-payment of calls applies. This includes articles which allow the company to forfeit or sell shares and to claim interest.

**26. Power to Differentiate**

On or before an issue of shares, the directors can decide that shareholders can be called on to pay different amounts or that they can be called on at different times.

**27. Payment of Calls in Advance**

The directors can accept payment in advance of some or all of the money from a shareholder before he is called on to pay that money. The directors can agree to pay interest on money paid in advance until it would otherwise be due to the company. The rate of interest will be decided by the directors, but must not exceed the Bank of England base rate by more than five per cent. unless the company passes an ordinary resolution to allow a higher rate.

**28. Notice if Call or Instalment Not Paid**

If a shareholder fails to pay a call or an instalment of a call when due, the directors can send the shareholder a notice requiring payment of the unpaid amount, together with any interest accrued and any expenses incurred by the company as a result of the failure to pay.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**29. Form of Notice**

This notice must:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)demand payment of the amount immediately payable, plus any interest and expenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)give the date by when the total amount due must be paid. This must be at least 14 clear days after the date of the notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)say where the payment must be made; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)say that if the full amount demanded is not paid by the time and at the place stated, the company can forfeit the shares on which the call or instalment is outstanding.

**30. Forfeiture for Non-Compliance with Notice**

If the notice is not complied with, the shares it relates to can be forfeited at any time while any amount is still outstanding. This is done by the directors passing a resolution stating that the shares have been forfeited. The forfeiture will extend to all dividends and other sums payable in respect of the forfeited shares which have not been paid before the forfeiture. The directors can accept the surrender of any share which would otherwise be forfeited. Where they do so, references in these articles to forfeiture include surrender.

**31. Notice after Forfeiture**

After a share has been forfeited, the company will notify the person whose share has been forfeited. However, the share will still be forfeited even if such notice is not given.

**32. Sale of Forfeited Shares**

(A)A forfeited share becomes the property of the company and the directors can sell or dispose of it on any terms and in any way that they decide. This can be with, or without, a credit for any amount previously paid up for the share. It can be sold or disposed of to any person, including the previous shareholder or the person who was previously entitled to the share by law. The directors can, if necessary, authorise any person to transfer a forfeited share.

(B)After a share has been forfeited, the directors can cancel the forfeiture, but only before the share has been sold or disposed of. This cancellation of forfeiture can be on any terms the directors decide.

**33. Arrears to be Paid Notwithstanding Forfeiture**

When a person's shares have been forfeited, he will lose all rights as shareholder in respect of those forfeited shares. He must return any share certificate for the forfeited shares to the company for cancellation. However, he will remain liable to pay calls which have been made, but not paid, before the shares were forfeited. The shareholder also continues to be liable for all claims and demands which the company could have made relating to the forfeited share. He must pay interest on any unpaid amount until it is paid. The directors can fix the rate of interest, but it must not exceed the Bank of England base rate by more than five per cent. He is not entitled to any credit for the value of the share when it was forfeited or for any consideration received on its disposal unless the directors decide to allow credit for all or any of that value.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**34. Statutory Declaration as to Forfeiture**

(A)A director or the secretary can make a statutory declaration declaring:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)that he is a director or the secretary of the company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)that a share has been properly forfeited under these articles; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)when the share was forfeited.

The declaration will be evidence of these facts which cannot be disputed.

(B)If such a declaration is delivered to a new holder of a share along with a completed transfer form (if one is required), this gives the buyer good title. The new shareholder does not need to take any steps to see how any money paid for the share is used. His ownership of the share will not be affected if the steps taken to forfeit, sell or dispose of the share were invalid or irregular, or if anything that should have been done was not done.

**35. Transfer**

(A)Certificated shares

Unless these articles say otherwise, any shareholder can transfer some or all of his certificated shares to another person. A transfer of certificated shares must be made in writing and either in the usual standard form or in any other form approved by the directors.

(B)CREST shares

Unless these articles say otherwise, any shareholder can transfer some or all of his CREST shares to another person. A transfer of CREST shares must be made through CREST and must comply with the uncertificated securities rules.

(C)Entry on register

The person making a transfer will continue to be treated as a shareholder until the name of the person to whom the share is being transferred is put on the register for that share.

**36. Signing of Transfer**

(A)A share transfer form for certificated shares must be signed or made effective in some other way by, or on behalf of, the person making the transfer.

(B)In the case of a transfer of a certificated share, where the share is not fully paid, the share transfer form must also be signed or made effective in some other way by, or on behalf of, the person to whom the share is being transferred.

(C)If the company registers a transfer of a certificated share, it can keep the transfer form.

**37. Rights to Decline Registration of Partly Paid Shares**

The directors can refuse to register the transfer of any shares which are not fully paid.

**38. Other Rights to Decline Registration**

(A)Certificated shares

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)A share transfer form cannot be used to transfer more than one class of shares. Each class needs a separate form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Transfers cannot be in favour of more than four joint holders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)The share transfer form must be properly stamped to show payment of any applicable stamp duty or certified or otherwise shown to the satisfaction of the directors to be exempt from stamp duty and must be delivered to the office, or any other place decided on by the directors. The transfer form must be accompanied by the share certificate relating to the shares being transferred, unless the transfer is being made by a person to whom the company was not required to, and did not send, a certificate. The directors can also ask (acting reasonably) for any other evidence to show that the person wishing to transfer the share is entitled to do so and, if the share transfer form is signed by another person on behalf of the person making the transfer, evidence of the authority of that person to do so.

(B)CREST shares

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Registration of a transfer of CREST shares can be refused in the circumstances set out in the uncertificated securities rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Transfers cannot be in favour of more than four joint holders.

(C)Renunciations

Where a share has not yet been entered on the register, the directors can recognise a renunciation by that person of his right to the share in favour of some other person. Such renunciation will be treated as a transfer and the directors have the same powers of refusing to give effect to such a renunciation as if it were a transfer.

**39. No Fee for Registration**

No fee is payable to the company for transferring shares or registering changes relating to the ownership of shares.

**40. Untraced Shareholders**

(A)The company can sell any certificated shares at the best price reasonably obtainable at the time of the sale if:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)during the 10 years before the notice referred to in <u>paragraph (ii)</u> below, the shares have been in issue either as certificated shares or as CREST shares, at least three cash dividends have become payable on the shares and no dividend has been cashed during that period;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)after the 10 year period referred to in <u>paragraph (i)</u> above, the company has sent a notice of its intention to sell the shares to such member's last known address. Before sending any such notice, the company shall have made reasonable enquires to establish the address of the member, engaging, if considered appropriate, a professional asset reunification company or tracing agent; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)during the 10 year period referred to in <u>paragraph (i)</u> above and for three months after the notice referred to in <u>paragraph (ii)</u> above appears, the company has not heard from the shareholder or any person entitled to the shares by law.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(B)The company can also sell at the best price reasonably obtainable at the time of the sale any additional certificated shares in the company issued either as certificated shares or as CREST shares during the said 10 year period referred to in <u>paragraph</u> <u>[(A)(i)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>in right of any share to which <u>paragraph [(A)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>applies (or in right of any share so issued), if the criteria in <u>paragraph [(A)(ii)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>and <u>paragraph [(A)(iii)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>are satisfied in relation to the additional shares (but as if the words "after the 10 year period referred to in <u>paragraph (i)</u> above" were omitted from <u>paragraph [(A)(ii)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>and the words "during the 10 year period referred to in <u>paragraph (i)</u> above and" were omitted from <u>paragraph [(A)(iii)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>and no dividend has been cashed on these shares.

(C)To sell any shares in this way, the directors can appoint anyone to transfer the shares. This transfer will be just as effective as if it had been signed by the holder, or by a person who is entitled to the shares by law. The person to whom the shares are transferred will not be bound to concern himself as to what is done with the purchase moneys nor will his ownership be affected even if the sale is irregular or invalid in any way.

(D)The proceeds of sale will belong to the company, but it must pay an amount equal to the sale proceeds less the costs of the sale to the shareholder who could not be traced, or to the person who is entitled to his shares by law, if that shareholder, or person, asks for it unless and until forfeited under this article.

(E)After the sale, the company must record the name of the shareholder, or (if known) the person who would have been entitled to the shares by law, as a creditor for the money in its accounts. The company will not be a trustee of the money and will not be liable to pay interest on it. The company can use the money, and any money earned by using the money, for its business or in any other way that the directors decide. If no valid claim for the money has been received by the company during a period of six years from the date on which the relevant shares were sold by the company under this article, the money will be forfeited and will belong to the company.

**41. Transmission on Death**

(A)When a sole shareholder or a shareholder who is the last survivor of joint shareholders dies, his personal representatives will be the only people who will be recognised as being entitled to his shares.

(B)If a joint shareholder dies, the surviving joint shareholder or shareholders will be the only people who will be recognised as being entitled to his shares.

(C)However, this article does not discharge the estate of any shareholder from any liability.

**42. Entry of Transmission in Register**

A person who becomes entitled to a share as a result of the death or bankruptcy of a shareholder or some other event which gives rise to the transmission of the share by operation of law must provide any evidence of his entitlement which is reasonably required. In the case of certificated shares, the directors must note this entitlement in the register within two months of receiving such evidence.

**43. Election of Person Entitled by Transmission**

(A)Subject to these articles, a person who becomes entitled to a share by law can either be registered as the shareholder or choose another person to become the shareholder.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(B)If a person who is entitled to a certificated share by law wants to be registered as a shareholder, he must deliver or send a notice to the company saying that he has made this decision. This notice will be treated as a transfer form. All the provisions of these articles about registering transfers of certificated shares apply to it. The directors have the same power to refuse to register a person entitled to certificated shares by law as they would have had to refuse to register a transfer by the person who was previously entitled to the shares.

(C)If a person entitled to a CREST share by law wants to be registered as a shareholder, he must do so in accordance with the uncertificated securities rules. All the provisions of these articles about registering transfers of CREST shares will apply and the same power to refuse to register a person entitled to a CREST share by law will apply as would have applied to refuse to register a transfer by the person who was previously entitled to the shares.

(D)If a person who is entitled to a certificated share by law wants the share to be transferred to another person, he must do this by signing a transfer form to the person he has selected. The directors have the same power to refuse to register the person selected as they would have had to refuse to register a transfer by the person who was previously entitled to the shares.

(E)If a person who is entitled to a CREST share by law wants the share to be transferred to another person, he must do this using CREST. The same power to refuse to register the person selected will apply as would have applied to refuse to register a transfer by the person who was previously entitled to the shares.

**44. Rights of Person Entitled by Transmission**

(A)Where a person becomes entitled to a share by law, the rights of the registered shareholder in relation to that share will cease to have effect.

(B)A person who is entitled to a share by law is entitled to any dividends or other money relating to the share, even though he is not registered as the holder of the share, on supplying evidence reasonably required to show his title to the share. However, the directors can send written notice to the person saying the person must either be registered as the holder of the share or transfer the share to some other person. If the person entitled to a share by law does not do this within 60 days of the notice, the directors can withhold all dividends or other money relating to the share until he does.

(C)Unless he is registered as the holder of the share, the person entitled to a share by law is not entitled to:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)receive notices of general meetings or attend or vote at these general meetings; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)exercise any of the other rights of a shareholder in relation to these general meetings, unless the directors decide to allow this.

**45. Sub-division**

Any resolution authorising the company to sub-divide any of its shares can provide that, as between the holders of the divided shares, different rights (including deferred rights) and restrictions of a kind which the company can apply to new shares can apply to different divided shares.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**46. Fractions**

If any shares are consolidated, consolidated and then divided or divided, the directors have power to deal with any fractions of shares which result. For example, they can decide that fractions are aggregated and sold or deal with fractions in some other way. The directors can arrange for any shares representing fractions to be entered in the register as certificated shares if they consider that this makes it easier to sell them. The directors can sell those shares to anyone, including the company, and can authorise any person to transfer or deliver the shares to the buyer or in accordance with the buyer's instructions. The buyer does not have to take any steps to see how any money he is paying is used and his ownership will not be affected if the sale is irregular or invalid in any way.

**47. Omission or Non-Receipt of Notice**

(A)If any notice, document or other information relating to any general meeting or other proceeding is accidentally not sent or supplied, or is not received (even if the company becomes aware of such failure to send or supply or non-receipt), the general meeting or other proceeding will not be invalid as a result.

(B)A shareholder present in person (including by means of electronic facility or facilities) or by proxy (including by means of electronic facility or facilities) at a general meeting is treated as having received proper notice of that general meeting and, where necessary, of the purpose of that general meeting.

**48. Convening General Meetings**

The board shall determine in relation to each general meeting the means of attendance at and participation in the general meeting, including whether the persons entitled to attend and participate in the general meeting shall be enabled to do so by simultaneous attendance and participation at a physical place or by means of electronic facility or facilities determined by it in accordance with <u>Article 49</u>, or partly in one way and partly in another.

**49. General Meetings by Means of Electronic Facility**

(A)The board may determine to enable persons entitled to attend and participate in a general meeting to do so (wholly or partly) by simultaneous attendance and participation by means of electronic facility or facilities and determine the means, or all different means, of attendance and participation used in relation to a general meeting. The members present in person (including by means of electronic facility or facilities) or by proxy (including by means of electronic facility or facilities) shall be counted in the quorum for, and entitled to participate in, the general meeting in question. That general meeting shall be duly constituted and its proceedings valid if the chair of the meeting is satisfied that adequate facilities are available throughout the general meeting to ensure that members attending the meeting by all means (including by means of electronic facility or facilities) are able to:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)participate in the business for which the general meeting has been convened;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)hear all persons who speak at the general meeting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)be heard by all other persons present (including by means of electronic facility or facilities) at the general meeting.

(B)A member seeking to be present in person or by proxy at a general meeting by means of electronic facility or facilities is responsible for ensuring they have access to and can use the

&nbsp;&nbsp;&nbsp;&nbsp;

------

facility or facilities. That general meeting shall be duly constituted and its proceedings valid notwithstanding the inability of the member to gain access to or use the facility or facilities, or the loss of access to or use of the facility or facilities during the general meeting.

(C)If the board determines that a general meeting shall be held wholly or partly by means of electronic facility or facilities, the notice shall specify the means, or all different means, of attendance and participation determined in accordance with this article and any access, identification and security arrangements determined in accordance with <u>Article 53</u>.

**50. Postponement of General Meetings**

If the directors consider that it is impracticable or undesirable to hold a general meeting on the date or at the time or place (including by means of electronic facility or facilities) stated in the notice calling the general meeting, they can move or postpone the general meeting (or do both). If the directors do this, an announcement of the date, time and place (including by means of electronic facility or facilities) of the rearranged general meeting will be made available on the company's website. Notice of the business of the general meeting does not need to be given again. The directors must take reasonable steps to ensure that any shareholder trying to attend the general meeting at the original time and by the original means of attendance and participation is informed of the new arrangements. If a general meeting is rearranged in this way, proxy forms are valid if they are received as required by these articles not less than 48 hours before the time of the rearranged general meeting. The directors can also move or postpone the rearranged general meeting (or do both) under this article.

**51. Quorum**

Before a general meeting starts to do business, there must be a quorum present. Unless these articles say otherwise, two or more persons entitled to vote at least one-third of the company's issued shares (excluding any shares held as treasury shares) at the general meeting shall constitute a quorum for all purposes. They can be shareholders who are personally present (including by means of electronic facility or facilities) or proxies for shareholders (who are present by any means, including by means of electronic facility or facilities) or a combination of both. If a quorum is not present, a chair of the general meeting can still be chosen and this will not be treated as part of the business of the general meeting.

**52. Procedure if Quorum Not Present**

(A)This article applies if a quorum is not present within five minutes of the time fixed for a general meeting to start or within any longer period not exceeding one hour which the chair of the general meeting can decide or if a quorum ceases to be present during a general meeting.

(B)If the general meeting was called by shareholders it will be cancelled. Any other general meeting will be adjourned to a day (being not less than ten days later, excluding the day on which the general meeting is adjourned and the day for which it is reconvened), time and place (including by means of electronic facility or facilities) decided on by the chair of the general meeting.

(C)One shareholder present (including by means of electronic facility or facilities) or by proxy (including by means of electronic facility or facilities) and entitled to vote will constitute a quorum at any adjourned general meeting and any notice of an adjourned general meeting will say this.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**53. Security Arrangements**

(A)The directors can put in place arrangements, both before and during any general meeting, which they consider to be appropriate for the proper and orderly conduct of the general meeting and the safety of people attending it. This authority includes power to refuse entry to, or remove from general meetings, people who fail to comply with the arrangements.

(B)If a general meeting is held wholly or partly by means of electronic facility or facilities, the board may make any arrangement and impose any requirement or restriction that is:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)necessary to ensure the identification of those taking part and the security of the electronic communication; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)proportionate to the achievement of those objectives.

**54. Chair of General Meeting**

(A)The chair will be the chair of the general meeting at every general meeting, if he is willing and able to take the chair.

(B)If the company does not have a chair, or if he is not willing and able to take the chair, a deputy chair will chair the general meeting if he is willing and able to take the chair. If more than one deputy chair is present, they will agree between themselves who will take the chair and if they cannot agree, the deputy chair who has been a director longest will take the chair.

(C)If the company does not have a chair or a deputy chair, or if neither the chair nor a deputy chair is willing and able to chair the general meeting, after waiting five minutes from the time that a general meeting is due to start, the directors who are present (including by means of electronic facility or facilities) will choose one of themselves to act as chair of the general meeting. If there is only one director present, he will be the chair of the general meeting, if he agrees.

(D)If there is no director willing and able to be the chair of the general meeting, then the persons who are present at the general meeting (including by means of electronic facility or facilities) and entitled to vote will decide which one of them is to be the chair of the general meeting.

(E)Nothing in these articles is intended to restrict or exclude any of the powers or rights of a chair of a general meeting which are given by law.

**55. Orderly Conduct**

The chair of a general meeting can take any action he considers appropriate for proper and orderly conduct at a general meeting. The chair's decision on points of order, matters of procedure or on matters that arise incidentally from the business of a general meeting is final, as is the chair's decision on whether a point or matter is of this nature.

**56. Entitlement to Attend and Speak**

Each director can attend and speak at any general meeting of the company. The chair of a general meeting can also allow anyone to attend and speak where he considers that this will help the business of the general meeting.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**57. Adjournments**

(A)The chair of a general meeting can adjourn the general meeting before or after it has started, and whether or not a quorum is present, if he considers that:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)there is not enough room for the number of shareholders and proxies who can and wish to attend the general meeting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the behaviour of anyone present (including by means of electronic facility or facilities) prevents, or is likely to prevent, the business of the general meeting being carried out in an orderly way;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)an adjournment is necessary for any other reason, so that the business of the general meeting can be properly carried out; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)an electronic facility has become inadequate for the purposes referred to in <u>Article 49</u>.

(B)The chair of the general meeting does not need the consent of the general meeting to adjourn it for any of these reasons to a time, date and place (including by means of electronic facility or facilities) which he decides. He can also adjourn the general meeting to a later time on the same day or indefinitely. If a general meeting is adjourned indefinitely, the directors will fix the time, date and place (including by means of electronic facility or facilities) of the adjourned general meeting.

(C)The chair of a general meeting can also adjourn a general meeting which has a quorum present if this is agreed by the general meeting. This can be to a time, date and place (including by means of electronic facility or facilities) proposed by the chair of the general meeting or the adjournment can be indefinite. The chair of the meeting must adjourn the general meeting if the general meeting directs him to. In these circumstances the meeting will decide how long the adjournment will be and where it will adjourn to. If a general meeting is adjourned indefinitely, the directors will fix the time, date and place (including by means of electronic facility or facilities) of the adjourned general meeting.

(D)A reconvened meeting can only deal with business that could have been dealt with at the general meeting which was adjourned.

(E)General meetings can be adjourned more than once.

**58. Notice of Adjournment**

If the continuation of an adjourned general meeting is to take place three months or more after it was adjourned or if business is to be considered at an adjourned general meeting the general nature of which was not stated in the notice of the original meeting, notice of the adjourned general meeting must be given in the same way as was required for the original general meeting. Except as provided in this article, there is no need to give notice of the adjourned general meeting or of the business to be considered there.

**59. Amendments to Resolutions**

(A)Amendments can be proposed to any resolution if they are clerical amendments or amendments to correct some other obvious error in the resolution. No other amendments can be proposed to any special resolution.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(B)Amendments to an ordinary resolution which are within the scope of the resolution can be proposed if:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)notice of the proposed amendment has been received by the company at the office at least two working days before the date of the general meeting, or adjourned general meeting; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the chair of the general meeting decides that the amendment is appropriate for consideration by the general meeting.

No other amendment can be proposed to an ordinary resolution. The chair of the general meeting can agree to the withdrawal of any proposed amendment before it is put to the vote.

**60. Amendments Ruled Out of Order**

If the chair of a general meeting rules that a proposed amendment to any resolution under consideration is out of order, any error in that ruling will not affect the validity of a vote on the original resolution.

**61. Votes of Members**

Shareholders will be entitled to vote at a general meeting, whether on a show of hands or a poll, as provided in the legislation. Where a proxy is given discretion as to how to vote on a show of hands this will be treated as an instruction by the relevant shareholder to vote in the way in which the proxy decides to exercise that discretion.

This is subject to any special rights or restrictions as to voting which are given to any shares or upon which any shares may be held at the relevant time and to these articles.

**62. Method of Voting**

(A)For so long as any shares are held in a settlement system operated by DTC and a DTC Depositary holds legal title to shares in the capital of the company for DTC, (i) any resolution put to the vote of a general meeting must be decided on a poll and (ii) this <u>Article 62(A)</u> may only be removed, amended or varied by resolution of the members passed unanimously at a general meeting of the company.

(B)Subject to <u>Articles 62(A)</u> and 62(C), a resolution put to the vote at any general meeting will be decided on a show of hands unless a poll is demanded when, or before, the chair of the general meeting declares the result of the show of hands. Subject to the legislation, a poll can be demanded by:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the chair of the general meeting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)at least five persons at the general meeting who are entitled to vote;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)one or more shareholders at the general meeting who are entitled to vote (or their proxies) and who have between them at least ten per cent. of the total votes of all shareholders who have the right to vote at the general meeting; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)one or more shareholders at the general meeting who have shares which allow them to vote at the general meeting (or their proxies) and on which the total amount which has been paid up is at least ten per cent. of the total sum paid up on all shares which give the right to vote at the general meeting.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(C)A resolution put to the vote at a general meeting held wholly or partly by means of electronic facility or facilities shall, unless the chair of the meeting determines that it shall be decided on a show of hands, be decided on a poll.

(D)The chair of the general meeting can also demand a poll before a resolution is put to the vote on a show of hands.

(E)A demand for a poll can be withdrawn if the chair of the general meeting agrees to this.

(F)If no poll is demanded or a demand for a poll is withdrawn, any declaration by the chair of the general meeting of the result of a vote on that resolution by a show of hands will stand as conclusive evidence of the result without proof of the number or proportion of the votes recorded for or against the resolution.

**63. Procedure if Poll Demanded**

If a poll is demanded in the way allowed by these articles, the chair of the general meeting can decide when, where and how it will be taken. The result will be treated as the decision of the general meeting at which the poll was demanded, even if the poll is taken after the general meeting.

**64. When Poll to be Taken**

If a poll is demanded on a vote to elect the chair of the general meeting, or to adjourn a general meeting, it must be taken immediately at the general meeting. Any other poll demanded can either be taken immediately or within 30 days from the date it was demanded and at a time and place (including by means of electronic facility or facilities) decided on by the chair of the general meeting. It is not necessary to give notice for a poll which is not taken immediately.

**65. Continuance of Other Business after Poll Demand**

A demand for a poll on a particular matter (other than on the election of the chair of the general meeting or on the adjournment of the general meeting) will not stop a general meeting from continuing to deal with other matters.

**66. Votes of Joint Holders**

If more than one joint shareholder votes (including voting by proxy), the only vote which will count is the vote of the person whose name is listed before the other voters on the register for the share.

**67. Voting on behalf of Incapable Member**

This article applies where a court or official claiming jurisdiction to protect people who are unable to manage their own affairs has made an order about the shareholder. The person appointed to act for that shareholder can vote for him. He can also exercise any other rights of the shareholder relating to general meetings. This includes appointing a proxy, voting on a show of hands and voting on a poll. Before the representative does so however, such evidence of his authority as the directors require must be received by the company not later than the latest time at which proxy forms must be received to be valid for use at the relevant general meeting or on the holding of the relevant poll.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**68. No Right to Vote where Sums Overdue on Shares**

Unless the directors decide otherwise, a shareholder cannot attend or vote shares at any general meeting of the company or upon a poll or exercise any other right conferred by membership in relation to general meetings or polls if he has not paid all amounts relating to those shares which are due at the time of the general meeting.

**69. Objections or Errors in Voting**

(A)If:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)any objection to the right of any person to vote is made;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)any votes have been counted which ought not to have been counted or which might have been rejected; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)any votes are not counted which ought to have been counted,

the objection or error must be raised or pointed out at the general meeting (or the adjourned general meeting) or poll at which the vote objected to is cast or at which the error occurs. Any objection or error must be raised with or pointed out to the chair of the general meeting. His decision is final. If a vote is allowed at a meeting or poll, it is valid for all purposes and if a vote is not counted at a general meeting or poll, this will not affect the decision of the general meeting or poll.

(B)The company will not be obliged to check whether a proxy or representative of a corporation has voted in accordance with a shareholder's instructions and if a proxy or representative fails to do so, this will not affect the decision of the general meeting (or adjourned general meeting) or poll.

**70. Appointment of Proxies**

In the case of a proxy relating to shares in the capital of the company held in the name of a DTC Depositary, the appointment of a proxy shall be in a form or manner of communication approved by the board, which may include, without limitation, a voter instruction form to be provided to the company by certain third parties on behalf of the DTC Depositary. A proxy form must otherwise be in writing, signed by the shareholder appointing the proxy, or by his attorney. Where the proxy is appointed by a company, the proxy form should either be sealed by that company or signed by someone authorised to sign it. If a member appoints more than one proxy and the proxy forms appointing those proxies would give those proxies the apparent right to exercise votes on behalf of the member in a general meeting over more shares than are held by the member, then each of those proxy forms will be invalid and none of the proxies so appointed will be entitled to attend, speak or vote at the relevant general meeting.

**71. Receipt of Proxies**

(A)Proxy forms which are in hard copy form must be received at the office, or at any other place specified by the company for the receipt of appointments of proxy in hard copy form:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)48 hours (or such shorter time as the directors decide) before a general meeting or an adjourned general meeting;

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)24 hours (or such shorter time as the directors decide) before a poll is taken, if the poll is taken more than 48 hours after it was demanded; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)before the end of the general meeting at which the poll was demanded (or at such later time as the directors decide), if the poll is taken after the end of the general meeting or adjourned general meeting but not more than 48 hours after it was demanded.

If such a proxy form is signed by an attorney and the directors require this, the power of attorney or other authority relied on to sign it (or a copy which has been certified by a notary or in some other way approved by the directors, or an office copy) must be received with the proxy form.

(B)Proxy forms which are in electronic form must be received at the address specified by the company for the receipt of appointments of proxy by electronic means at least:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)48 hours (or such shorter time as the directors decide) before a general meeting or an adjourned general meeting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)24 hours (or such shorter time as the directors decide) before a poll is taken, if the poll is taken more than 48 hours after it was demanded; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)before the end of the general meeting at which the poll was demanded (or at such later time as the directors decide), if the poll is taken after the end of the general meeting or adjourned general meeting but not more than 48 hours after it was demanded.

If such a proxy form is signed by an attorney and the directors require this, the power of attorney or other authority relied on to sign it (or a copy which has been certified by a notary or in some other way approved by the directors, or an office copy) must be received at such address, at the office or at any other place specified by the company for the receipt of such documents by the time set out in <u>paragraph [(i)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>or <u>[(ii)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>or <u>[(iii)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>above, as applicable.

(C)If the above requirements are not complied with, the proxy will not be able to act for the person who appointed him.

(D)If more than one valid proxy form is received in respect of the same share for use at the same general meeting or poll, the one which is received last (regardless of its date or the date on which it is signed) will be treated as the valid form. If it is not possible to determine the order of receipt, none of the forms will be treated as valid.

(E)A shareholder can attend and vote at a general meeting or on a poll even if he has appointed a proxy to attend and vote on his behalf at that general meeting or on that poll.

(F)The proceedings at a general meeting will not be invalidated where an appointment of a proxy in respect of that general meeting is sent in electronic form as provided in these articles, but because of a technical problem it cannot be read by the recipient.

(G)When calculating the periods mentioned in this article the directors can decide not to take account of any part of a day that is not a working day.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**72. Maximum Validity of Proxy**

A proxy form will cease to be valid 12 months from the date of its receipt. But it will be valid, unless the proxy form itself states otherwise, if it is used at an adjourned general meeting or on a poll after a general meeting or an adjourned general meeting even after 12 months, if it was valid for the original general meeting.

**73. Form of Proxy**

A proxy form can be in any form which the directors approve. A proxy form gives the proxy the authority to demand a poll or to join others in demanding a poll and to vote on any amendment to a resolution put to, or any other business which may properly come before, the general meeting. Unless it says otherwise, a proxy form is valid for the general meeting to which it relates and also for any adjournment of that general meeting.

**74. Cancellation of Proxy's Authority**

(A)Any vote cast in the way a proxy form authorises or any demand for a poll made by a proxy will be valid even though:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the person who appointed the proxy has died or is of unsound mind;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the proxy form has been revoked; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)the authority of the person who signed the proxy form for the shareholder has been revoked.

(B)Any vote cast or poll demanded by a company representative will also be valid even though his authority has been revoked.

(C)However, this does not apply if written notice of the relevant fact has been received at the office (or at any other place specified by the company for the receipt of proxy forms) not later than the last time at which a proxy form should have been received to be valid for use at the general meeting or on the holding of the poll at which the vote was given or the poll taken.

**75. Separate General Meetings**

If a separate general meeting of holders of shares of a class is called otherwise than for changing or abrogating the rights of the shares of that class, the provisions of these articles relating to general meetings will apply to such a meeting with any necessary changes. A general meeting where ordinary shareholders are the only shareholders who can attend and vote in their capacity as shareholders will also constitute a separate general meeting of the holders of the ordinary shares.

**76. Proposed Member Resolutions**

(A)On and after the Determination Date, where a member or members, in accordance with the provisions of the Companies Act, requests the company to (x) call a general meeting for the purposes of bringing a resolution before the general meeting, or (y) give notice of a resolution to be proposed at an annual general meeting, such request must, in each case and in addition to the requirements of the Companies Act, contain the following:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)to the extent that the request relates to the nomination of a director, as to each person whom the member(s) propose(s) to nominate for election or re-election as a director, all information relating to such person that is required to be disclosed in a proxy

&nbsp;&nbsp;&nbsp;&nbsp;

------

statement or other filings required to be made in connection with solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act, and the regulations promulgated thereunder, including such person's written consent to being named in the proxy statement as a nominee and to serving as a director if elected or re-elected;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)to the extent that the request relates to any business other than the nomination of a director that the member(s) propose(s) to bring before the general meeting, a brief description of the business desired to be brought before the general meeting, the reasons for conducting such business at the general meeting and any material interest in such business of such member(s) and any Member Associated Person (as defined below), individually or in the aggregate, including any anticipated benefit to the member(s) or the Member Associated Person(s) therefrom; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)as to the member(s) giving the notice and the Member Associated Person(s), if any, on whose behalf the nomination or proposal is made:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the name and address of such member(s), as they appear on the company's books, and of such Member Associated Person(s), if any;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the class and number of shares of the company which are owned beneficially and of record by such member(s) and such Member Associated Person(s), if any;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)a description of any derivative instruments and short interests, if any, held directly or indirectly by such member(s) and such Member Associated Person(s), if any;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)a description of all agreements, arrangements and understandings between such member(s) and such Member Associated Person(s), if any, each proposed nominee and any other person or persons (including their names) in connection with the nomination of a director or the proposal of any other business by such member(s) or such Member Associated Person(s), if any;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)any other information relating to such member(s) and such Member Associated Person(s), if any, that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies pursuant to Section 14 of the Exchange Act; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)to the extent known by the member(s) giving the notice and the Member Associated Person(s), if any, on whose behalf the nomination or proposal is made, the name and address of any other member or Member Associated Person(s) supporting the nominee for election or re-election as a director or the proposal of other business on the date of such request.

(B)For the purposes of this <u>Article 76</u>, a Member Associated Person of any member shall mean:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)any person controlling, directly or indirectly, or acting in concert with, such member;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)any beneficial owner of shares in the capital of the company owned of record or beneficially by such member; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)any person controlling, controlled by or under common control with such Member Associated Person.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(C)If a request made in accordance with <u>Article 76(A)</u> does not include the information specified in that article, or if, without prejudice to the rights of any member under the Companies Act, such request is not received in the time and manner required by <u>Article 76(D)</u>, in respect of shares owned beneficially by the requesting member(s) and any Member Associated Person(s), such holders shall not be entitled to vote, either personally (including by means of electronic facility or facilities), by proxy (including by means of electronic facility or facilities) or, in the case of a corporation, by a company representative (including by means of electronic facility or facilities) at a general meeting or at a separate general meeting of the holders of that class of shares (or at an adjournment of any such meeting).

(D)Without prejudice to the rights of any member under the Companies Act, a member who makes a request of the kind referred to in <u>Article 76(A)(y)</u>, must deliver any such request in writing to the secretary at the office not earlier than the close of business on the one hundred and twentieth (120th) calendar day nor later than the close of business on the ninetieth (90th) calendar day prior to the date of the first anniversary of the preceding year's annual general meeting provided, however, that in the event that the date of an annual general meeting is more than thirty (30) calendar days before or more than sixty (60) calendar days after the date of the first anniversary of the preceding year's annual general meeting, notice by the member must be so delivered in writing not earlier than the close of business on the one hundred and twentieth (120th) calendar day prior to such annual general meeting and not later than the close of business on the later of (i) the ninetieth (90th) calendar day prior to such annual general meeting and (ii) the tenth (10th) calendar day after the day on which public announcement of the date of such annual general meeting is first made by the company. In no event shall any adjournment or postponement of an annual general meeting or the public announcement thereof commence a new time period for the giving of a member's notice as described in this <u>Article 76(D)</u>.

Notwithstanding the provisions of <u>Articles 76(A)</u> or <u>76(C)</u> or the foregoing provisions of this <u>Article 76(D)</u>, a member shall also comply with all applicable requirements of the Companies Act and of the Exchange Act with respect to the matters set forth in <u>Articles 76(A)</u>, <u>76(C)</u> and in this <u>Article 76(D)</u>. Nothing in <u>Articles 76(A)</u> or <u>76(C)</u> or in this <u>Article 76(D)</u> shall be deemed to affect any rights of members to request inclusion of proposals in, nor the right of the company to omit proposals from, the company's proxy statement pursuant to Rule 14a-8 (or any successor provision) under the Exchange Act, subject in each case to compliance with the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)Subject to the provisions of these Articles, only such persons who are eligible pursuant to Article 84 shall be eligible to serve as directors and only such business shall be conducted at a general meeting as shall have been brought before the general meeting by or at the direction of the directors or pursuant to a member request that complies with the procedures set forth in this Article 76. Except as otherwise provided by law or these Articles, the chair of the general meeting shall have the power and duty to determine whether a member request was made in compliance with the procedures set forth in this Article 76 and, if any request is not in compliance with this Article 76, to declare that such defective request shall be disregarded.

**77. Number of Directors**

The company must have a minimum of two directors and a maximum of 15 directors (disregarding alternate directors). The shareholders can change this restriction by passing an ordinary resolution.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**78. Directors' Shareholding Qualification**

The directors are not required to hold any shares in the company.

**79. Power of Company to Appoint Directors**

Subject to these articles, the company can, by passing an ordinary resolution, appoint any willing person to be a director, either as an extra director or to fill a vacancy where a director has stopped being a director for some reason.

**80. Power of Directors to Appoint Directors**

Subject to these articles, the directors can appoint any willing person to be a director, either as an extra director or as a replacement for another director. Any director appointed in this way must retire from office at the first annual general meeting after his appointment. A director who retires in this way is then eligible for re-appointment.

**81. Retirement of Directors by Rotation**

(A)At every annual general meeting all directors shall retire from office.

(B)Any director who retires at an annual general meeting may offer himself for re- appointment by the shareholders.

**82. Filling Vacancies**

Subject to these articles, at the general meeting at which a director retires, shareholders can pass an ordinary resolution to re-appoint the director or to appoint some other eligible person in his place.

**83. Power of Removal by Special Resolution**

In addition to any power to remove directors conferred by the legislation, the company can pass a special resolution to remove a director from office even though his time in office has not ended and can (subject to these articles) appoint a person to replace a director who has been removed in this way by passing an ordinary resolution.

**84. Persons Eligible as Directors**

The only people who can be appointed as directors at a general meeting are the following:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)directors retiring at the general meeting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)anyone recommended by the directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)before the Determination Date, anyone nominated by a shareholder (not being the person to be nominated) in the following way:-

The shareholder must be entitled to vote at the general meeting. He must deliver to the office not less than seven nor more than 42 days before the day of the general meeting:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)a letter stating that he intends to nominate another person for appointment as a director; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)written confirmation from that person that he is willing to be appointed; and

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)on or after the Determination Date, they are proposed for appointment pursuant to and in accordance with <u>Article 76.</u>

**85. Position of Retiring Directors**

A director retiring at a general meeting retires at the end of that general meeting or (if earlier) when a resolution is passed to appoint another person in the director's place. Where a retiring director is re-appointed, he continues as a director without a break.

**86. Vacation of Office by Directors**

(A)Any director automatically stops being a director if:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)he gives the company a written notice of resignation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)he gives the company a written notice in which he offers to resign and the directors decide to accept this offer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)all of the other directors (who must comprise at least three people) pass a resolution or sign a written notice removing him as a director;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)he is or has been suffering from mental or physical ill health and the directors pass a resolution removing the director from office;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)he has missed directors' meetings (whether or not an alternate director appointed by him attends those meetings) for a continuous period of six months without permission from the directors and the directors pass a resolution removing the director from office;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)a bankruptcy order is made against him or he makes any arrangement or composition with his creditors generally;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)he is prohibited from being a director under the legislation; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)he ceases to be a director under the legislation or he is removed from office under these articles.

(B)If a director stops being a director for any reason, he will also automatically cease to be a member of any committee or sub-committee of the directors.

**87. Executive Directors**

(A)The directors or any committee authorised by the directors can appoint one or more directors to any executive position, on such terms and for such period as they think fit. They can also terminate or vary an appointment at any time. The directors or any committee authorised by the directors will decide how much remuneration a director appointed to an executive office will receive (whether as salary, commission, profit share or any other form of remuneration) and whether this is in addition to or in place of his fees as a director.

(B)If the directors terminate the appointment, the termination will not affect any right of the company or the director in relation to any breach of any employment contract which may be involved in the termination.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**88. Additional Remuneration**

(A)The directors or any committee authorised by the directors can award extra fees to any director who, in their view, performs any special or extra services for the company.

(B)Extra fees can take the form of salary, commission, profit-sharing or other benefits (and can be paid partly in one way and partly in another). This is all decided by the directors or any committee authorised by the directors.

**89. Expenses**

The company can pay the reasonable travel, hotel and incidental expenses of each director incurred in attending and returning from general meetings, meetings of the directors or committees of the directors or any other meetings which as a director he is entitled to attend. The company will pay all other expenses properly and reasonably incurred by each director in connection with the company's business or in the performance of his duties as a director. The company can also fund a director's or former director's expenditure and that of a director or former director of any holding company of the company for the purposes permitted by the legislation and can do anything to enable a director or former director or a director or former director of any holding company of the company to avoid incurring such expenditure all as provided in the legislation.

**90. Pensions and Gratuities for Directors**

(A)The directors or any committee authorised by the directors can decide whether to provide pensions, annual payments or other benefits to any director or former director of the company, or any relation or dependant of, or person connected to, such a person. The directors can also decide to contribute to a scheme or fund or to pay premiums to a third party for these purposes. The company can only provide pensions and other benefits to people who are or were directors but who have not been employed by, or held an office or executive position in, the company or any of its subsidiary undertakings or former subsidiary undertakings or any predecessor in business of the company or any such other company or to relations or dependants of, or persons connected to, these directors or former directors if the shareholders approve this by passing an ordinary resolution.

(B)A director or former director will not be accountable to the company or the shareholders for any benefit provided pursuant to this article. Anyone receiving such a benefit will not be disqualified from being or becoming a director of the company.

**91. Directors' Interests**

*Conflicts of interest requiring authorisation by directors*

(A)The directors may, subject to the quorum and voting requirements set out in this article, authorise any matter which would otherwise involve a director breaching his duty under the legislation to avoid conflicts of interest ("Conflict").

(B)A director seeking authorisation in respect of a Conflict must tell the directors of the nature and extent of his interest in a Conflict as soon as possible. The director must give the directors sufficient details of the relevant matter to enable them to decide how to address the Conflict together with any additional information which they may request.

(C)Any director (including the relevant director) may propose that the relevant director be authorised in relation to any matter the subject of a Conflict. Such proposal and any authority

&nbsp;&nbsp;&nbsp;&nbsp;

------

given by the directors shall be effected in the same way that any other matter may be proposed to and resolved upon by the directors under the provisions of these articles except that:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the relevant director and any other director with a similar interest will not count in the quorum and will not vote on a resolution giving such authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the relevant director and any other director with a similar interest may, if the other directors so decide, be excluded from any meeting of the directors while the Conflict is under consideration.

(D)Where the directors give authority in relation to a Conflict or where any of the situations described in <u>paragraph [(F)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>applies in relation to a director ("Relevant Situation"):-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the directors may (whether at the relevant time or subsequently) (a) require that the relevant director is excluded from the receipt of information, the participation in discussion and/or the making of decisions (whether at directors' meetings or otherwise) related to the Conflict or Relevant Situation; and (b) impose upon the relevant director such other terms for the purpose of dealing with the Conflict or Relevant Situation as they think fit;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the relevant director will be obliged to conduct himself in accordance with any terms imposed by the directors in relation to the Conflict or Relevant Situation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)the directors may also provide that where the relevant director obtains (otherwise than through his position as a director of the company) information that is confidential to a third party, the director will not be obliged to disclose that information to the company, or to use or apply the information in relation to the company's affairs, where to do so would amount to a breach of that confidence;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)the terms of the authority shall be recorded in writing (but the authority shall be effective whether or not the terms are so recorded); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)the directors may revoke or vary such authority at any time but this will not affect anything done by the relevant director prior to such revocation or variation in accordance with the terms of such authority.

*Other conflicts of interest*

(E)If a director knows that he is in any way directly or indirectly interested in a proposed contract with the company or a contract that has been entered into by the company, he must tell the other directors of the nature and extent of that interest in accordance with the legislation.

(F)If he has disclosed the nature and extent of his interest in accordance with <u>paragraph [(E)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>a director can do any one or more of the following:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)have any kind of interest in a contract with or involving the company or another company in which the company has an interest;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)hold any other office or place of profit with the company (except that of auditor) in conjunction with his office of director for such period and upon such terms, including as to remuneration, as the directors may decide;

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)alone, or through a firm with which he is associated do paid professional work for the company or another company in which the company has an interest (other than as auditor);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)be or become a director or other officer of, or employed by or a party to a transaction or arrangement with, or otherwise be interested in any holding company or subsidiary company of the company or any other company in which the company has an interest; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)be or become a director of any other company in which the company does not have an interest and which cannot reasonably be regarded as giving rise to a conflict of interest at the time of his appointment as a director of that other company.

*Benefits*

(G)A director does not have to hand over to the company or the shareholders any benefit he receives or profit he makes as a result of anything authorised under <u>paragraph [(A)](#i540905e2ce5c4158a775816c0c5568b4_4)</u> or allowed under <u>paragraph [(F)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>nor is any type of contract authorised under <u>paragraph</u> <u>[(A)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>or allowed under <u>paragraph [(F)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>liable to be avoided.

*Quorum and voting requirements*

(H)A director cannot vote or be counted in the quorum on a resolution of the directors relating to appointing that director to a position with the company or a company in which the company has an interest or the terms or the termination of the appointment.

(I)This paragraph applies if the directors are considering proposals about appointing two or more directors to positions with the company or any company in which the company has an interest. It also applies if the directors are considering setting or changing the terms of their appointment. These proposals can be split up to deal with each director separately. If this is done, each director can vote and be included in the quorum for each resolution, except any resolution concerning him or concerning the appointment of another director to a position with a company in which the company is interested where the director has a Relevant Interest in it.

(J)A director cannot vote or be counted in the quorum on a resolution of the directors about a contract in which he has an interest and, if he does vote, his vote will not be counted, but this prohibition will not apply to any resolution where that interest cannot reasonably be regarded as likely to give rise to a conflict of interest or where that interest is included in the following list:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)a resolution about giving him any guarantee, indemnity or security for money which he or any other person has lent or obligations he or any other person has undertaken at the request of or for the benefit of the company or any of its subsidiary undertakings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)a resolution about giving any guarantee, indemnity or security to another person for a debt or obligation which is owed by the company or any of its subsidiary undertakings to that other person if the director has taken responsibility for some or all of that debt or obligation. The director can take this responsibility by giving a guarantee, indemnity or security;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)a resolution about giving him any other indemnity where all other directors are also being offered indemnities on substantially the same terms;

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)a resolution about the company funding his expenditure on defending proceedings or the company doing something to enable him to avoid incurring such expenditure where all other directors are being offered substantially the same arrangements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)a resolution relating to an offer by the company or any of its subsidiary undertakings of any shares or debentures or other securities for subscription or purchase if the director takes part because he is a holder of shares, debentures or other securities or if he takes part in the underwriting or sub-underwriting of the offer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)a resolution about a contract in which he has an interest because of his interest in shares or debentures or other securities of the company or because of any other interest in or through the company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)a resolution about a contract involving any other company if the director has an interest of any kind in that company (including an interest by holding any position in that company or by being a shareholder in that company). This does not apply if he knows that he has a Relevant Interest in that company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)a resolution about a contract relating to a pension fund, superannuation or similar scheme or retirement, death or disability benefits scheme or employees' share scheme which gives the director benefits which are also generally given to the employees to whom the fund or scheme relates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)a resolution about a contract relating to an arrangement for the benefit of employees of the company or of any of its subsidiary undertakings which only gives him benefits which are also generally given to the employees to whom the arrangement relates; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)a resolution about a contract relating to any insurance which the company can buy or renew for the benefit of directors or of a group of people which includes directors.

(K)A director will be treated as having a Relevant Interest in a company if he holds an interest in shares representing one per cent. or more of a class of equity share capital (calculated exclusive of any shares of that class in that company held as treasury shares) or of the voting rights of that company. In relation to an alternate director, an interest of his appointor shall be treated as an interest of the alternate director without prejudice to any interest which the alternate director has otherwise. Interests which are unknown to the director and which it is unreasonable to expect him to know about are ignored.

(L)Where a company in which a director has a Relevant Interest is interested in a contract, the director will also be treated as being interested in that contract.

(M)Subject to these articles, the directors can exercise or arrange for the exercise of the voting rights attached to any shares in another company held by the company and the voting rights which they have as directors of that company in any way that they decide. This includes voting in favour of a resolution appointing any of them as directors or officers of that company and deciding their remuneration. Subject to these articles, they can also vote and be counted in the quorum as directors of the company in connection with any of these things.

(N)If a question comes up at a meeting of the directors about whether a director (other than the chair of the meeting) has an interest in a contract and whether it is likely to give rise to a conflict of interest or whether he can vote or be counted in the quorum and the director does not agree to abstain from voting on the issue or not to be counted in the quorum, the question

&nbsp;&nbsp;&nbsp;&nbsp;

------

must be referred to the chair of the meeting. The chair of the meeting's ruling about any other director is final and conclusive unless the nature or extent of the director's interest (so far as it is known to him) has not been fairly disclosed to the directors. If the question comes up about the chair of the meeting, the question shall be decided by a resolution of the directors. The chair of the meeting cannot vote on the question but can be counted in the quorum. The directors' resolution about the chair of the meeting is conclusive, unless the nature or extent of the chair's interest (so far as it is known to him) has not been fairly disclosed to the directors.

*General*

(O)References in this article to:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)a contract include references to an existing or proposed contract and to an existing or proposed transaction or arrangement whether or not it is a contract; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)a conflict of interest include a conflict of interest and duty and a conflict of duties.

(P)The company can by ordinary resolution suspend or relax the provisions of this article to any extent or ratify any contract which has not been properly authorised in accordance with this article.

**92. General Powers of Company Vested in Directors**

(A)The directors will manage the company's business. They can use all the company's powers except where these articles say that powers can only be used by the shareholders voting to do so at a general meeting. The general management powers under this article are not limited in any way by specific powers given to the directors by other articles.

(B)The directors are, however, subject to:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the requirements of these articles; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)any regulations laid down by the shareholders by passing a special resolution at a general meeting.

(C)If a change is made to these articles or if the shareholders lay down any regulation relating to something which the directors have already done which was within their powers, that change or regulation cannot invalidate the directors' previous action.

**93. Borrowing Powers**

(A)The directors can exercise all the company's powers:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)to borrow money;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)to guarantee;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)to indemnify;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)to mortgage or charge all or any of the company's undertaking, property and assets (present and future) and uncalled capital;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)to issue debentures and other securities; and

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)to give security, either outright or as collateral security, for any debt, liability or obligation of the company or of any third party.

(B)(i)&nbsp;&nbsp;&nbsp;&nbsp;The directors must limit the borrowings of the company and exercise all voting and other rights or powers of control exercisable by the company in relation to its subsidiary undertakings so as to ensure that no money is borrowed if the total amount of the group's borrowings then exceeds, or would as a result of such borrowing exceed, three times the company's adjusted capital and reserves. This affects subsidiary undertakings only to the extent that the directors can do this by exercising these rights or powers of control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)This limit can be exceeded if the consent of the shareholders has been given in advance by passing an ordinary resolution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)This limit does not include any borrowings owing by one member of the group to another member of the group.

(C)Adjusted capital and reserves

The company's adjusted capital and reserves will be established by the following calculations:-

Add:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the amount paid up or credited or deemed to be paid up on the company's issued share capital (including any shares held as treasury shares); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the amount standing to the credit of the reserves of the company (which include any share premium account, capital redemption reserve and retained earnings),

using the figures shown on the then latest audited balance sheet.

Then:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)deduct any debit balance on retained earnings at the date of the audited balance sheet (if such a deduction has not already been made),

and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)make any adjustments needed to reflect any changes since the date of the audited balance sheet to the amount of paid up share capital or reserves.

(D)Borrowings

When calculating the group's borrowings, the directors will include not only borrowings but also the following (unless these have already been included in borrowings):-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the amount of any issued and paid up share capital (other than equity share capital) of any subsidiary undertaking beneficially owned otherwise than by a member of the group;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the amount of any other issued and paid up share capital and the principal amount of any debentures or borrowed moneys not beneficially owned by a member of the group where a member of the group has given a guarantee or indemnity for its redemption or repayment or where a member of the group may have to buy such share capital, debenture or borrowed money;

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)the amount outstanding under any acceptance credits opened for or in favour of any member of the group;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)the principal amount of any debenture (whether secured or unsecured) issued by any member of the group which is not beneficially owned by any other member of the group;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)any fixed or minimum premium payable on the final repayment of any borrowing or deemed borrowing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)the minority proportion of moneys borrowed by a member of the group and owing to a partly-owned subsidiary undertaking.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)However, the directors will not include the following items in the borrowings:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)amounts borrowed by any member of the group to repay some or all of any other borrowings of any member of the group (but this exclusion will only apply if the original debt is discharged within six months from the new borrowing);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)amounts borrowed by any member of the group to finance any contract where part of the price receivable by any member of the group is guaranteed or insured by the Export Credits Guarantee Department or any other similar government department or agency (but this exclusion will only apply up to an amount equal to the amount guaranteed or insured);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)amounts borrowed by, or amounts secured on assets of, an undertaking which became a subsidiary undertaking of the company after the date of the last audited balance sheet (but this exclusion will only apply up to an amount equal to the amount of borrowing, or amounts secured on assets, of the undertaking at the time immediately after it became a subsidiary undertaking); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)the minority proportion of moneys borrowed by a partly-owned subsidiary undertaking which is not owing to another member of the group.

(E)Any foreign currency amounts will be translated into US dollars when calculating total borrowings. The exchange rate applied will be the exchange rate on:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the last business day before the date of the calculation; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the last business day six months before the date of the calculation, whichever exchange rate produces the lower figure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)The exchange rate will be taken as the spot rate in London which is recommended by a London clearing bank (chosen by the directors for this purpose) as the most appropriate rate for buying the relevant currency for US dollars on the relevant day.

(G)If the amount of adjusted capital and reserves is being calculated in connection with a transaction involving a company becoming or ceasing to be a member of the group, the amount is to be calculated as if the transaction had already occurred.

(H)The audited balance sheet of the company will be taken as the audited balance sheet of the company prepared for the purposes of the legislation. However, if an audited consolidated balance sheet relating to the company and its subsidiary undertakings has been prepared for

&nbsp;&nbsp;&nbsp;&nbsp;

------

the same financial year, the audited consolidated balance sheet will be used instead. In that case, all references to reserves will be taken to be references to consolidated reserves.

(I)The company can from time to time change the accounting convention applied in the preparation of the audited balance sheet, but any new convention applied must comply with the requirements of the legislation. If the company prepares a supplementary audited balance sheet applying a different convention from the main audited balance sheet, the main audited balance sheet will be taken as the audited balance sheet for the purposes of the calculations under these articles.

(J)The group will be taken as the company and its subsidiary undertakings (if any).

(K)For the purposes of this article the minority proportion means a proportion equal to the proportion of the issued share capital of a partly-owned subsidiary undertaking which does not belong to a member of the group.

(L)A certificate or report by the company's auditors:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)as to the amount of the adjusted capital and reserves;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)as to the amount of any borrowings; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)to the effect that the limit imposed by this article has not been or will not be exceeded at any particular time,

will be conclusive evidence of that amount or that fact.

**94. Agents**

(A)The directors can appoint anyone as the company's attorney by granting a power of attorney or by authorising them in some other way. Attorneys can either be appointed directly by the directors or the directors can give someone else the power to select attorneys. The directors or the persons who are authorised by them to select attorneys can decide on the purposes, powers, authorities and discretions of attorneys. But they cannot give an attorney any power, authority or discretion which the directors do not have under these articles.

(B)The directors can decide how long a power of attorney will last for and attach any conditions to it. The power of attorney can include any provisions which the directors decide on for the protection and convenience of anybody dealing with the attorney. The power of attorney can allow the attorney to grant any or all of his power, authority or discretion to any other person.

(C)The directors can:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)delegate any of their authority, powers or discretions to any manager or agent of the company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)allow managers or agents to delegate to another person;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)remove any people they have appointed in any of these ways; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)cancel or change anything that they have delegated, although this will not affect anybody who acts in good faith who has not had any notice of any cancellation or change.

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)Any appointment or delegation by the directors which is referred to in this article can be on any conditions decided on by the directors.

(E)The ability of the directors to delegate under this article applies to all their powers and is not limited because certain articles refer to powers being exercised by the directors or by a committee authorised by the directors while other articles do not.

**95. Delegation to Individual Directors**

(A)The directors can give a director any of the powers which they have jointly as directors (with power to sub-delegate). These powers can be given on terms and conditions decided on by the directors either in parallel with, or in place of, the powers of the directors acting jointly.

(B)The directors can change the basis on which such powers are given or withdraw such powers. But if a person deals with an individual director in good faith without knowledge of the change or withdrawal, he will not be affected by it.

(C)The ability of the directors to delegate under this article applies to all their powers and is not limited because certain articles refer to powers being exercised by the directors or by a committee authorised by the directors while other articles do not.

**96. Registers**

The company can keep an overseas, local or other register. The directors can make and change any regulations previously made by them relating to any of such registers.

**97. Provision for Employees**

The directors can exercise the powers under the legislation to make provision for the benefit of employees or former employees of the company or any of its subsidiaries in connection with the cessation or transfer of the whole or part of the business of the company or that subsidiary.

**98. Directors' Meetings**

The chair, chief executive officer, lead independent director (if any) or a majority of the directors can each call a directors' meeting and decide when and where to have meetings and how they will be conducted. They can also adjourn their meetings. The secretary must call a directors' meeting if asked to by any of the aforementioned persons.

**99. Notice of Directors' Meetings**

Directors' meetings are called by giving notice to all the directors. Notice is treated as properly given if it is given personally, by word of mouth or in writing to the director's last known address or any other address given by him to the company for this purpose. Any director can waive his entitlement to notice of any directors' meeting, including one which has already taken place and any waiver after the meeting has taken place will not affect the validity of the meeting or any business conducted at the meeting.

**100. Quorum**

If no other quorum is fixed by the directors, two directors are a quorum. Subject to these articles, if a director ceases to be a director at a directors' meeting, he can continue to be present and to act as a director and be counted in the quorum until the end of the meeting if no other director objects and if otherwise a quorum of directors would not be present.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**101. Directors below Minimum through Vacancies**

(A)The directors can continue to act even if one or more of them stops being a director. If the number of directors falls below the minimum which applies under these articles (including any change to that minimum number approved by an ordinary resolution of shareholders), or the number fixed as the quorum for directors' meetings, the remaining director(s) may appoint further directors and convene general meetings to make up the shortfall.

(B)If no director or directors are willing or able to act under this article, any two shareholders (excluding any shareholder holding shares as treasury shares) can call a general meeting to appoint extra directors(s).

**102. Appointment of Chair**

(A)The directors can appoint any director as chair or as deputy chair and can remove him from that office at any time. If the chair is at a directors' meeting, he will chair it. In his absence, the chair will be taken by a deputy chair, if one is present. If more than one deputy chair is present, they will agree between them who should chair the meeting or, if they cannot agree, the deputy chair longest in office as a director will take the chair. If there is no chair or deputy chair present within five minutes of the time when the directors' meeting is due to start, the directors who are present can choose which one of them will be the chair of the meeting.

(B)References in these articles to a deputy chair include, if no one has been appointed with that title, a person appointed to a position with another title which the directors designate as equivalent to the position of deputy chair.

**103. Competence of Meetings**

A directors' meeting at which a quorum is present can exercise all the powers and discretions of the directors.

**104. Voting**

Matters to be decided at a directors' meeting will be decided by a majority vote. If votes are equal, the chair of the meeting has a second, casting vote.

**105. Delegation to Committees**

(A)The directors can delegate any of their powers or discretions to committees of one or more persons. If the directors have delegated any power or discretion to a committee, any references in these articles to using that power or discretion include its use by the committee. Any committee must comply with any regulations laid down by the directors. These regulations can require or allow people who are not directors to be members of the committee, and can give voting rights to such people. But:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)there must be more directors on a committee than persons who are not directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)a resolution of the committee is only effective if a majority of the members of the committee present at the time of the resolution were directors.

(B)Unless the directors decide not to allow this, any committee can sub-delegate any of its powers or discretions to sub-committees. Reference in these articles to committees include sub-committees permitted under this article.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(C)If a committee consists of more than one person, the articles which regulate directors' meetings and their procedure will also apply to committee meetings (if they can apply to committee meetings), unless these are inconsistent with any regulations for the committee which have been laid down under this article.

(D)The ability of the directors to delegate under this article applies to all their powers and discretions and is not limited because certain articles refer to powers and discretions being exercised by committees authorised by directors while other articles do not.

**106. Participation in Meetings**

All or any of the directors can take part in a meeting of the directors by way of a conference telephone or any communication equipment which allows everybody to take part in the meeting by being able to hear each of the other people at the meeting and by being able to speak to all of them at the same time. A person taking part in this way will be treated as being present at the meeting and will be entitled to vote and be counted in the quorum.

**107. Resolution in Writing**

A resolution in writing must be signed by all of the directors who at the time are entitled to receive notice of a directors' meeting and who would be entitled to vote on the resolution at a directors' meeting, and who together meet the quorum requirement for directors' meetings. This kind of resolution is just as valid and effective as a resolution passed by those directors at a meeting which is properly called and held. The resolution can be passed using several copies of the resolution if each copy is signed by one or more directors.

**108. Validity of Acts of Directors or Committee**

Everything which is done by any directors' meeting, or by a committee of the directors, or by a person acting as a director, or as a member of a committee, will be valid even if it is discovered later that any director, or person acting as a director, was not properly appointed. This also applies if it is discovered later that anyone was disqualified from being a director, or had ceased to be a director or was not entitled to vote. In any of these cases, anything done will be as valid as if there was no defect or irregularity of the kind referred to in this article.

**109. Use of Seals**

(A)The directors must arrange for every seal of the company to be kept safely.

(B)A seal can only be used with the authority of the directors or a committee authorised by the directors.

(C)Subject as otherwise provided in these articles, every document which is sealed using the common seal must be signed by one director and the secretary, or by two directors or by one director in the presence of a witness who attests the signature or by any other person or persons authorised by the directors.

(D)Any document to which the official seal is applied need not be signed, unless the directors decide otherwise or the legislation requires otherwise.

(E)The directors can resolve that the requirement for any counter-signature in this article can be dispensed with on any occasion.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**110. Declaration of Dividends by Company**

The company's shareholders can declare dividends in accordance with the rights of the shareholders by passing an ordinary resolution. No such dividend can exceed the amount recommended by the directors.

**111. Payment of Interim and Fixed Dividends by Directors**

(A)If the directors consider that the financial position of the company justifies such payments, they can:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)pay the fixed or other dividends on any class of shares on the dates prescribed for the payment of those dividends; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)pay interim dividends on shares of any class of any amounts and on any dates and for any periods which they decide.

(B)If the directors act in good faith, they will not be liable for any loss that any shareholders may suffer because a lawful dividend has been paid on other shares which rank equally with or behind their shares.

**112. Calculation and Currency of Dividends**

(A)All dividends will be declared and paid in proportions based on the amounts paid up on the shares during any period for which the dividend is paid. Sums which have been paid up in advance of calls will not count as paid up for this purpose. If the terms of any share say that it will be entitled to a dividend as if it were a fully paid up, or partly paid up, share from a particular date (in the past or future), it will be entitled to a dividend on this basis. This article applies unless these articles, the rights attached to any shares, or the terms of any shares, say otherwise.

(B)Unless the rights attached to any shares, the terms of any shares or these articles say otherwise, a dividend or any other money payable in respect of a share can be paid in whatever currency the directors decide using an exchange rate selected by the directors for any currency conversions required. The directors can also decide how any costs relating to the choice of currency will be met.

**113. Amounts Due on Shares can be Deducted from Dividends**

If a shareholder owes the company any money for calls on shares or money in any other way relating to his shares, the directors can deduct any of this money from any dividend or other money payable to the shareholder on or in respect of any share held by him. Money deducted in this way can be used to pay amounts owed to the company.

**114. No Interest on Dividends**

Unless the rights attached to any shares, or the terms of any shares, say otherwise, no dividend or other sum payable by the company on or in respect of its shares carries a right to interest from the company.

**115. Payment Procedure**

(A)Any dividend or other money payable in cash relating to a share can be paid by sending a cheque, warrant or similar financial instrument payable to the shareholder who is entitled to it by post addressed to his registered address. Or it can be made payable to someone else

&nbsp;&nbsp;&nbsp;&nbsp;

------

named in a written instruction from the shareholder (or all joint shareholders) and sent by post to the address specified in that instruction. A dividend can also be paid by inter-bank transfer or by other electronic means (including payment through CREST) directly to an account with a bank or other financial institution (or other organisations operating deposit accounts if allowed by the company) in the United Kingdom named in a written instruction from the person entitled to receive the payment under this article. Alternatively, a dividend can be paid in some other way requested in writing by the shareholder (or all joint shareholders) and agreed with the company.

(B)For joint shareholders or persons jointly entitled to shares by law, payment can be made to the shareholder whose name stands first in the register. The company can rely on a receipt for a dividend or other money paid on shares from any one of them on behalf of all of them.

(C)Cheques, warrants and similar financial instruments are sent, and payment in any other way is made, at the risk of the person who is entitled to the money. The company is treated as having paid a dividend if the cheque, warrant or similar financial instrument is cleared or if a payment is made through CREST, bank transfer or other electronic means. The company will not be responsible for a payment which is lost or delayed.

(D)Dividends can be paid to a person who has become entitled to a share by law as if he were the holder of the share.

**116. Uncashed Dividends**

(A)The company can stop sending dividend payments through the post, or cease using any other method of payment (including payment through CREST), for any dividend if:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)for two consecutive dividends:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the dividend payments sent through the post have been returned undelivered or remain uncashed during the period for which they are valid; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the payments by any other method have failed; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)for any one dividend:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the dividend payment sent through the post has been returned undelivered or remains uncashed during the period for which it is valid; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the payment by any other method has failed,

and reasonable enquiries have failed to establish any new postal address or account of the registered shareholder.

(B)Subject to these articles, the company must recommence sending dividend payments if requested in writing by the shareholder, or the person entitled to a share by law.

**117. Forfeiture of Unclaimed Dividends**

Where any dividends or other amounts payable on a share have not been claimed, the directors can invest them or use them in any other way for the company's benefit until they are claimed. The company will not be a trustee of the money and will not be liable to pay interest on it. If a dividend or other money has not been claimed for six years after being declared or becoming due for payment, it will be forfeited and go back to the company unless the directors decide otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**118. Dividends Not in Cash**

If recommended by the directors, the company can pass an ordinary resolution that a dividend be paid, and the directors can decide that an interim dividend be paid, wholly or partly by distributing specific assets (and, in particular, paid up shares or debentures of any other company). Where any difficulty arises on such a distribution, the directors can resolve it as they decide. For example, they can:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)authorise any person to sell and transfer any fractions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)ignore any fractions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)value assets for distribution purposes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)pay cash of a similar value to adjust the rights of shareholders; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)vest any assets in trustees for the benefit of more than one shareholder.

**119. Scrip Dividends**

The directors can offer ordinary shareholders (excluding any shareholder holding shares as treasury shares) the right to choose to receive extra ordinary shares, which are credited as fully paid up, instead of some or all of their cash dividend. Before they can do this, shareholders must have passed an ordinary resolution authorising the directors to make this offer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)The ordinary resolution can apply to some or all of a particular dividend or dividends. Or it can apply to some or all of the dividends which may be declared or paid in a specified period. The specified period must not end later than the fifth anniversary of the date on which the ordinary resolution is passed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)The directors can also offer shareholders the right to request new shares instead of cash for all future dividends (if a share alternative is available), until they tell or are treated as telling the company that they no longer wish to receive new shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)A shareholder will be entitled to ordinary shares whose total "relevant value" is as near as possible to the cash dividend he would have received (disregarding any tax credit), but not more than it. The relevant value of a share is the average value of the company's ordinary shares for five consecutive dealing days selected by the directors starting on or after the day when the shares are first quoted "ex dividend". For this purpose, the value of each new share shall be equal to the average quotation for the company's ordinary shares, that is, the average of the closing prices for the company's ordinary shares on the Nasdaq Global Select Market (or if a Nasdaq quote is not available, such other exchange or quotation service on which the company's ordinary shares are listed or quoted as derived from such source as the board may deem appropriate) on the day on which the company's ordinary shares are first quoted *"*ex" the relevant dividend and the four subsequent business days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)The ordinary resolution can require that the relevant value is worked out in some different way. A certificate or report by the auditors stating the relevant value of a share for any dividend will be conclusive evidence of that value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)After the directors have decided how many new shares ordinary shareholders will be entitled to, they can notify them in writing of their right to opt for new shares. This

&nbsp;&nbsp;&nbsp;&nbsp;

------

notice should also say how, where and when shareholders must notify the company if they wish to receive new shares. Where shareholders have opted to receive new shares in place of all future dividends, if new shares are available, the company will not need to notify them of a right to opt for new shares. No shareholders will receive a fraction of a share. The directors can decide how to deal with any fractions left over. For example, they can decide that the benefit of these fractions belongs to the company or that fractions are ignored or deal with fractions in some other way.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)If a notice informing any shareholders of their right to opt for new shares is accidentally not sent or supplied or is not received (even if the company becomes aware of such failure to send or supply or non-receipt), the offer will not be invalid as a result nor give rise to any claim, suit or action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)The directors can exclude or restrict the right to opt for new shares or make any other arrangements where they decide that this is necessary or convenient to deal with any of the following legal or practical problems:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)problems relating to laws of any territory, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)problems relating to the requirements of any recognised regulatory body or stock exchange in any territory,

or where the directors believe that for any other reason the right should not be given.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)If a shareholder has opted to receive new shares, no dividend on the shares for which he has opted to receive new shares (which are called the "elected shares"), will be declared or payable. Instead, new ordinary shares will be allotted on the basis set out earlier in this article. To do this, the directors will convert into capital the sum equal to the total amount of the new ordinary shares to be allotted. They will use this sum to pay up in full the appropriate number of new ordinary shares. These will then be allotted and distributed to the holders of the elected shares on the basis set out above. The sum to be converted into capital can be taken from:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)any amount which is then in any reserve or fund (including the share premium account, any capital redemption reserve and the profit and loss account or retained earnings); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any other sum which is available to be distributed.

The directors can do anything they think necessary to give effect to any such conversion into capital.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)The new ordinary shares will rank equally in all respects with the existing fully paid up ordinary shares at the time when the new ordinary shares are allotted. But, they will not be entitled to share in the dividend from which they arose, or to have new shares instead of that dividend.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)The directors can decide that new shares will not be available in place of any cash dividend. They can decide this at any time before new shares are allotted in place of such dividend, whether before or after shareholders have opted to receive new shares.

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)The directors can decide how any costs relating to making new shares available in place of a cash dividend will be met. For example, they can decide that an amount will be deducted from the entitlement of a shareholder under this article.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii)Unless the directors decide otherwise or unless the uncertificated securities rules require otherwise, any new ordinary shares which a shareholder has chosen to receive instead of some or all of his cash dividend will be:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)CREST shares if the corresponding elected shares were CREST shares on the record date for that dividend; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)certificated shares if the corresponding elected shares were certificated shares on the record date for that dividend.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii)The directors may not proceed with any election unless the company has sufficient reserves or funds that may be capitalised, and the directors have authority to allot sufficient shares, to give effect to it after the basis of allotment is determined.

**120. Power to Capitalise Reserves and Funds**

(A)If recommended by the directors, the company's shareholders can pass an ordinary resolution to capitalise any sum:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)which is part of any of the company's reserves (including premiums received when any shares were issued, capital redemption reserves or other undistributable reserves); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)which the company is holding as net profits.

(B)Unless the ordinary resolution states otherwise, the directors will use the sum which is capitalised by setting it aside for the ordinary shareholders on the register at the close of business on the day the resolution is passed (or another date stated in the resolution or fixed as stated in the resolution) and in the same proportions as the ordinary shareholders' entitlement to dividends (or in other proportions stated in the resolution or fixed as stated in the resolution). The sum set aside can be used:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)to pay up some or all of any amount on any issued shares which has not already been called, or paid in advance; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)to pay up in full shares, debentures or other securities of the company which would then be allotted and distributed, credited as fully paid, to shareholders.

However, a share premium account, a capital redemption reserve, or any reserve or fund representing unrealised profits, can only be used to pay up in full the company's shares that are then to be allotted and distributed, credited as fully paid, to shareholders. Where the sum capitalised is used to pay up in full shares that are then to be allotted and distributed, credited as fully paid, to shareholders, the company is also entitled to participate in the relevant distribution in relation to any shares of the relevant class held by it as treasury shares and the proportionate entitlement of the relevant class of shareholders to the distribution will be calculated on this basis.

(C)The directors can appoint any person to sign a contract with the company on behalf of those who are entitled to shares, debentures or other securities under the resolution. Such a contract is binding on all concerned.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**121. Settlement of Difficulties in Distribution**

If any difficulty arises in connection with any distribution of any capitalised reserve or fund, the directors can resolve it in any way which they decide. For example, they can deal with entitlements to fractions by deciding that the benefit of fractions belong to the company or that fractions are ignored or deal with fractions in some other way.

**122. Power to Choose Any Record Date**

This article applies to any dividend on any shares, or any distribution, allotment or issue to the holders of any shares. This can be paid or made to the registered holder or holders of the shares, or to anyone entitled in any other way, at a particular time on a particular day selected by the directors. It will be based on the number of shares registered at that time on that day, even if this is before any resolution to authorise what is being done was passed. This article applies whether what is being done is the result of a resolution of the directors, or a resolution at a general meeting. The time and date can be before the dividend and so on is to be paid or made, or before any relevant resolution was passed.

**123. Inspection of Records**

A shareholder is not entitled to inspect any of the company's accounting records or other books or papers unless:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the legislation or a proper court order gives him that right;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the directors authorise him to do so; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)the shareholders authorise him to do so by ordinary resolution.

**124. Strategic Reports with Supplementary Material**

The company can send or supply copies of its strategic reports with supplementary material to its shareholders instead of copies of its full reports and accounts.

**125. Method of Service**

(A)The company can send or supply any notice, document, including a share certificate, or other information to a shareholder:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)by delivering it to him personally;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)by addressing it to him and posting it to, or leaving it at, the shareholder's registered address;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)through CREST, where it relates to CREST shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)as authorised in writing by the relevant shareholder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)where appropriate, by sending or supplying it in electronic form to an address notified by the relevant shareholder to the company for that purpose; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)where appropriate, by making it available on a website and notifying the shareholder of its availability in accordance with this article.

&nbsp;&nbsp;&nbsp;&nbsp;

------

Where there are joint shareholders, the notice, document or other information can be sent or supplied to any one of the joint holders and will be treated as having been sent or supplied to all the joint holders.

The company shall be entitled, at its discretion, to utilize and rely on the notice and access method of delivering shareholder general meeting materials, soliciting proxies and receiving voting instructions from registered shareholders and beneficial owners adopted by the U.S. Securities and Exchange Commission in the rules for communication between reporting issuers and their shareholders under Rule 14a-16 of the Exchange Act, as such rules may be modified from time to time, or in accordance with any similar electronic delivery or access method permitted by applicable securities legislation from time to time.

(B)Where there are joint shareholders, anything which needs to be agreed or specified in relation to any notice, document or other information to be sent or supplied to them can be agreed or specified by any one of the joint shareholders. The agreement or specification of the senior will be accepted to the exclusion of the agreement or specification of the other joint shareholder(s). For this purpose, seniority will be determined by the order in which the joint shareholders' names stand in the register in respect of the joint shareholding.

(C)If any notice, document or other information sent or supplied to a shareholder at the shareholder's registered address has been returned undelivered and thereafter, the company (or its agents) has made customary efforts to establish such shareholder's current address without success, the company need not send or supply further notices, documents or other information to that shareholder until he has communicated with the company and supplied the company (or its agents) with a new registered address, or a postal address for the service of notices and the despatch or supply of documents and other information, or has informed the company of an address for the service of notices and the sending or supply of documents and other information in electronic form. Any notice, document or other information sent by post will be treated as returned undelivered if the notice, document or other information is sent back to the company (or its agents), and any notice, document or other information sent or supplied in electronic form will be treated as returned undelivered if the company (or its agents) receives notification that the notice, document or other information was not delivered to the address to which it was sent.

(D)The company may at any time and in its sole discretion choose (a) to serve, send or supply notices, documents or other information in hard copy form alone to some or all shareholders; and (b) not to serve, send or supply a notice, document or other information to a particular shareholder where it considers this necessary or appropriate to deal with legal, regulatory or practical problems in, or under the laws of, any territory.

**126. Record Date for Service**

Where the company sends or supplies notices, documents or other information to shareholders, it can do so by reference to the shareholders' register as it stands at any time not more than 15 days before the date the notice, document or other information is sent or supplied. Any change of details on the register after that time will not invalidate the sending or supply and the company is not obliged to send or supply the same notice, document or other information to any person entered on the shareholders' register after the date selected by the company.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**127. Members Resident Abroad or on Branch Registers**

(A)If a shareholder's address on the register is outside the United Kingdom, he can give the company a United Kingdom postal address to which notices, documents or other information can be sent or supplied to him. If he does, he is entitled to have notices, documents or other information set to him at that address or, where applicable, to be notified at that address of the availability of the notice, documents or other information on a website. Alternatively, a shareholder whose address on the register is outside the United Kingdom can give the company an address for the purposes of communications in electronic form. If he does, notices, documents or other information may, subject to these articles, be set or supplied to him at that address. Otherwise he is not entitled to receive any notices, documents or other information from the company.

(B)For a shareholder registered on a branch register, notices, documents or other information can be posted or despatched in the United Kingdom or in the country where the branch register is kept.

**128. Service of Notices on Persons Entitled by Transmission**

(A)This article applies where a shareholder has died or become bankrupt or is in liquidation, or where someone else has otherwise become entitled by law to that shareholder's shares, but is still registered as a shareholder. It applies whether he is registered as a sole or joint shareholder.

(B)A person who is entitled to that shareholder's shares by law, and who proves this to the reasonable satisfaction of the directors, can give the company a postal address for the sending or supply of notices, documents and other information and/or an address for the purposes of communications by electronic means. If this is done, the company can send notices, documents and other information or, where applicable, a notification about the availability of the notice, document or other information on a website, to that address.

(C)Otherwise, if any notice, document or other information is sent or supplied to the shareholder named on the register, this will be valid despite his death, bankruptcy or liquidation or the fact that any other event giving rise to an entitlement to the shares by law has occurred. This applies even if the company knew about these things. If any notice, document or other information is sent or supplied in accordance with this article, there is no need to send or supply it to any other people who may be involved.

(D)The company may at any time and in its sole discretion choose to serve, send or supply notices, documents or other information in hard copy form alone to some or all persons who are entitled to a shareholder's shares by law and may also in its sole discretion, where it considers necessary or appropriate to deal with legal, regulatory or practical problems n, or under the laws of, any territory, determine not to serve, send or supply a particular notice, document or other information to any particular such person.

**129. Deemed Delivery**

(A)If any notice, document or other information is given, sent or supplied by the company by post, it is treated as being received the day after it was posted if first class post was used or 48 hours after it was posted if first class post was not used. In proving that any notice, document or other information was given, sent or supplied, it is sufficient to show that the envelope was properly addressed and put into the postal system with postage paid.

&nbsp;&nbsp;&nbsp;&nbsp;

------

(B)If any notice, document or other information is left by the company at a shareholder's registered address or at a postal address notified to the company in accordance with these articles by a shareholder or a person who is entitled to a share by law, it is treated as being received on the day it was left.

(C)If a notice is sent through CREST, it is treated as being received when the company, or any CREST participant acting for the company, sends the issuer-instruction relating to the notice, document or other information.

(D)If any notice, document or other information is given, sent or supplied by the company using electronic means, it is treated as being received on the day it was sent even if the company subsequently sends a hard copy of such notice, document or other information by post. In the case of any notice, document or other information made available on a website, the notice, document or other information is treated as being received on the day on which the notice, document or other information was first made available on the website, or, if later, when a notice of availability is received or treated as being received by the shareholder in accordance with these articles. In proving that any notice, document or other information was given, sent or supplied by electronic means, it is sufficient to show that it was properly addressed.

(E)If any notice, document or other information is given, sent or supplied by the company by any other means authorised in writing by a shareholder, it is treated as being received when the company has done what it was authorised to do by that shareholder.

**130. Notice When Post Not Available**

If the postal service in the United Kingdom or some part of the United Kingdom is suspended or restricted, the directors only need to give notice of a general meeting to shareholders with whom the company can communicate by electronic means and who have provided the company with an address for this purpose. The company must also make the notice available on its website from the date of such publication until the conclusion of the general meeting or any adjournment of the general meeting. If it becomes generally possible to send or supply notices by post in hard copy form at least six clear days before the general meeting, the directors will send or supply a copy of the notice by post to those who would otherwise receive it in hard copy form by way of confirmation.

**131. Presumptions Where Documents Destroyed**

(A)The company can destroy or delete:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)all transfer forms or Operator-instructions transferring shares, and documents sent to support a transfer, and any other documents which were the basis for making an entry by the company on the register, after six years from the date of registration;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)all dividend and other payment instructions and notifications of a change of address or name, after two years from the date these were recorded;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)all cancelled share certificates, after one year from the date they were cancelled; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)all proxy forms after one year from the date they were used if they were used for a poll, or after one month from the end of the general meeting to which they relate if they were not used for a poll.

(B)If the company destroys or deletes a document under this article, it is conclusively treated as having been a valid and effective document in accordance with the company's records

&nbsp;&nbsp;&nbsp;&nbsp;

------

relating to the document. Any action of the company in dealing with the document in accordance with its terms before it was destroyed or deleted is conclusively treated as having been properly taken.

(C)This article only applies to documents which are destroyed or deleted in good faith and where the company is not on notice of any claim to which the document may be relevant.

(D)If the documents relate to CREST shares, the company must comply with any requirements of the uncertificated securities rules which limit its ability to destroy or delete these documents.

(E)This article does not make the company liable if:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)it destroys or deletes a document earlier than the time limit referred to in <u>paragraph [(A);](#i540905e2ce5c4158a775816c0c5568b4_4)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)it does not comply with the conditions in <u>paragraph [(C)](#i540905e2ce5c4158a775816c0c5568b4_4)</u>[;](#i540905e2ce5c4158a775816c0c5568b4_4)or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)the company would not be liable if this article did not exist.

(F)This article applies whether a document is destroyed or deleted or disposed of in some other way.

**132. Indemnity of Directors**

(A)As far as the legislation allows this, the company:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)can indemnify any director or former director of the company or of any associated company against any liability; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)can purchase and maintain insurance against any liability for any director or former director of the company or of any associated company.

(B)A director or former director of the company or of any associated company will not be accountable to the company or the shareholders for any benefit provided pursuant to this article. Anyone receiving such a benefit will not be disqualified from being or becoming a director of the company.

**133. Arbitration**

(A)Unless <u>Article 134</u> applies:

All disputes:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)between a shareholder in that shareholder's capacity as such and the company and/or its directors arising out of or in connection with these articles or otherwise; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)so far as permitted by law, between the company and any of its directors in their capacities as such or as employees of the company, including all claims made by or on behalf of the company against its directors; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)between a shareholder in that shareholder's capacity as such and the company's professional service providers; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)between the company and the company's professional service providers arising in connection with any claim within the scope of <u>sub-paragraph (A)(iii)</u>,

&nbsp;&nbsp;&nbsp;&nbsp;

------

will be exclusively and finally resolved under the Rules of Arbitration of the International Chamber of Commerce ("ICC") (the "ICC Rules"), as amended from time to time.

(B)The tribunal will consist of three arbitrators to be appointed in accordance with the ICC Rules.

(C)The chair of the tribunal must have at least 20 years' experience as a lawyer qualified to practise in a common law jurisdiction within the Commonwealth (as constituted on the date of adoption of this article) and each other arbitrator must have at least 20 years' experience as a qualified lawyer.

(D)The place of arbitration will be London, England.

(E)The language of the arbitration will be English.

(F)These articles are a contract between the company and its shareholders and between the company's shareholders amongst themselves. This article (as supplemented from time to time by any agreement to a similar effect between the company and its directors or professional service providers) also contains or evidences an express submission to arbitration by each shareholder, the company, its directors and professional service providers and such submissions will be treated as a written arbitration agreement under the Arbitration Act 1996 of England and Wales and Article II of the United Nations Convention on the Recognition and Enforcement of Foreign Arbitral Awards (1958).

(G)Each person to whom this article applies hereby waives, as far as permitted by law: (i) any right under the laws of any jurisdiction to apply to any court of law or other judicial authority to determine any preliminary point of law, and/or (ii) any right he or she may otherwise have under the laws of any jurisdiction to appeal or otherwise challenge the award, ruling or decision of the tribunal.

**134. Exclusive Jurisdiction**

(A)This article applies to:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)a dispute (which would otherwise be subject to <u>Article 133</u>) in any jurisdiction if a court in that jurisdiction determines that <u>Article 133</u> is invalid or unenforceable in relation to that dispute in that jurisdiction; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)any derivative claim under the Companies Acts.

(B)For the purposes of <u>paragraph (A)</u>, "court" means any court of competent jurisdiction or other competent authority including for the avoidance of doubt, a court or authority in any jurisdiction which is not a signatory to the New York Convention.

(C)Any proceeding, suit or action:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)between a shareholder in that shareholder's capacity as such and the company and/or its directors arising out of or in connection with these articles or otherwise; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)so far as permitted by law, between the company and any of its directors in their capacities as such or as employees of the company, including all claims made by or on behalf of the company against its directors; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)between a shareholder in that shareholder's capacity as such and the company's professional service providers and/or

&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)between the company and the company's professional service providers arising in connection with any claim within the scope of <u>sub-paragraph 134(C)(iii)</u>,

can only be brought in the courts of England and Wales.

(D)Damages alone may not be an adequate remedy for any breach of this article, so that in the event of a breach or anticipated breach, the remedies of injunction and/or an order for specific performance would in appropriate circumstances be available.

**135. General Dispute Resolution Provisions**

(A)For the purposes of <u>Articles 133</u> and <u>134,</u> a "dispute" means any dispute, controversy or claim, other than:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)any dispute, controversy or claim relating to any failure or alleged failure by the company to pay all or part of a dividend which has been declared and which has fallen due for payment; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)in the case of <u>Article 134</u> only, any derivative claim under the Companies Acts.

(B)The governing law of these articles, including the submissions to arbitration and written arbitration agreement contained in or evidenced by <u>Article 133</u> and any dispute, controversy or claim arising out of or in connection with these articles (whether contractual or non-contractual), is the substantive law of England.

(C)The company is entitled to enforce <u>Articles 133</u> and <u>134</u> for its own benefit, and that of its directors, subsidiary undertakings and professional service providers.

(D)References in <u>Articles 133</u> and <u>134</u> to:-

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)"company" includes each and any of the company's subsidiary undertakings from time to time; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)"director" includes each and any director of the company from time to time in his or her capacity as such or as employee of the company and extends to any former director of the company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)"professional service providers" includes the company's auditors, legal counsel, bankers and any other similar professional service providers in their capacity as such from time to time but only if and to the extent such person has agreed with the company in writing to be bound by <u>Article 133</u> and/or <u>134</u> (or has otherwise agreed to submit disputes to arbitration and/or exclusive jurisdiction in a materially similar way).

&nbsp;&nbsp;&nbsp;&nbsp;

------

**GLOSSARY**

**About the Glossary**

This Glossary is to help readers understand the company's articles. Words are explained as they are used in the articles - they might mean different things in other documents. This Glossary is not legally part of the articles and it does not affect their meaning. The explanations are intended to be a general guide - they are not precise. Words and expressions which are printed in bold in a definition have their own general explanation of their meaning which is contained in this Glossary.

**abrogate** If the **special rights** of a share are abrogated, they are cancelled or withdrawn.

**adjourn** Where a meeting breaks up, to be continued at a later time or day, at the same or a different place.

**allot** When new shares are allotted, they are set aside for the person they are intended for. This will normally be after the person has agreed to pay for a new share, or has become entitled to a new share for any other reason. As soon as a share is allotted, that person has the right to have his name put on the register of shareholders. When he has been registered, the share has also been **issued**.

**asset** Anything which is of any value to its owner.

**attorney** An attorney is a person who has been appointed to act for another person. The person is appointed by a formal document, called a "**power of attorney**".

**brokerage** Commission which is paid to a broker by a company **issuing** shares where the broker's clients have applied for shares.

**call** A call to pay money which is due on shares which has not yet been paid. This happens if the company **issues** shares which are partly paid, where money remains to be paid to the company for the shares. The money which has not been paid can be "called" for. If all the money to be paid on a share has been paid, the share is called a "**fully paid share**".

**capitalise** To convert some or all of the **reserves** of a company into capital (such as shares).

**capital redemption reserve** A **reserve** which a company may have to set up to maintain the level of its capital base when shares are **redeemed** or bought back.

**certificated form** A shareholder holds a share or other security in certificated form if it is not able to be held in **uncertificated form** or, if it is able to be held in **uncertificated form** but that shareholder has requested that a certificate be issued for that share or other security (see also **uncertificated form**).

**company representative** If a corporation owns shares, it can appoint a company representative to attend a shareholders' general meeting to speak and vote for it.

**consolidate** When shares are consolidated, they are combined with other shares - for example, three £1 shares might be consolidated into one new £3 share.

**debenture** A typical debenture is a long-term borrowing by a company. The loan usually has to be repaid at a fixed date in the future and carries a fixed rate of interest.

**declare** Generally, when a dividend is declared, it becomes due to be paid.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**derivative claim** An action which may be brought by a member on behalf of the company to enforce liability for breach by a director of his duties to the company.

**electronic form** A document is in electronic form if it is either sent by **electronic means** or it is sent by other means while in an electronic form e.g. a CD ROM.

**electronic means** A communication is sent by electronic means if it is sent by means of a telecommunications system. It includes fax and telephone communications and also electronic mail.

**entitled to a share by law** In some situations, a person will be entitled to have shares which are registered in somebody else's name registered in his own name or to require the shares to be transferred to another person. When a shareholder dies, or the sole survivor of joint shareholders dies, his **personal representatives** have this right. If a shareholder is made bankrupt, his **trustee** in bankruptcy has the right.

**ex dividend** Once a share has gone ex-dividend, a person who buys the share in the market will not be entitled to the dividend which has been declared shortly before it was bought. The seller remains entitled to this dividend even though it will be paid after he has sold his share.

**executed** A document is executed when it is signed or sealed or made valid in some other way.

**exercise** When a power is exercised, it is used.

**forfeit and forfeiture** When a share is forfeited it is taken away from the shareholder and goes back to the company. This process is called "forfeiture". This can happen if a **call** on a **partly paid share** is not paid on time.

**fully paid shares** When all of the money or other property which is due to the company for a share has been paid or received, a share is called a "fully paid share".

**hard copy form** A document is in hard copy form if it is in a paper copy or similar form.

**indemnity and indemnify** If a person gives another person an indemnity, he promises to make good any losses or damage which the other might suffer. The person who gives the indemnity is said to "indemnify" the other person.

**in issue** See **issue**.

**instruments** Formal legal documents.

**issue** When a share has been issued, everything has been done by a company to make the shareholder the owner of the share. In particular, the shareholder's name has been put on the register. Existing shares which have been issued are called "**in issue**".

**joint and several liability** A person who is jointly and severally liable is liable together with others and is also liable separately.

**lien** Where the company has a lien over shares, it can take the dividends, and any other payments relating to the shares which it has a lien over, or it can sell the shares, to repay the debt and so on.

**members** Shareholders.

**nominal amount or nominal value** The amount of the share shown in a company's account. The nominal value of the company's ordinary shares is 0.50 US Dollars. This amount is shown on the share certificate for a share. When a company **issues** new shares this can be for a price which is at a

&nbsp;&nbsp;&nbsp;&nbsp;

------

**premium** to the nominal value. When shares are bought and sold on the stock market this can be for more, or less, than the nominal value. The nominal value is sometimes also called the "par value".

**officer** The term officer includes (subject to the provisions of the articles) a director, secretary, any employee who reports directly to a director or any other person who the directors decide should be an officer.

**Operator** A person approved by the Treasury under the Uncertificated Securities Regulations 2001 as operator of a **relevant system**.

**Operator-instruction** A properly authenticated instruction sent by or on behalf of an **Operator** and sent or received by means of a **relevant system**.

**ordinary resolution** A decision reached by a simple majority of votes - that is by more than 50 per cent. of the votes cast.

**partly paid shares** If any money remains to be paid on a share, it is said to be partly paid. The unpaid money can be "**called**" for.

**personal representatives** A person who is entitled to deal with the property (the "estate") of a person who has died. If the person who has died left a valid will, the will appoints "executors" who are personal representatives. If the person died without a will, the courts will appoint one or more "administrators" to be the personal representatives.

**poll** On a vote taken on a poll, the number of votes which a shareholder has will depend on the number of shares which he owns. An ordinary shareholder has one vote for each share he owns. A poll vote is different to a vote taken on a **show of hands**, where each person who is entitled to vote has just one vote, however many shares he owns.

**power of attorney** A formal document which legally appoints one or more persons to act on behalf of another person.

**pre-emption rights** The right of some shareholders which is given by the legislation to be offered a proportion of certain classes of newly issued shares and other securities before they are offered to anyone else. This offer must be made on terms which are at least as favourable as the terms offered to anyone else.

**premium** If a company **issues** a new share for more than its **nominal value**, the amount above the **nominal value** is the premium.

**proxy** A proxy is a person who is appointed by a shareholder to attend a general meeting and vote for that shareholder. A proxy is appointed by using a **proxy form,** which may be electronic. A proxy does not have to be a shareholder. A proxy can vote on a poll and on a show of hands under the company's articles.

**proxy form** A form (including an electronic form) which a shareholder uses to appoint a **proxy** to attend a general meeting and vote for him. The proxy forms are sent out by the company and must be returned to the company before the meeting to which they relate.

**quorum** The minimum number of shareholders or directors who must be present before a shareholders' or, as appropriate, directors' meeting can start. When this number is reached, the meeting is said to be "quorate".

&nbsp;&nbsp;&nbsp;&nbsp;

------

**rank** When either capital or income is distributed to shareholders, it is paid out according to the rank (or ranking) of the shares. For example, a share which ranks ahead of (or above) another share in sharing in a company's income is entitled to have its dividends paid first, before any dividends are paid on shares which rank below (or after) it. If there is not enough income to pay dividends on all shares, the available income must be used first to pay dividends on shares which rank first, and then to shares which rank next. The same applies for repayments of capital. Capital must be paid first to shares which rank first in sharing in the company's capital, and then to shares which rank next. A company's preference shares (if it has any) generally rank ahead of its ordinary shares.

**recognised investment exchange** An investment exchange which has been officially recognised by the UK authorities. An investment exchange is a place where investments, such as shares, are traded. The London Stock Exchange is a recognised investment exchange.

**redeem, redemption and redeemable** When a share is redeemed, it goes back to the company in return for a sum of money which was fixed (or calculated from a formula fixed) before the share was **issued**. This process is called "redemption". A share which can be redeemed is called a "redeemable" share.

**relevant system** This is a term used in the legislation for a computer system which allows shares without share certificates to be transferred without using transfer forms. The CREST system for paperless share dealing is a "relevant system".

**renounces and renunciation** Where a share has been **allotted**, but nobody has been entered on the share register for the share, it can be renounced to another person. This transfers the right to have the share registered to another person. This process is called "renunciation".

**reserves** A fund which has been set aside in the accounts of a company - profits which are not paid out to shareholders as dividends, or used up in some other way, are held in a reserve by the company.

**retire by rotation** Directors must retire at an annual general meeting after they have been in office for three years or if they have been appointed since the last annual general meeting. This gives the shareholders the chance to confirm or renew their appointments by voting on whether to re-appoint them. In addition, non-executive directors who have acted as such for nine years must retire at every annual general meeting.

**revoke** To withdraw or cancel.

**shadow director** Where the directors of a company are accustomed to act in accordance with directions or instructions given by a person, that person is known as a shadow director. This does not include the company's professional advisers.

**share premium account** If a new share is **issued** by a company for more than its **nominal value**, the amount above the **nominal value** is the **premium** and the total of these **premiums** is held in a **reserve** (which cannot be used to pay dividends) called the share premium account.

**show of hands** A vote where each person who is entitled to vote has just one vote, however many shares he holds.

**special resolution** A decision reached by a majority of at least 75 per cent. of votes cast.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**special rights** These are the rights of a particular class of shares as distinct from rights which apply to all shares generally. Typical examples of special rights are: where the shares **rank**; their rights to sharing in income and **assets**; and voting rights.

**statutory declaration** A formal way of declaring something in writing. Particular words and formalities must be used - these are laid down by the Statutory Declarations Act of 1835.

**sub-divide** When shares are subdivided they are split into shares which have a smaller.

**nominal amount**. For example, a £1 share might be subdivided into two 50p shares.

**subject to** Means that something else has priority, or prevails, or must be taken into account. When a statement is subject to something this means that the statement must be read in the light of that other thing, which will prevail if there is any conflict.

**subsidiary** A company which is controlled by another company (for example, because the other company owns a majority of its shares) is called a subsidiary of that company. This is defined in more detail in the legislation.

**subsidiary undertaking** This is a term used by the legislation. It has a wider meaning than **subsidiary**. Generally speaking, it is a company which is controlled by another company because the other company:

• has a majority of the votes in the company, either alone or acting with others;

• is a shareholder who can appoint or remove a majority of the directors; or

• can **exercise** dominant influence over the company because of anything in the company's memorandum or articles or because of a certain kind of contract.

**treasury shares** Shares in the company which were bought by the company as provided by the legislation and which have been held by the company continuously since being bought are called treasury shares.

**trustees** People who hold property of any kind for the benefit of one or more other people under a kind of arrangement which the law treats as a "trust".

**uncertificated form** A share or other security is held in uncertificated form if no certificate has been issued for it. A share or other security held in uncertificated form is eligible for settlement in CREST or any other **relevant system**.

**underwriting** A person who agrees to buy new shares if they are not bought by other people underwrites the share offer.

**warrant or dividend warrant** Similar to a cheque for a dividend.

&nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 10.2

![image_11.jpg](image_11.jpg)

**<u>Exhibit 10.2</u>**

[Date]

[Name]

[Address]

[City, ST Zip]

Re: **APPOINTMENT AS NON-EXECUTIVE DIRECTOR**

Dear [Name],

We are delighted that you are [willing to join us][continuing] as a Non-Executive Director of Indivior PLC (the "**Company**"), your appointment to be effective from [Date]. I am now writing to formalise and confirm the terms of such appointment. It is agreed that this will be a contract for services and is not a contract of employment. You will also be [invited to be a member of certain Committees of the Board; the specific committees will be determined later][a member of the [x] Committee and the [x] Committee of the Board].

**Appointment**

Your appointment is subject to and conditional on satisfactory performance, the terms of the Company's Articles of Association, and election by the shareholders at the AGM and to re-election at any subsequent shareholders' meeting at which you stand for re-election. Your appointment will terminate automatically if you fail to be elected/re-elected by the shareholders or otherwise stop being a director in accordance with the Company's Articles of Association. Your appointment may be terminated by either party upon one month's written notice.

The Company may also terminate your appointment with immediate effect if you have committed a material breach of your obligations under this letter, if you have committed any serious breach or non-observance of your obligations to the Company (which include an obligation not to breach your statutory, fiduciary, contractual or common-law duties), or if you do not provide complete and accurate responses to any confirmations sought by the Company for the purposes of assessing your ongoing suitability as a Non-Executive Director.

If your appointment expires or is terminated in accordance with the terms of this letter, you shall at the request of the Company resign from your office as a Non-Executive Director of the Company and all offices held by you in any group company. If you fail to do so, you irrevocably appoint the Company Secretary to be your attorney to sign any documents and do anything to give effect to your resignation from office. This letter does not confer any right to hold office for any period. You shall only be entitled to such fees as may have accrued to the date of termination together with reimbursement in the normal way of any expenses properly incurred prior to that date. You shall not be entitled to any compensation or damages for loss of office, and no fee will be payable to you in respect of any unexpired portion of the term of the appointment.

By accepting the appointment, you confirm that you are not subject to restrictions which prevent you from holding office as a Non-Executive Director of the Company.

**Time commitment**

The Board meets formally at least five times a year. These meetings are planned to be held in the US going forward. In addition, you will be expected to devote appropriate preparation time ahead of each meeting. Overall, we anticipate a typical time commitment of 20 days per year after the induction phase.

![image_21.jpg](image_21.jpg)

------

[Name] Appointment Letter

You may be required to devote additional time to your duties when the Company is undergoing a period of particularly increased activity (such as an acquisition or takeover), or as a result of some major difficulty with one or more of its operations. By accepting this appointment, you have confirmed that you are able to allocate sufficient time to meet the expectations of your role and you have disclosed all significant other commitments to the Chair of the Board and the Company Secretary with an indication of the time involved. You confirm that you will inform the Board of any subsequent changes to your circumstances which may affect the time you can commit to your duties under this letter. Our Board/Committee dates for the remainder of 2025 and for 2026 will be provided to you.

In accordance with the Company's External Appointments Policy, the agreement of the Board must be sought before accepting additional commitments, including other directorships, which might affect the time you are able to devote to your role as a Non-Executive Director of the Company. A copy of the Company's External Appointments Policy will be provided to you.

**Role**

Non-Executive Directors have the same general legal responsibilities to the Company as any other director. The Board as a whole is collectively responsible for promoting the success of the Company by directing and supervising the Company's affairs. You will be expected to perform your duties faithfully, efficiently, and diligently to a standard commensurate with both the functions of your role and your knowledge, skills, and experience. In order to discharge your duties as a Non-Executive Director, you are entitled to request, and should insist on receiving, all relevant information about the Company's affairs as is reasonably necessary. You will exercise your powers in your role as a Non-Executive Director in accordance with the Company's Articles of Association, policies and procedures and internal control framework, and having regard to relevant obligations under prevailing law and regulation, including but not limited to the UK Companies Act 2006, applicable SEC regulations, and the Nasdaq listing rules.

As a Non-Executive Director, you do not have authority to commit the Company in any way without the express authorisation of the Board.

A copy of the Board's Corporate Governance Guidelines, which describe the principles and practices the Board will follow in carrying out its responsibilities, will be provided to you.

**Fees**

With effect from [Date], you will be paid a retainer of $250,000 per year (the "**NED Retainer**"). Additional fees will be paid in respect of your membership of the committees on which you serve (the "**Additional Fees**"). The NED Retainer and the Additional Fees payable for the relevant calendar year or any part thereof make up the total annual fees for your membership of the Board (the "**Total Fees**").

Subject to "NED Share Program" below, the Total Fees will be paid in arrears. Fees will be subject to review by the Board periodically. In addition, the Company will reimburse you for all reasonable and properly documented expenses you incur in performing the duties of your office.

You will have no entitlement to any bonus during the appointment and no entitlement to participate in any pension scheme operated by the Company.

Any payment or benefit made to you under this letter is subject to and conditional on such approval by the shareholders of the Company as may be required by law. The Company reserves the right to withhold or require repayment of all or part of any such payment or benefit if and to the extent that it is necessary to do so in order to comply with regulatory or legal requirements.

![image_01.jpg](image_01.jpg)

------

[Name] Appointment Letter

**NED Share Program**

You are required to use [70][80]% of the NED Retainer (after taxes) to purchase shares in the Company by entering into an arrangement satisfactory to the Company. You will receive separate information on the arrangement the Company has put in place to facilitate such purchases. You are required to hold the shares you so purchase for at least one year following acquisition (or until termination of appointment, if earlier).

**Shareholding Guidelines**

You are required to comply with the Company's shareholding guidelines, as may be amended from time to time. The current requirement is that Non-Executive Directors build a shareholding of shares with a value equivalent to [400][600]% of the cash element of your NED Retainer. You are expected to achieve this holding within five years of the date of your appointment.

**Inside / material non-public information and dealing in the Company's shares**

You must refrain from making any public statement regarding the Company or any group company which would infringe the requirements of law and regulation regarding the disclosure of material non-public information or inside information, in particular, section 52 of the UK Criminal Justice Act 1993 on insider dealing and applicable US securities laws, including Regulation FD (Fair Disclosure) (in each case, as amended or replaced).

During your appointment you are required to comply with the provisions of the Company's Insider Trading Policy relating to dealing in the Company's listed securities and any applicable legislation and regulatory guidance relating to the same (in each case, as amended from time to time). A copy of the Company's Insider Trading Policy will be provided to you.

**Outside interests**

It is accepted and acknowledged that you may have business interests other than those of the Company and have declared any conflicts that are apparent at present. In the event that you become aware of any potential conflicts of interest, these, together with any information of knowledge acquired or gained by you in any manner whatsoever whilst you continue in office which may be of value or which may be to the detriment of the Company or any group company (subject to any overarching duty of confidentiality), must be disclosed to the Chair of the Board and Company Secretary as soon as apparent.

It has been determined that you are independent according to the provisions of the Nasdaq listing rules and will be identified as such in the annual report and other documentation. If circumstances change which may impact this assessment, you should inform the Chair of the Board and Company Secretary as soon as practicable.

**Confidentiality**

All information acquired during your appointment is confidential to the Company and should not be released, either during your appointment or following termination (by whatever means) to third parties without prior clearance from the Chair of the Board.

Your attention is also drawn to the requirements under both legislation and regulation as to the disclosure of inside information or material non-public information. Consequently, you should avoid making any statements that might risk a breach of these requirements without prior clearance from the Chair of the Board or the Company Secretary.

On termination of your appointment you will deliver to the Company all books, documents, papers and other property of or relating to the business of the Company or any group company which are in your possession, custody or power by virtue of your position as a Non-Executive Director of the Company and you should ensure that you have not kept any copies thereof.

![image_01.jpg](image_01.jpg)

------

[Name] Appointment Letter

**Review process**

The performance of individual Directors, and the Board and its Committees, is evaluated annually. If, in the interim, there are any matters which cause you concern about your role, you should discuss them with the Chair of the Board as soon as is appropriate.

**Insurance**

The Company has Directors' and Officers' liability insurance, the current indemnity limit of which is $80 million. The Company will use reasonable endeavours to purchase and maintain insurance cover for directors' and officers' liabilities on reasonable commercial terms and such cover shall continue for your benefit as long as you are a director and for at least six years thereafter. In addition, the Company shall grant you a deed of indemnity against certain liabilities that may be incurred as a result of your office to the extent permitted by s234 of the UK Companies Act 2006.

**Independent professional advice**

Occasions may arise when you consider that you need professional advice in the furtherance of your duties as a director. Circumstances may occur when it will be appropriate for you to seek advice from independent advisors at the Company's expense. A copy of the Board's Policy for Directors Obtaining Independent Professional Advice will be provided to you. The Company will reimburse the full cost of expenditure incurred in accordance with the policy.

**Committees**

This letter refers to your appointment as a Non-Executive Director of the Company and your [future] appointment to [certain committees] of the Board. Should you Chair a committee a further additional fee would be payable. Charters for the Board's five principal Committees will be provided to you.

**Data protection**

Your attention is drawn to the Company's Privacy Notice, a copy of which will be provided to you. The Company will hold and process, both electronically and manually, your personal and sensitive personal data for personnel, administrative and management purposes and for compliance with applicable procedures, laws, and regulations.

The Company may make your personal data available to any group company, those who provide products or services to the Company (such as advisors and payroll administrators), regulatory authorities, governmental or quasi-governmental organisations and potential purchasers of the Company. The Company may transfer your personal data outside the European Economic Area in order to further the Company's and/or any group company's business interests.

You will use all reasonable endeavours to keep the Company informed of any changes to your personal data and you will comply at all times with the Company's data protection policy.

The Privacy Notice does not form part of this letter agreement and may be updated from time to time. Any such updates will be notified to you.

**Induction and professional development**

The Company will provide an appropriate onboarding for you to help you gain information about the Company and the Board. We will also arrange for site visits and meetings with executive and senior management as requested.

**Governing law**

This letter and any non-contractual obligations arising out of or in connection with it, including any non-contractual obligations arising out of the negotiations, will be governed by and construed in accordance with English law and the parties irrevocably submit to the exclusive jurisdiction of the English Courts.

![image_01.jpg](image_01.jpg)

------

[Name] Appointment Letter

Please sign this letter in the presence of a witness, in acceptance of the above terms, and return it (i) by email to [email address] or (ii) in hard copy to the Company's corporate office address:

10710 Midlothian Turnpike, Suite 125

North Chesterfield, VA 23235

Attn: [Name]

Sincerely,

[Name]

[Title]

I hereby agree to terms set out above.

Signed as a deed and delivered by

Name: .........................................................

Signature: ...................................................

Date ............................................................

In the presence of:

Witness's Signature:

Witness's Name:

Witness's Address:

Date:

![image_01.jpg](image_01.jpg)

## Exhibit 10.3

**<u>Exhibit 10.3</u>**

**[Date]**

**(1) Indivior PLC**

**(2) [Name]**

**DEED OF INDEMNITY**<br>

![image_0.jpg](image_0.jpg)

------

**CONTENTS**

**CLAUSE&nbsp;&nbsp;&nbsp;&nbsp;PAGE**

<u>[2.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[INDEMNITY](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[4](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[3.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[EXCLUSIONS AND LIMITATIONS](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[4](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[4.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[FUNDING OF DEFENCE COSTS](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[5](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[5.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[NOTIFICATION AND CONDUCT OF CLAIMS](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[6](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[6.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[NO DOUBLE RECOVERY](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[7](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[7.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[TAX](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[8](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[8.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[D&O INSURANCE](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[8](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[9.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[SUBROGATION](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[9](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[10.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[TERM](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[9](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[11.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[ASSIGNMENT](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[9](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[12.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[ENTIRE AGREEMENT](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[9](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[13.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[SEVERANCE](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[10](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[14.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[NOTICES](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[10](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[15.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[VARIATION](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[11](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[16.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[WAIVER](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[11](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[17.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[COUNTERPARTS](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[11](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[18.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[NO THIRD PARTY RIGHTS](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[12](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[19.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[GOVERNING LAW](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[12](#i7003b4c513a44119b43bc8a06f7f401f_7)

<u>[20.](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)<u>[JURISDICTION](#i7003b4c513a44119b43bc8a06f7f401f_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i7003b4c513a44119b43bc8a06f7f401f_7)[12](#i7003b4c513a44119b43bc8a06f7f401f_7)

<br> -i- <br>

![image_0.jpg](image_0.jpg)

------

<br> -ii- <br>

EUROPE-LEGAL-265430417/6 168111-0003<br>

------

**THIS DEED OF INDEMNITY** is dated [Date]

**PARTIES:**

(1)**Indivior PLC**, a public limited company registered in England and Wales with company number 09237894 whose registered office is at 234 Bath Road, Slough, Berkshire, United Kingdom, SL1 4EE (the ***Company***); and

(2)[Name and Address] (the ***Director***).

**RECITALS:**

(A)The Director is a director of the Company.

(B)The Company's Articles of Association contemplate that the Company may indemnify and insure the Company's directors in relation to certain specific liabilities incurred by them in the performance of their duties as directors of the Company.

The Company has agreed to enter into this Deed with the Director.

**It is agreed:**

**1. Interpretation**

The following definitions and rules of interpretation apply in this Deed.

1.1Definitions:

***Act*** means the Companies Act 2006;

***Application for Relief*** means an application for relief made by the Director to the court under sections 661(3) or 661(4) or section 1157 of the Act;

***Associated Company*** means a company or body corporate associated with the Company within the meaning of section 256 of the Act;

***Board*** means the board of directors of the Company, acting as such;

***Business Day*** means a day other than a Saturday, Sunday or public holiday in England, when banks in London are open for business;

***D&O Insurance*** has the meaning given in clause 8.1;

***Final*** in relation to any conviction, judgment or refusal of relief, has the meaning given in section 234(5) of the Act;

***Indemnity*** has the meaning given in clause 2.1;

***Indemnity Claim*** means any demand, claim, action or proceeding by the Director against the Company under the Indemnity;

***Law*** means any statute, law, rule, regulation, guideline, ordinance, code or rule of law issued, administered or enforced by any governmental authority, and any judicial or administrative interpretation of any of these;

![image_0.jpg](image_0.jpg)

------

***Loan Amounts*** has the meaning given in clause 4.1;

***Losses*** means all liabilities, costs, charges, expenses, judgments, settlements, compensation and other awards, damages, penalties, fines, compensation and losses (including any direct, indirect or consequential losses and all interest, Taxes and legal costs (calculated on a full indemnity basis) and all other reasonable professional costs and expenses);

***Proceedings*** means any claims, actions or other proceedings, whether civil, criminal, administrative, regulatory or investigative;

***Relevant Companies*** has the meaning given in clause 2.1;

***Restricted Proceedings*** means: the proceedings referred to in clause 3.1(a)(iii)(A), (B) or (C) to the extent that they arise in connection with the Director having acted or purported to act as a director of the Company or of any other Relevant Companies;

***Subsidiary*** has the meaning given in section 1159 of the Act;

***Tax*** includes, without limitation, all taxes on gross or net income, profits and gains and all other taxes, levies, duties, imposts, charges and withholdings of any nature, including any payroll taxes (including any national insurance or social security contributions and any apprenticeship levy); and

***Working Hours*** means 9.30am to 5.30pm in the relevant location on a Business Day.

1.2Interpretation

In this Deed, unless the context requires otherwise:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)references to a ***person*** include any individual, firm, body corporate (wherever incorporated), government, state or agency of a state or any joint venture, association, partnership, works council or employee representative body (in any case, whether or not it has separate legal personality);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)references to a paragraph, clause or Schedule are to those of this Deed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)headings do not affect its interpretation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)the singular shall include the plural and vice versa, and references to one gender include all genders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)references to any English law legal term or concept shall, in respect of any jurisdiction other than England and Wales, be construed as references to the term or concept that most nearly corresponds to it in that jurisdiction; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)any phrase introduced by the terms ***including***, ***include***, ***in particular*** or any similar expression shall be construed as merely illustrative and shall not limit the sense of the words preceding those terms.

1.3Enactments

------

1.4Except as otherwise expressly provided in this Deed, any reference to an enactment (which includes any legislation in any jurisdiction) includes references to: (i) that enactment as amended, consolidated or re-enacted by or under any other enactment whenever made; (ii) any enactment that that enactment re-enacts (with or without modification); and (iii) any subordinate legislation (including regulations) whenever made under that enactment, as amended, consolidated or re-enacted as described at (i) or (ii).

**2. Indemnity**

2.1Subject to the terms of this Deed, the Company shall indemnify the Director in respect of all Losses arising out of or in connection with any Proceedings brought or threatened against the Director in any jurisdiction for negligence, default, breach of duty, breach of trust or otherwise, or relating to any Application for Relief, in connection with the Director's acts or omissions while in the course of acting or purporting to act as a director of the Company or of any of its Subsidiaries or any other company in which the Company is, directly or indirectly, legally or beneficially interested and in respect of which the Director's appointment as a director is related to the Director's appointment as a director of the Company (in this Deed, any such companies are referred to together with the Company and its Subsidiaries as ***Relevant Companies***) or which otherwise arises by virtue of the Director holding or having held such a position (the ***Indemnity***).

2.2References in clause 2.1 to acts or omissions are to acts or omissions made or omitted to be made on or after the date of the Director's appointment as a director of the Company, however:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)if a body corporate ceases to be a Relevant Company, the Company shall only be liable to indemnify the Director in respect of Losses in relation to that body corporate arising from acts or omissions before the date on which that body corporate ceased to be a Relevant Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the Director, as director of any body corporate which becomes a Relevant Company after the date of this Deed, shall be indemnified only in respect of Losses in relation to that body corporate arising from acts or omissions after the date on which that body corporate became a Relevant Company.

**3. Exclusions and limitations**

3.1The Indemnity shall not apply to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the extent prohibited by the Act or otherwise prohibited by law, including, for the avoidance of doubt:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)any Losses incurred by the Director to the Company or any Associated Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)a fine imposed in criminal proceedings, or a sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature (however arising); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)other than as provided in clause 4, any Losses incurred by the Director:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)in defending criminal proceedings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)in defending civil proceedings brought by the Company or any Associated Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)in connection with an Application for Relief;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any Losses relating to any Tax payable by the Director in connection with their remuneration or other payments or benefits received from the Company or any other Relevant Companies (other than any payments made under this Deed); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)the extent that the Director is entitled to recover from any other person (including under any policy of insurance) any amount in relation to a matter giving rise (or which may give rise) to an Indemnity Claim, unless such amount is contingent on the Director having first exhausted their rights to indemnification in respect of the relevant Losses under this Deed.

**4. Funding of defence costs**

4.1Subject to the terms of this Deed, the Company shall loan to the Director such amounts as are required for the Director to meet such legal and other reasonable costs of Restricted Proceedings as are incurred (or are to be incurred) by the Director, in accordance with any terms and conditions imposed by law, under the Articles of Association of the Company or under the Listing Rules of the United Kingdom Financial Conduct Authority from time to time or such other body as may be applicable (***Loan Amounts***).

4.2Any loan pursuant to clause 4.1 shall be on such terms as the Company, in its reasonable discretion, deems appropriate and desirable, provided always that the loan shall in any event be repaid as required by the Act.

4.3All Loan Amounts outstanding to a Director in respect of particular Restricted Proceedings shall be repaid by the Director if, in respect of those proceedings (as applicable):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the Director is convicted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)judgment is given against the Director; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)the court refuses to grant the Director relief on the Application for Relief,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)and such outstanding Loan Amounts shall be repaid no later than the date when the conviction, judgment or the refusal of relief (as applicable) becomes Final.

4.4In respect of a Restricted Proceeding, in the event that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)such Restricted Proceeding is:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)abandoned, withdrawn or discontinued;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)settled;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)a permanent stay is granted; or

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)a determination of the court is made and becomes Final; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)none of the events referred to in clause 4.3(a) to (c) (as applicable) has occurred and become Final,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)the Indemnity shall thereafter apply with respect to all legal and other reasonable costs of such Restricted Proceeding as are incurred by the Director. Any liability of the Company to indemnify the Director shall be set-off against any liability of the Director to repay to the Company any Loan Amounts pursuant to this clause 4 and shall be subject to the exclusions and limitations contained in clause 3.

4.5The Company may deduct from any money due to the Director (including remuneration) in connection with their services to the Company or any Associated Company, any amount which the Director owes to the Company under this clause 4.

**5. Notification and conduct of claims**

5.1Where the Director becomes aware of any Proceedings giving rise to, or any circumstances which may reasonably be expected to give rise to, an Indemnity Claim, the Director shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)as soon as reasonably practicable, give written notice of the Proceedings or circumstances to the Company, as well as any other information which the Company may reasonably request from time to time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)take all reasonable action to mitigate any Loss suffered by the Director in respect of the Proceedings or circumstances;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)take all such action as the Company may reasonably request to avoid, dispute, resist, appeal or defend any claim and not make any admission of liability, agreement or compromise with any person in relation to any Proceedings without the prior written consent of the Company (such consent not to be unreasonably withheld);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)forward all documents received by the Director in respect of the Proceedings or circumstances to the Company as soon as reasonably practicable following receipt;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)assist the Company as it may reasonably require in resisting, defending or settling the Proceedings; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)provide to the Company such information about the nature and amount of costs incurred by the Director in respect of the Proceedings or circumstances as the Company may reasonably request.

5.2Any obligation on the Company to make a payment to the Director pursuant to clause 2.1 or 4.1 is conditional upon the Director having made an application in writing to the Company supported by the production of documentation which, in the reasonable opinion of the Board, is satisfactory evidence that:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the relevant Loss has been, or is to be, suffered or incurred by the Director and of the date(s) on which it was, or is to be, suffered or incurred and that it falls within the scope of clause 2.1 or 4.1 (as applicable); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any legal costs and expenses which are to be reimbursed were properly incurred and are reasonable in amount.

5.3If the Board is satisfied that the conditions set out in clause 5.2 have been fulfilled, it shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)in respect of a payment pursuant to clause 2.1, make a payment to the Director within 14 days; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)in respect of a loan pursuant to clause 4.1, lend such Loan Amounts to the Director within 14 days;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)in each case, of the receipt of the evidence referred to in clause 5.

5.4Notwithstanding the provisions of clause 5.1 and 5.2, the Director shall not be required to provide any documents or information to the Company where doing so would result in a loss of privilege in such documents or information or where the Director is legally or contractually prevented from providing such documents or information.

5.5The Company or another Relevant Company (as the case may be) will be entitled to take over, negotiate and conduct in the Director's name the defence or settlement of any Proceedings giving rise to, or that may reasonably be expected to give rise to, an Indemnity Claim (or to prosecute in the Director's name for its own benefit any such Proceedings).

5.6If the Company or another Relevant Company exercises its rights under clause 5.5, the Company shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)consult with the Director in relation to the conduct of the relevant Proceedings on aspects of the Proceedings materially relevant to the Director and keep the Director reasonably informed of material developments in the Proceedings, provided that the Company or other Relevant Company shall be under no obligation to provide any information the provision of which is reasonably likely to adversely affect the Company's or other Relevant Company's ability to claim in respect of the relevant loss under any applicable policy of insurance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)consult with the Director as to his/her reasonable requests related to the Proceedings (including any settlement) on issues which may be reasonably likely to result in material damage to the Director's reputation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)have full discretion in the conduct or settlement of the Proceedings provided the Director is not required to make any contribution to the settlement and the settlement contains no admission of liability by the Director.

------

5.7Any failure by the Director to comply with the provisions of this clause 5 shall not relieve the Company of any obligations under this Deed except to the extent that the Company is materially prejudiced by such failure.

**6. No double recovery**

6.1The Director shall not be entitled to recover under this Deed more than once in respect of the same Loss.

6.2In the event that a payment is made to the Director under this Deed in respect of a particular Loss, the Company shall be entitled to recover from the Director an amount equal to any payment received by the Director under any policy of insurance or from any other third party source (net of reasonable costs of recovery and any Tax thereon) to the extent that such net payment relates to the Loss, or if the net payment received by the Director is greater than the payment made under this Deed (less Tax thereon), a sum equal to the payment made under this Deed (less Tax thereon). The Director shall pay over such sum promptly on the Company's request.

**7. Tax**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1Where any amount payable under this Deed is subject to Tax (whether in the hands of the Director or by way of withholding or deduction from such payment), the Company shall increase the amount paid to the Director to such amount as shall, after the payment of any Tax thereon, leave the Director with sufficient funds to meet any Losses to which this Deed applies. When calculating the amount of any such Tax the amount of any Tax deductions, credits or reliefs which are or may be available to the Director in respect of the relevant payment under this Deed received by the Director or any payment made by the Director to a third party in respect of (or in or towards the discharge of) the relevant Loss (but no other deductions, credits, reliefs or payments) is to be taken into account. In the event that any amount is paid to the Director under this Deed but a Tax deduction, credit or relief is (or becomes) available to the Director in respect of the relevant payment under this Deed, or in respect of any payment made by the Director to a third party in respect of (or in or towards the discharge of) the relevant Loss, which was not taken into account in calculating the amount payable in respect of the relevant payment under this Deed, the Director shall promptly make a payment to the Company of such an amount as is equal to the benefit of such deduction, credit or relief which was not taken into account.

**8. D&O Insurance**

8.1The Company irrevocably undertakes to purchase and maintain directors' and officers' liability insurance (***D&O Insurance***) to insure the Director as a director of the Company (and any other Relevant Companies) during the period of the Director's appointment and for a period of six years thereafter, and such insurance shall include a level of cover which is customary in the market for companies with similar characteristics to the Company, taking into account in particular the stock exchanges on which the Company's securities are listed from time to time, to the extent that such

------

insurance can be obtained at such cost and on such terms as the Board considers to be reasonable.

8.2The Company shall not be in breach of its obligations under this clause 8 where its inability to purchase and maintain D&O Insurance to insure the Director is attributable to a failure by the Director to comply with the Director's obligations to the insurers or any failure to meet or comply with a condition of the coverage of the D&O Insurance is attributable to acts or omissions of the Director.

8.3The Company shall ensure that the Director is provided at all times with a copy, or a summary of the terms, of the Company's current D&O Insurance policy, to the extent it relates to the Director.

8.4In the event that the Director shall have a right to make a claim under the provisions of clause 2.1 and clause 8.1, the Director shall claim first under the provisions of clause 2.1. To the extent that the Director is not adequately protected under the provisions of clause 2.1, then the Director shall be entitled subsequently to bring a claim under clause 8.1. subject to the exclusions and limitations contained in clause 3, and clause 5 shall be applied with such changes as are appropriate.

8.5Nothing in this Deed modifies or limits any obligation on the Director under the terms of any applicable D&O Insurance maintained by the Company from time to time. Furthermore, the terms of this Deed shall not negate any obligation that the Director might have to assist the Company in complying with any obligations it may have under the terms of the D&O Insurance and the Director shall not take, or fail to take, any action which may prejudice the ability of the Company to recover under any D&O Insurance.

**9. Subrogation**

9.1In the event that the Company makes any payment to the Director under this Deed, the Company shall be subrogated to the extent of such payment to all of the Director's rights of recovery against third parties (including any claim under any applicable D&O Insurance) in respect of the payment. The Director shall provide all such information, documentation and assistance as the Company may reasonably request in connection with the exercise of its rights of subrogation.

**10. Term**

10.1This Deed shall remain in force until such time as any relevant limitation periods for bringing Proceedings against the Director have expired, or (if longer) for so long as the Director remains liable for any Losses, notwithstanding that the Director may have ceased to be a director of the Company or any other Relevant Companies.

**11. Assignment** 

11.1Subject to clause 11.2, the Company may assign, transfer, charge, subcontract, delegate or otherwise deal with any of its rights or obligations under this Deed.

11.2If the Company assigns, transfers, charges, subcontracts, delegates or otherwise deals with any of its rights or obligations under this Deed, then:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the Director shall have no greater liability under this Deed than it would otherwise have had;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the Company shall notify the Director as soon as practicable after the assignment, transfer, charge, dealing, delegation or sub-contracting, together with full particulars of the assignee, transferee, charge, delegatee or sub-contractor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)the Director shall, on request from the Company, execute any agreement or other instrument (including any supplement or amendment to this Deed) that may be required to give effect to or perfect the assignment, transfer, charge, delegation, dealing or sub-contracting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)any sub-contracting shall not relieve the Director from liability to perform the sub-contracted obligation.

11.3The Director may not assign, transfer, charge, delegate, subcontract or otherwise deal with any of its rights or obligations under this Deed.

**12. Entire agreement**

12.1This Deed sets out the whole agreement between the parties in respect of the subject matter of this Deed and supersedes any previous draft, agreement, arrangement or understanding, whether in writing or not, relating to its subject matter.

12.2It is agreed that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)no party has relied on or shall have any claim or remedy arising under or in connection with any statement, representation, warranty or undertaking made by or on behalf of the other party in relation to the subject matter of this Deed that is not expressly set out in this Deed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any terms or conditions implied by Law in any jurisdiction in relation to the subject matter of this Deed are excluded to the fullest extent permitted by Law or, if incapable of exclusion, any rights or remedies in relation to them are irrevocably waived;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)the only right or remedy of a party in relation to any provision of this Deed shall be for breach of this Deed; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)except for any liability in respect of a breach of this Deed, neither party shall owe any duty of care or have any liability in tort or otherwise to the other party in relation to the subject matter of this Deed.

12.3Nothing in this clause 12 shall limit any liability for (or remedy in respect of) fraud or fraudulent misrepresentation.

**13. Severance**

13.1Each of the provisions of this Deed is severable. If and to the extent that any provision of this Deed:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)is held to be, or becomes, invalid or unenforceable under the Law of any jurisdiction; but

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)would be valid, binding and enforceable if some part of the provision were deleted or amended,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)then the provision shall apply with the minimum modifications necessary to make it valid, binding and enforceable and neither the validity or enforceability of the remaining provisions of this Deed, nor the validity or enforceability of that provision under the Law of any other jurisdiction, shall in any way be affected or impaired as a result of this clause 13.1.

13.2The parties shall negotiate in good faith to amend or replace any invalid, void or unenforceable provision with a valid, binding and enforceable substitute provision or provisions, so that, after the amendment or replacement, the commercial effect of the Deed is as close as possible to the effect it would have had if the relevant provision had not been invalid, void or unenforceable.

**14. Notices**

14.1Any notice to be given by one party to the other party in connection with this Deed shall be in writing in English and signed by or on behalf of the party giving it. It shall be delivered by hand, email, registered post or courier using an internationally recognised courier company.

14.2A notice shall be effective upon receipt and shall be deemed to have been received (i) at the time of delivery, if delivered by hand, registered post or courier or (ii) at the time of transmission if delivered by email. Where delivery occurs outside Working Hours, notice shall be deemed to have been received at the start of Working Hours on the next following Business Day.

14.3The addresses and email addresses of the parties for the purpose of clause 14.1 are:

---

| | | |
|:---|:---|:---|
| **<u>Company</u>** |  |  |
| **For the attention of:**<br>Alice Givens,<br>Company Secretary | **Address:** <br>234 Bath Road, Slough, Berkshire, United Kingdom, SL1 4EE | **Email:**<br>alice.givens@indivior.com |
| **<u>Director</u>** |  |  |
| **For the attention of:**<br>[Name] | **Address:**<br>[Address] | **Email:**<br>[Email] |

---

14.4Each party shall notify the other party in writing of a change to its details in clause 14.3 from time to time.

------

**15. Variation**

15.1No variation of this Deed shall be effective unless it is in writing and signed by or on behalf of the parties.

15.2If this Deed is varied:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the variation shall not constitute a general waiver of any provisions of this Deed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the variation shall not affect any rights, obligations or liabilities under this Deed that have already accrued up to the date of variation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)the rights and obligations of the parties under this Deed shall remain in force, except as, and only to the extent that, they are varied.

**16. Waiver**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.1No failure to exercise, or delay in exercising, any right under this Deed or provided by Law shall affect that right or operate as a waiver of the right. The single or partial exercise of any right under this Deed or provided by Law shall not preclude any further exercise of it.

**17. Counterparts**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.1This Deed may be executed in any number of counterparts, and by each party on separate counterparts. Each counterpart is an original, but all counterparts shall together constitute one and the same instrument. Delivery of a counterpart of this Deed by e-mail attachment shall be an effective mode of delivery.

**18. No third party rights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.1A person who is not a party to this Deed shall have no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any of its terms.

**19. Governing law**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.1This Deed and any non-contractual obligations arising out of, or in connection with, it shall be governed by, and interpreted in accordance with, English law.

**20. Jurisdiction**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.1The English courts shall have exclusive jurisdiction in relation to all disputes arising between the parties out of or in connection with this Deed. For these purposes, each party irrevocably submits to the jurisdiction of the English courts and waives any objection to the exercise of that jurisdiction.

------

**IN WITNESS** whereof this **DEED** has been executed the day and year first above written.

**EXECUTED** as a **DEED** by **INDIVIOR PLC** acting by two directors/a director and the secretary:

Signature:

[Signature]

Name: &nbsp;&nbsp;&nbsp;&nbsp;[Name]

Signature:

[Signature]

Name: &nbsp;&nbsp;&nbsp;&nbsp;[Name]

**SIGNED** as a **DEED** and **DELIVERED** by [Name] in the presence of:

Signature: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Witness**

Signature: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Address: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 31.1

**<u>Exhibit 31.1</u>**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO RULES 13a-14(A) AND 15d-14(A)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

I, Joe Ciaffoni, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of Indivior PLC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the

------

audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 31, 2025

---

| |
|:---|
| /s/ Joe Ciaffoni |
| Joe Ciaffoni, <br>Chief Executive Officer |

---

## Exhibit 31.2

**<u>Exhibit 31.2</u>**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO RULES 13a-14(A) AND 15d-14(A)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

I, Ryan Preblick, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of Indivior PLC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 31, 2025

---

| |
|:---|
| /s/ Ryan Preblick |
| Ryan Preblick, <br>Chief Financial Officer |

---

## Exhibit 32.1

**<u>Exhibit 32.1</u>**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Chief Executive Officer of Indivior PLC (the "Company"), does hereby certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Quarterly Report on Form 10-Q for the fiscal period ended June 30, 2025 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: July 31, 2025

---

| |
|:---|
| /s/ Joe Ciaffoni |
| Joe Ciaffoni, <br>Chief Executive Officer |

---

## Exhibit 32.2

**<u>Exhibit 32.2</u>**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Chief Financial Officer of Indivior PLC (the "Company"), does hereby certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Quarterly Report on Form 10-Q for the fiscal period ended June 30, 2025 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: July 31, 2025

---

| |
|:---|
| /s/ Ryan Preblick |
| Ryan Preblick, Chief Financial Officer |

---

<br>